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Abstract
Prostate cancer is a major health problem among aging men worldwide. This pathology
is easier to cure in its early stages, when it is still organ-confined. However, it hardly
ever produces any symptom until it becomes excessively large or has invaded other
tissues. Hence, the current approach to combat prostate cancer is a combination of
prevention and regular screening for early detection. Indeed, most cases of prostate
cancer are diagnosed and treated when it is localized within the organ. Despite the wealth
of accumulated knowledge on the biological basis and clinical management of the disease,
we lack a comprehensive theoretical model into which we can organize and understand
the abundance of data on prostate cancer. Additionally, the standard clinical practice
in oncology is largely based on statistical patterns, which is not sufficiently accurate to
individualize the diagnosis, prediction of prognosis, treatment, and follow-up.
Recently, mathematical modeling and simulation of cancer and their treatments have
enabled the prediction of clinical outcomes and the design of optimal therapies on a
patient-specific basis. This new trend in medical research has been termed mathematical
oncology. Prostate cancer is an ideal candidate to benefit from this technology for several
reasons. First, patient-specific clinical approaches may contribute to reduce the rates of
overtreatment and undertreatment of prostate cancer. Multiparametric magnetic resonance
is increasingly used to monitor and diagnose this disease. This imaging technology can
provide abundant information to build a patient-specific mathematical model of prostate
cancer growth. Moreover, the prostate is a sufficiently small organ to pursue tissue-scale
predictive simulations. Prostate cancer growth can also be estimated using the serum
concentration of a biomarker known as the prostate specific antigen. Additionally, some
prostate cancer patients do not receive any treatment but are clinically monitored and
periodically imaged, which opens the door to in vivo model validation. The advent of
versatile and powerful technologies in computational mechanics permits to address the
challenges posed by the prostate anatomy and the resolution of the mathematical models.
Finally, mathematical oncology technologies can guide the future research on prostate
cancer, e.g., proposing new treatment strategies or unveiling mechanisms involved in
tumor growth.
iii
Therefore, the aim of this thesis is to provide a computational framework for the tissue-
scale, patient-specific modeling and simulation of organ-confined PCa growth within
the context of mathematical oncology. We present a model for localized prostate cancer
growth that reproduces the growth patterns of the disease observed in experimental
and clinical studies. To capture the coupled dynamics of healthy and tumoral tissue,
we use the phase-field method together with reaction-diffusion equations for nutrient
consumption and prostate specific antigen production. We leverage this model to run the
first tissue-scale, patient-specific simulations of prostate cancer growth over the organ
anatomy extracted from medical images. Our results show similar tumor progression as
observed in clinical practice.
We leverage isogeometric analysis to handle the nonlinearity of our set of equations,
as well as the complex anatomy of the prostate and the intricate tumoral morphologies.
We further advocate dynamical mesh adaptivity to speed up calculations, rationalize
computational resources, and facilitate simulation in a clinically relevant time. We
present a set of efficient algorithms to accommodate local h-refinement and h-coarsening
of hierarchical splines in isogeometric analysis. Our methods are based on Bézier
projection, which we extend to hierarchical spline spaces. We also introduce a balance
parameter to control the overlapping of basis functions across the levels of the hierarchy,
leading to improved numerical conditioning. Our simulations of cancer growth show
remarkable accuracy with very few degrees of freedom in comparison to the uniform
mesh that the same simulation would require.
Finally, we study the interaction between prostate cancer and benign prostatic hyperplasia,
another common prostate pathology that causes the organ to gradually enlarge. In
particular, we investigate why tumors originating in larger prostates present favorable
pathological features. We perform a qualitative simulation study by extending our
mathematical model of prostate cancer growth to include the equations of mechanical
equilibrium and the coupling terms between them and tumor dynamics. We assume that
the deformation of the prostate is a quasistatic phenomenon and we model prostatic tissue
as a linear elastic, heterogeneous, isotropic material. This model is calibrated by studying
the deformation caused by either disease independently. Our simulations show that a
history of benign prostatic hyperplasia creates mechanical stress fields in the prostate that
hamper prostatic tumor growth and limit its invasiveness.
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Resumen
El cáncer de próstata es un gran problema de salud en hombres de edad avanzada en
todo el mundo. Esta patología es más fácil de curar en sus estadios iniciales, cuando
aún es órgano-confinada. Sin embargo, casi nunca produce ningún síntoma hasta que es
demasiado grande o ha invadido otros tejidos. Por tanto, el enfoque actual para combatir
el cáncer de próstata es una combinación de prevención y exámenes rutinarios para una
detección precoz. De hecho, la mayoría de casos de cáncer de próstata son diagnosticados
y tratados cuando aún está localizado dentro del órgano. A pesar de la riqueza del
conocimiento acumulado sobre las bases biológicas y la gestión clínica de la enfermedad,
carecemos de un modelo teórico completo en el que podamos organizar y comprender
la enorme cantidad de datos existentes sobre el cáncer de próstata. Además, la práctica
clínica estándar en oncología está basada en gran medida en patrones estadísticos, lo
cual no es suficientemente preciso para individualizar el diagnóstico, la predicción de la
prognosis, el tratamiento y el seguimiento.
Recientemente, la modelización y la simulación matemáticas del cáncer y sus trata-
mientos han permitido predecir resultados clínicos y el diseño de terapias óptimas de
forma personalizada. Esta nueva corriente de investigación médica se ha denominado
oncología matemática. El cáncer de próstata es un candidato ideal para beneficiarse de
esta tecnología por varios motivos. En primer lugar, un enfoque clínico personalizado
podría contribuir a reducir las tasas de tratamiento excesivo o insuficiente de cáncer de
próstata. La resonancia magnética multiparamétrica se usa cada vez más para monitorizar
y diagnosticar esta enfermedad. Esta tecnología de imagen puede proporcionar abundante
información para construir un modelo matemático de crecimiento de cáncer de próstata
personalizado. Además, la próstata es un órgano suficientemente pequeño para perseguir
la realización de simulaciones predictivas a escala tisular. El crecimiento del cáncer de
próstata también se puede estimar usando la concentración en sangre de un biomarcador
conocido como el antígeno prostático específico. Adicionalmente, algunos pacientes de
cáncer de próstata no reciben tratamiento pero son monitorizados clínicamente y se les
toman imágenes médicas periódicamente, lo que abre la puerta a la validación in vivo de
modelos. El desarrollo de tecnologías versátiles y potentes en mecánica computacional
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permite hacer frente a los retos derivados de la anatomía prostática y la resolución de los
modelos matemáticos. Finalmente, las tecnologías de oncología matemática pueden guiar
las investigaciones futuras sobre cáncer de próstata, por ejemplo, proponiendo nuevas
estrategias de tratamiento o descubriendo mecanismos involucrados en el crecimiento
tumoral.
Por tanto, el objeto de esta tesis es proporcionar un marco computacional para la mo-
delización y simulación del crecimiento del cáncer de próstata órgano-confinado de
forma personalizada y a escala tisular dentro del contexto de la oncología matemática.
Presentamos un modelo de crecimiento de cáncer de próstata localizado que reproduce
los patrones de crecimiento de la enfermedad observados en estudios experimentales y
clínicos. Para capturar las dinámicas acopladas de los tejidos sano y tumoral, usamos el
método de campo de fase junto con ecuaciones de reacción-difusión para el consumo
de nutriente y la producción de antígeno prostático específico. Empleamos este modelo
para realizar las primeras simulaciones personalizadas a escala tisular del crecimiento de
cáncer de próstata sobre la anatomía del órgano extraída de imágenes médicas. Nuestros
resultados muestran una progresión tumoral similar a la observada en la práctica clínica.
Utilizamos el análisis isogeométrico para resolver la no-linealidad de nuestro sistema de
ecuaciones, así como la compleja anatomía de la próstata y las intricadas morfologías
tumorales. Adicionalmente, proponemos el uso de adaptatividad dinámica de malla para
acelerar los cálculos, racionalizar los recursos computacionales y facilitar la simulación en
un tiempo clínicamente relevante. Presentamos un conjunto de algoritmos eficientes para
introducir el refinamiento y el engrosado locales tipo h en análisis isogeométrico. Nuestros
métodos están basados en la proyección de Bézier, que extendemos a los espacios de
splines jerárquicas. También introducimos un parámetro de balance para controlar la
superposición de funciones de base a través de los niveles de la jerarquía, lo cual conduce
a un condicionamiento numérico mejorado. Nuestras simulaciones de crecimiento de
cáncer muestran una notable precisión con muy pocos grados de libertad en comparación
con la malla uniforme que la misma simulación requeriría.
Finalmente, estudiamos la interacción entre el cáncer de próstata y la hiperplasia benigna
de próstata, otra patología prostática común que hace crecer al órgano gradualmente. En
particular, investigamos por qué los tumores que se originan en próstatas más grandes
presentan características patológicas favorables. Realizamos un estudio de simulación
cualitativo extendiendo nuestro modelo matemático de crecimiento de cáncer de próstata
para incluir las ecuaciones de equilibrio mecánico y los términos de acoplamiento entre
estas y la dinámica tumoral. Asumimos que la deformación de la próstata es un fenómeno
cuasiestático y modelamos el tejido prostático como un material elástico lineal, hete-
rogéneo e isotrópico. Este modelo es calibrado estudiando la deformación causada por
cada enfermedad independientemente. Nuestras simulaciones muestran que un historial
de hiperplasia benigna de próstata crea campos de tensión mecánica en la próstata que
obstaculizan el crecimiento del cáncer de próstata y limitan su invasividad.
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Resumo
O cancro de próstata é un gran problema de saúde en homes de idade avanzada en todo
o mundo. Esta patoloxía é máis fácil de curar nos seus estadios iniciais, cando aínda
é órgano-confinada. Porén, case nunca produce ningún síntoma ata que é demasiado
grande ou ten invadido outros tecidos. Polo tanto, o enfoque actual para combater o
cancro de próstata é unha combinación de prevención e exames rutinarios para unha
detección precoz. De feito, a maioría de casos de cancro de próstata son diagnosticados e
tratados cando aínda está localizado dentro do órgano. Malia a riqueza do coñecemento
acumulado sobre as bases biolóxicas e a xestión clínica da doenza, carecemos dun modelo
teórico completo no que podamos organizar e comprender a enorme cantidade de datos
existentes sobre o cancro de próstata. Ademais, a práctica clínica estándar en oncoloxía
está baseada en gran medida en patróns estatísticos, o cal non é suficientemente preciso
para individualizar a diagnose, a predición da prognose, o tratamento e o seguimento.
Recentemente, a modelización e a simulación matemáticas do cancro e os seus trata-
mentos permitiron predicir resultados clínicos e o deseño de terapias óptimas de forma
personalizada. Esta nova corrente de investigación médica denomínase oncoloxía mate-
mática. O cancro de próstata é un candidato ideal para beneficiarse desta tecnoloxía por
varios motivos. En primeiro lugar, un enfoque clínico personalizado podería contribuír a
reducir as taxas de tratamento excesivo ou insuficiente de cancro de próstata. A resonancia
magnética multiparamétrica úsase cada vez máis para monitorizar e diagnosticar esta
enfermidade. Esta tecnoloxía de imaxe pode proporcionar abundante información para
construír un modelo matemático de crecemento de cancro de próstata personalizado.
Ademais, a próstata é un órgano suficientemente pequeno para perseguir a realización
de simulacións preditivas a escala tisular. O crecemento do cancro de próstata tamén
se pode estimar usando a concentración en sangue dun biomarcador coñecido como o
antíxeno prostático específico. Adicionalmente, algúns pacientes de cancro de próstata
non reciben tratamento pero son monitorizados clinicamente e se lles toman imaxes
médicas periodicamente, o que abre a porta á validación in vivo de modelos. O desenvol-
vemento de tecnoloxías versátiles e potentes en mecánica computacional permite facer
fronte aos retos derivados da anatomía prostática e a resolución dos modelos matemáticos.
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Finalmente, as tecnoloxías de oncoloxía matemática poden guiar as investigacións futuras
sobre cancro de próstata, por exemplo, propoñendo novas estratexias de tratamento ou
descubrindo mecanismos involucrados no crecemento tumoral.
Polo tanto, o obxecto desta tese é proporcionar un marco computacional para a mode-
lización e simulación do crecemento do cancro de próstata órgano-confinado de forma
personalizada e a escala tisular dentro do contexto da oncoloxía matemática. Presentamos
un modelo de crecemento de cancro de próstata localizado que reproduce os patróns de
crecemento da enfermidade observados en estudos experimentais e clínicos. Para capturar
as dinámicas acopladas dos tecidos san e tumoral, usamos o método de campo de fase
xunto con ecuacións de reacción-difusión para o consumo de nutriente e a produción
de antíxeno prostático específico. Empregamos este modelo para realizar as primeiras
simulacións personalizadas a escala tisular do crecemento de cancro de próstata sobre
a anatomía do órgano extraída de imaxes médicas. Os nosos resultados amosan unha
progresión tumoral similar á observada na práctica clínica.
Utilizamos a análise isoxeométrica para resolver a non-linealidade do noso sistema
de ecuacións, así como a complexa anatomía da próstata e as intricadas morfoloxías
tumorais. Adicionalmente, propoñemos o uso de adaptatividade dinámica de malla para
acelerar os cálculos, racionalizar os recursos computacionais e facilitar a simulación nun
tempo clinicamente relevante. Presentamos un conxunto de algoritmos eficientes para
introducir o refinamento e o engrosado locais tipo h en análise isoxeométrica. Os nosos
métodos están baseados na proxección de Bézier, que estendemos aos espazos de splines
xerárquicas. Tamén introducimos un parámetro de balance para controlar a superposición
de funcións de base a través dos niveis da xerarquía, o cal conduce a un condicionamento
numérico mellorado. As nosas simulacións de crecemento de cancro amosan unha notable
precisión con moi poucos graos de liberdade en comparación coa malla uniforme que a
mesma simulación requiriría.
Finalmente, estudamos a interacción entre o cancro de próstata e a hiperplasia benigna
de próstata, outra patoloxía prostática común que fai crecer ao órgano gradualmente. En
particular, investigamos por que os tumores que se orixinan en próstatas máis grandes
presentan características patolóxicas favorables. Realizamos un estudo de simulación
cualitativo estendendo o noso modelo matemático de crecemento de cancro de próstata
para incluír as ecuacións de equilibrio mecánico e os termos de acoplamento entre estas e
a dinámica tumoral. Asumimos que a deformación da próstata é un fenómeno cuasies-
tático e modelamos o tecido prostático como un material elástico lineal, heteroxéneo e
isotrópico. Este modelo é calibrado estudando a deformación causada por cada enfermi-
dade independientemente. As nosas simulacións amosan que un historial de hiperplasia
benigna de próstata crea campos de tensión mecánica na próstata que obstaculizan o
crecemento do cancro de próstata e limitan a súa invasividade.
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According to the World Health Organization (WHO), prostate cancer (PCa) is the second
most common cancer and the fifth leading cause of death from cancer among men
worldwide [89]. The data are revealing: in 2012, there was an estimate of 1,095,000
new cases and 308,000 deaths worldwide associated with this cancer and it will be
responsible for about 161,360 new cases and 26,730 deaths only in the U.S.A. in 2017
[5]. Additionally, national epidemiologic studies in Spain revealed an estimate of 33,370
new PCa cases in 2015 and 5,855 deaths from this disease in 2014 [96, 224].
In most cases, PCa is an adenocarcinoma, a form of cancer that originates and develops
in epithelial tissues with glandular organization, for example, the prostatic tissue in
charge of producing certain substances in semen [259, 265]. Adenocarcinomas arise as
a result of genetic alterations in cell nuclei, such as mutations and epigenetic changes.
Additionally, the influence of several environmental factors, such as diet, may promote
further modifications of the genome. Tumoral cells exhibit an aberrant and competitive
behavior, characterized by overproliferation and an invasive demeanor. Consequently,
they may endanger the structure and the normal operation of the tissue they belong to,
eventually jeopardizing the survival of the whole organism. The same tumor may present
different groups of cancerous cells, with different metabolism, local environment and
aggressiveness. Malignant cells may evolve during their life cycle, and thus belong to
a new group. The structure, behavior and evolution of a tumor depend on the specific
genetic alterations that may have originated it and supported its evolution [3].
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The development of a prostate adenocarcinoma requires a gradual accumulation of
mutations in a number of different genes, which varies from patient to patient, but is
usually at least seven [259, 265]. Thus, PCa is more frequent among older men. As
a result of these alterations of the genome over years, an initial moderate disorder of
cell behavior evolves gradually towards an advanced cancer. As the tumor develops, it
becomes more malignant and cell differentiation decreases. This evolutive phenomenon is
called tumor progression and, in general, comprises four steps: (1) local overproliferation
of cells, (2) extensive overproliferation of cells, (3) invasion of the surrounding tissues
and, finally, (4) metastasis, which is the process whereby some malignant cells escape
from the original tumor, enter the bloodstream and migrate to other tissue, which they
invade and colonize [3, 259, 265].
Medical practice for PCa has been developed upon the aforementioned genetic and
biological bases as well as on the accumulated experience of physicians treating this
disease [259, 265]. The current medical protocols include all these sources of knowledge
on PCa in the form of statistics for the probability of cancer stage and treatment success.
In brief, PCa is easier to cure in its early stages, before it becomes excessively aggressive
and spreads out of the prostate but, unfortunately, this disease hardly ever produces any
symptom until the tumor is either very large or has invaded other tissues. Therefore,
the best way to combat PCa is a combination of prevention and regular screening for
early detection. PCa is usually diagnosed and treated when it is still localized within the
prostate. Localized PCa is usually managed with a curative approach such as surgery
or radiotherapy, while advanced PCa is normally addressed with palliative strategies
based on hormonal therapy or chemotherapy. Patients with low-risk PCa may delay their
treatment until the tumor reaches an optimal stage (active surveillance). Patients that are
not eligible for local curative treatment, or those with a short life expectancy, may benefit
from a deferred palliative treatment, aimed at tackling specific symptoms of the disease,
while they continue on regular screening (watchful waiting).
Apart from PCa, the prostate is also the site of other major pathology affecting older men:
benign prostatic hyperplasia (BPH) [259, 265]. This disease consists of the pathological
enlargement of the prostate with age, with a prevalence increasing from 50% in men
in their fifties to about 70% in men in their seventies [26]. BPH obstructs urinary and
ejaculatory flow, hence causing bothersome lower-urinary tract symptoms. PCa and BPH
may coexist in the same patient and share numerous similarities [4, 191, 265], which
have suggested several connections or some interplay between them. However, solid
evidence confirming their existence is lacking. Recent studies on extensive series of
surgical prostate specimens have shown that tumors originating in larger prostates present
favorable pathological features [36, 55, 92, 126, 145, 184]. These studies provide solid
evidence to suggest that large prostates may exert a protective effect against PCa.
Biologists and physicians are actively engaged in the study of PCa in an attempt to shed
light on the intricate molecular, biological and physiological mechanisms that explain
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how tumors originate, grow, and spread within the body, also analyzing new options for
PCa treatment. Despite the number of experimental and clinical investigations, we lack a
comprehensive theoretical model into which all this abundance of data can be understood
and organized, also guiding future research efforts efficiently so as to enrich such model.
The emphasis of these investigations, as well as the standard clinical practice in oncology,
are based on statistical patterns, which is not sufficiently accurate for individualized
diagnosis, estimation of prognosis, treatment, and follow-up.
Alternatively, predictive medicine [231, 232] is an interdisciplinary approach whose
aims are the determination of patient-specific disease progression and optimal treatment.
Methods of predictive medicine are based on mathematical modeling and computer
simulation of both the disease and treatments. This new approach complements the
statistical and experiential basis of diagnosis and treatment planning, which constitute
current medical practice. In the particular case of cancer research, mathematical oncology
[7, 53, 97, 188, 274] is a new and promising field devoted to the development of models
and computational tools to simulate tumor growth and cancer treatment. Although
significant progress has been made in recent decades, accurately modeling the growth of
cancerous tumors remains an outstanding challenge [7, 9, 42, 52, 53, 97, 160, 167, 170,
174, 188, 206, 211, 212, 236, 251, 274].
The nonlinearity that usually characterizes the set of equations comprising tumor growth
models, the complex geometry of patient-specific anatomical models, and the intricate
morpohologies that growing tumors may exhibit demand very efficient methods of res-
olution in terms of memory and time of computation. Isogeometric analysis (IGA) is
a rapidly growing and cutting-edge technology that can handle all these computational
challenges [66, 130]. IGA can be seen as a generalization of the classic Finite Ele-
ment Analysis (FEA) [132]. Instead of using standard piecewise polynomials, IGA
leverages richer functions coming from computer graphics and computational geometry,
such as B-splines [66, 84, 130, 195, 204], Non-Uniform Rational B-splines (NURBS)
[66, 84, 130, 195, 204], and T-splines [18, 21, 22, 154]. Isogeometric methods based on
these functional spaces are geometrically exact, provide enhanced accuracy per degree of
freedom, and enable higher global continuity (Cp−1 for spline spaces with polynomial
degree p) [1, 66]. Additionally, IGA is compatible with dynamic mesh-adaptivity tech-
niques based on the concept of hierarchical refinement and coarsening [215, 219, 257],
which enables the local adaptation of the computational mesh dynamically throughout the
simulation. Hence, the mesh features finer elements with richer approximation functions
close to the tumor, and coarser elements elsewhere. This leads to dramatic savings of
memory and compute time. Thus, dynamic mesh-adaptivity techniques hold the potential
to speed up the calculations and create isogeometric methods that facilitate obtaining
solutions in a clinically relevant time.
PCa has received relatively little attention from the mathematical oncology community
[122, 133, 135, 136, 149, 176, 277]. However, PCa may be an ideal candidate to explore
3
1 · Introduction
tissue-scale, patient-specific modeling of cancer growth for several reasons:
• PCa is a major health problem, and a paradigmatic example in which a predictive
model could make a difference in clinical practice because there are currently many
patients being overtreated and undertreated [164, 260].
• Medical imaging is emerging as a diagnostic tool in PCa. Medical imaging is not
widely used in PCa diagnosis due to insufficient confidence in current imaging
modalities. However, multiparametric magnetic resonance (mpMR) imaging is
commonly used to monitor the evolution of the disesase and is emerging as a
promising technology that might be also used for PCa diagnosis [51, 75, 87, 111,
116, 123, 153, 227, 238].
• The prostate is a small organ, typically between 20 and 80 cc [24, 26, 31, 259, 265,
270], so it is feasible to create a patient-specific anatomical model of the prostate
from medical images to perform predictive simulations.
• The growth of the tumor in a given patient may be estimated using the concentration
of a PCa biomarker known as prostate specific antigen (PSA), which is measured
with a blood test and plays a crucial role during the diagnosis, treatment selection,
and follow-up of the patients [253, 254, 259, 265].
• Some PCa patients do not receive any treatment but have their PSA monitored
and are periodically imaged, for instance, during the time between diagnosis and
treatment or in active surveillance and watchful waiting protocols. This potentially
may open the door to in vivo model validation [261, 274].
• IGA provides a rich computational framework that guarantees the required accuracy
and efficiency to perform predictive tissue-scale, patient-specific simulations of
PCa growth.
• Mathematical oncology is also a promising approach to investigate the relationship
between PCa and BPH because it can provide solid mechanisms of interaction to
explain the current evidence and to guide further clinical research.
1.2 Research objectives
The main aim of this thesis is to provide a computational framework for the tissue-scale,
patient-specific modeling and simulation of organ-confined PCa growth within the context
of mathematical oncology. This general goal can be subdivided in a number of more
specific research objectives, which are summarized in the following points:
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u Definition of a computational framework for the clinical management of PCa.
Our first objective will be to devise a framework for the clinical management of
PCa in which the technologies of mathematical oncology complement the standard
medical protocols for this condition. For this purpose, we reviewed the current
knowledge on the biological basis of prostatic tumors, the standard procedures
in the clinical management of PCa, and the recent developments in mathematical
modeling and simulation of tumor growth. We also reviewed the current and
developing technologies of medical imaging for PCa because they provide a wealth
of patient-specific data to inform a computational tool for the prediction of tumor
growth.
u Design of a tissue-scale, patient-specific mathematical model of PCa growth.
We aim at defining a tissue-scale, patient-specific mathematical model to describe
localized PCa growth, for this is the stage at which it is normally diagnosed and
treated. The definition of the model will be based on the current biological and
medical knowledge of this condition. We will identify and mathematically and
physically describe the fundamental mechanisms that enable the construction of
a model for prostatic tumor growth. We will require the model to capture the
coupled dynamics of healthy and tumoral tissue and to describe the patient’s PSA
dynamics. Additionally, we will study the incorporation of the dynamics of other
key substances in PCa growth to the model.
u Development and implementation of algorithms to solve the equations in the
model and construct patient-specific prostate meshes. To perform numerical
simulations, we will develop algorithms based on the concept of IGA. This is
an ideal technology to handle the nonlinearity that characterizes tumor growth
problems, the complex anatomy of the prostate, and the intricate morphologies
of PCa in an efficient and accurate manner. We will also explore dynamic mesh
adaptivity techniques based on hierarchical spline spaces to rationalize the required
computational resources, speed up the calculations, and create a clinically relevant
technology. We will utilize our own libraries or available packages (e.g.: Trilinos
[120], PETSc [12], PetIGA [70]) together with message passing interface (MPI)
to obtain a powerful and flexible parallel implementation of our algorithms. A
computational approach for the tissue-scale, patient-specific prediction of PCa
growth requires an accurate mesh of the patient’s prostate. Hence, we will also
develop an algorithm to extract a NURBS mesh from the patient’s medical images,
such as computed tomography (CT) and magnetic resonance (MR) images. This
mesh can be globally and/or locally refined afterwards to perform simulations with
a good level of accuracy.
u Extension of the model to include the mechanical deformation of the prostate
caused by the growing tumor and BPH. PCa and BPH are major genitourinary
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diseases that may coexist in the same patient and deform the prostate over time.
The idea is to couple our mathematical model for PCa growth with the equations
of mechanical equilibrium in order to compute the displacement and stress fields
created by the growing tumor and BPH. We will also introduce a term in the
equation describing tumor dynamics to account for the inhibitory effect of the
stress fields generated by PCa and BPH. Leveraging this mechanically-coupled
model, we will study the deformation of the prostate induced by PCa and BPH
both independently and simultaneously. We will also utilize this model to analyze
how the deformational state of the prostate affects tumor growth and investigate
why larger prostates are less prone to tumors showing an aggressive demeanor and
adverse pathological features. Additionally, we will discuss several applications of
a mechanically-coupled model within a computational framework for the clinical
management of PCa.
u Calibration of the model and numerical methods to reproduce PCa growth
as observed in clinical practice efficiently and accurately. We will analyze the
value range of the parameters in the equations of our mathematical models and
numerical methods in order to reproduce the growth morphologies and clinical
features that characterize PCa growth in medical practice in an accurate and efficient
manner.
1.3 Thesis overview
Following this introduction, Chapter 2 presents a brief review of the current knowledge
that provided the basis for the research work presented herein, from the biological
mechanisms and clinical management of PCa to the latest advances in mathematical
modeling of cancer and IGA.
In Chapter 3, we present a continuous model that reproduces the growth patterns of
localized PCa, as this is the stage at which most prostatic tumors are diagnosed and
treated. This model reproduces the common clinical morphologies of PCa and the
transition between them based on nutrient availability and tumor metabolism. We also
used our model to perform the first tissue-scale, patient-specific simulation of PCa growth
based on a patient’s prostatic anatomy extracted from CT images.
Our model for PCa growth describes the coupled dynamics of healthy and tumoral
tissue as a moving interface problem by means of the phase-field method. This sort of
problems is ubiquitous in science and engineering. To develop an accurate and efficient
methodology to address them, in Chapter 4 we present a set of algorithms for local
h-adaptivity of hierarchical splines to be utilized in IGA. We analyze the performance
of our algorithms in a variety of simulation scenarios using our PCa model, including
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simple 2D and 3D domains as well as a more compelling tissue-scale, patient-specific
simulation.
In Chapter 5, we extend our model of PCa growth to include the equations of mechanical
equilibrium and define the coupling terms between them and tumor dynamics. We use
this mechanically-coupled model to explore the prostate deformation and the inhibition
of prostatic tumor growth due to mechanical stress fields caused by both the tumor and
BPH. This study provided a feasible mechanism to explain an unresolved clinical debate:
why tumors developing in larger prostates tend to be less aggressive.
Finally, in Chapter 6 we present a summary and the conclusions of this thesis, as well as
some future lines of research that originate from the work presented herein. At the end of
this document, the reader will find a list of publications that resulted from the work in






2.1 The fundamentals of cancer
With the generic name of cancer we refer to a vast host of diseases [3]. The different types
of cancer are classified and named depending on the type of cell within each tissue of our
body that brings forth the condition. The most common group of cancers in human beings
are carcinomas, which originate in epithelial tissues, i.e., those tissues that internally
line the organs, cavities, and ducts in our body. Other common types of cancer are:
melanomas, which originate in skin cells; lymphomas and leukimias, which are derived
from blood cells or their precursors; sarcomas, which originate in the cells that constitute
connective tissues and muscles; and cancers derived from cells of the nervous system,
such as glioma and glioblastoma multiforme.
Tumors originate and develop due to the progressive accumulation of genetic alterations
within cells’ nuclei. These alterations can be classified in two groups: mutations, which
are irreversible modifications of DNA, and epigenetic changes, which are alterations of
the expression of the genome without modifying DNA. Some mutations can be inherited
from the progenitors, but normally the genetic alterations that give birth to a tumor appear
randomly during a person’s lifetime due to errors in DNA replication or exposition to
carcinogens. Several external factors can promote these genetic alterations, such as diet,
lifestyle, and the individual’s environment. Certain viruses may also contribute to the
development of some tumors, for instance, the human papillomavirus can cause cervical
cancer. There exist molecular mechanisms codified in DNA that enable cells to control
the quality of their genome, to detect genetic alterations, and to induce cell suicide, or
9
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apoptosis, to avoid the propagation of genetic errors if necessary. However, some genetic
alterations might escape this control process and some of them may even confer the
cancerous cell the ability to avoid this DNA quality control mechanisms.
Cancerous cells present an asocial and competitive behavior within the organized cellular
architecture of the tissues in our body. This demeanor is characterized by a high rate
of net proliferation and invasiveness (see Fig. 2.1). Most of the tissues of our body
undergo continuous cell turnover under a rigorous balance between cell division and
cell death. The increase in the net proliferation cell in tumors can be caused by genetic
alterations that produce a direct increment in cell proliferation, a reduction in cell death
rate, or a combination of both. A deficient DNA quality control combined with a high net
proliferation rate promotes the gradual accumulation of more mutations and epigenetic
changes. Hence, this genetic drift contributes to increase the aggressiveness of cancer
and grants cancerous cells other abilities that characterize them (see Fig. 2.1), such as
conveniently adjusting their metabolism, resisting the attacks from the body immune
system, enabling replicative immortality, promoting favorable tumor environment (e.g.:
inflammation), and promote the formation of new blood vessels to nourish the tumor, a
process called angiogenesis [112, 113].
Angiogenesis begins in a situation of hypoxia, which is characterized by a low con-
centration of oxygen and nutrients that limits tumor growth. In such situation, tumor
cells produce a proangiogenic factor. This substance activates the tip endothelial cells
present in neighboring blood vessels, which change their quiescent phenotype to become
migratory. These cells begin their migration guided by chemotactic mechanisms towards
hypoxic regions and creating new capillaries as they advance. The incipient blood vessels
grow by cell proliferation and connect among themselves in order to bring forth a vascular
network that supplies oxygen and nutrients to the hypoxic cancerous cells, hence favoring
tumor growth [45].
Some malignant cells may acquire the ability to leave the tumor, enter the blood or
lymphatic vessels, migrate to other place in the body and create a secondary tumor
or metastasis. The ability to colonize a different tissue and thrive in it requires the
alteration of certain genes too. Additionally, angiogenesis creates capillaries with different
diameters, multiple branches, and high permeability, which might constitute an entrance to
the bloodstream for these independent cells. Thus, tumor growth does not only jeopardize
the structure and function of the organ where it originates, but might also endanger other
tissues in our body.
Most solid tumors go through four differentiated stages of growth, namely: local prolifera-
tion, extensive proliferation confined to the original tissue, invasion of nearby tissues, and
metastasis. The advance from one stage to the next one is motivated by the progressive
acquisition of advantageous abilities and the generation of a local environment that enable
the tumor to break the barriers that limit its growth and development.
10
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Figure 2.1. The hallmarks of cancer. This figure illustrates the characteristic capabilities of growing
cancers and examples of therapeutic drugs that have been developed to combat them. Reproduced from [112].
Therefore, tumor growth takes place at different spatial scales, from the initial proliferative
mass, measured in microns, to metastatic stage, featuring several tumor masses of various
millimeters or centimeters. As shown in Fig. 2.2, the processes involved in tumor growth
also occur at very different spatial scales: subcellular, such as mutations and metabolism;
cellular, such as cell division and intercellular adhesion; tissue, such as angiogenesis
and invasion; and corporal, such as metastasis. Additionally, the time scales of these
processes span several orders of magnitude (see Fig. 2.2). While cell metabolism takes
place in fractions of a second, cell division may take hours, and the invasion of tissues
prolongs over months or even years. The variability of the spatial and time scales of the
processes involved in tumor growth is one of the central challenges to study cancer.
Another great difficulty to research these pathologies is that the number and type of
genetic alterations that originate the same type of tumor varies from one patient to another.
Furthermore, a tumor may present several groups of cancerous cells with varying profiles
of genetic alteration, which translate into differences in metabolism, local environment,
and invasiveness. During tumor growth, these malignant cellular species may compete
and evolve throughout successive cycles of genetic alteration and clonal selection. The
11
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Figure 2.2. The spatial and time scales of cancer. The biological and physiological processes involved
in tumor growth span a wide range of spatial and time scales. This is one of the central challenges to investigate
these pathologies. Adapted from [167].
different tumor cellular types can also collaborate via cell specialization. In any case,
the structure, global behavior, and evolution of a tumor depend on the genetic alterations
that originated it and supported its development. For a thorough review on the biological
bases of cancer, the interested reader is referred to references [3, 45, 112, 113].
2.2 The prostate
2.2.1 Anatomy of the prostate
The prostate is a tiny gland, whose volume is approximately 20 cc in healthy men
[26, 259, 265]. It lies in the intersection of men’s urinary and reproductive tracts, deeply
confined in the pelvic area (see Fig. 2.3). Consequently, the prostate is surrounded by
vulnerable structures, such as the bladder, the rectum, the sphincters, several arteries
and veins, and a host of delicate nerves. The prostate is often described as an inverted
pyramidal body that surrounds the urethra from its base at the bladder wall to its apex in
contact with the membranous urethra. Though this organ has a capsule that protects it,
the prostate is still poorly insulated [259, 265].
The prostate is an heterogeneous organ composed of approximately 70% glandular
epithelium and 30% fibromuscular stroma. Hence, the cells that configurate the prostate
can be of two different types: epithelial cells, which are glandular cells that produce
certain secretions, or stromal cells, that is, muscular cells that hold the former in place
and may release some growth factors that play a role in the development of the prostate,
but also in some major prostatic diseases. The prostatic glands are connected by hundreds
of ducts that transport the fluids that they elaborate toward the urethra.
12
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Figure 2.3. Anatomic location of the prostate. The prostate is a tiny organ placed deeply within
the pelvic area at the intersection of the male urinary and reproductive tracts. It is surrounded by several
delicate organs and tissues, as shown in this figure. Provided by the National Cancer Institute of the USA at
https://visualsonline.cancer.gov/. Creator: Alan Hoofring (Illustrator).
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Figure 2.4. Local anatomy of the prostate. ED: ejaculatory ducts; SV: seminal vesicles; AFS: anterior
fibromuscular stroma. The periurethral glands surround the proximal part of the prostatic urethra. Reproduced
from [28].
From an histological perspective, the prostate is divided into five anatomical regions:
peripheral zone (PZ), transition zone, central zone, anterior fibromuscular stroma, and
periurethral glands [62, 252, 259, 265]. These zones are depicted in Fig. 2.4. While the
transition zone and the periurethral glands surround the proximal part of the prostatic
urethra, the central zone surrounds them and the ejaculatory ducts posterosuperiorly. In
turn, the PZ encloses the central zone and the distal prostatic urethra except anteriorly,
where there is a region of fibromuscular stroma. The glandular tissue of the prostate is
distributed among the PZ (70%), the central zone (25%), the transition zone (5%), and the
periurethral glands (<1%). The PZ and the transition zone are very similar histologically.
2.2.2 Physiology of the prostate
We call semen to the ejaculate which is made of sperm, made in the testes, and fluid,
which is composed by a number of substances made in the prostate and mostly in the
seminal vesicles [259, 265]. This fluid is the most abundant component of semen in terms
of volume.
In the prostate, the substances that contribute to the fluid part of semen are produced
in the glandular tissue. Then, the ductal network of the prostate takes these secretions
to the urethra, where they mix with sperm and other fluid components of semen. This
phenomenon of transport is promoted by the prostate muscles during orgasm. After
14
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admixture, semen is immediately pumped into the penis toward the exterior thanks to
muscular action through the final section of the male urinary tract.
These prostatic secretions sustain sperm to survive their trip and remain active as long as
possible. After ejaculation, the sperm immediately coagulates inside the vagina, lingering
therein to increase the odds of reproduction. After a certain lapse of time, the process of
breaking down again is due to the PSA, a prostatic enzyme with a major role in the the
clinical management of PCa. Infections in the reproductive tract can produce scar tissue
in the ducts that drain the testes, a situation that might cause infertility. The substances
produced in the prostate also protect the urinary tract and the reproductive system from
harmful bacteria or hazardous substances that may enter the urethra.
The prostate depends on hormones for its development, growth, and function. The hor-
monal activation of the prostate takes place during orgasm. First of all, the hypothalamus,
within the brain, produces the luteinizing hormone-releasing hormone. This hormone
travels to the nearby pituitary gland, where the luteinizing hormone is effectively pro-
duced. The luteinizing hormone controls the testes and once it reaches them, it boosts the
production of testosterone. This hormone is also produced in the adrenal glands, placed
on top of the kidneys. Testosterone is considered the chief male hormone because it is
the cause of fertility and secondary sex characteristics, such as body hair and deep voice.
Testosterone circulates in the bloodstream and, eventually, seeps into a prostate cell by
diffusion. Then, the combination of testosterone and an enzyme called 5-α reductase
gives raise to dihydrotestosterone. Finally, the combination of dihydrotestosterone and a
certain protein in prostatic cells’ nucleus activates the required genes that are behind the
production of the prostatic secretions.
2.2.3 Prostate pathologies
The prostate is the source of three major health problems in men: PCa, BPH, and
prostatitis [259, 265]. Indeed, the same man may endure more than one of these conditions
during his lifetime, even at the same time and more than once. However, a wide array of
treatments are available for these three diseases and continuous research is being carried
out to improve them and derive new alternatives, which aim at reducing the side effects
and optimizing both sensitivity and specificity.
Section 2.3 and Section 2.4 provide a review of the biological basis and the standard
clinical management of BPH and PCa, respectively. Prostatitis is the most common cause
of urinary tract infections in men and it is chiefly characterized for being significantly
painful [259, 265]. Almost half men in the world will experience its symptoms in their
lifetime. There are five types of prostatitis, namely: acute bacterial prostatitis, chronic
bacterial prostatitis, inflammatory prostatitis, non-inflammatory chronic prostatitis or
chronic pelvic pain syndrome, and asymptomatic prostatitis. Only the bacterial types
of prostatitis are caused by an infection. Inflammatory and non-inflammatory chronic
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prostatitis present similar symptoms to chronic bacterial prostatitis, but they are not
originated by a bacterial infection. Indeed, the origin of these variants of prostatitis is
not clear yet. Asymptomatic prostatitis produces no symptoms and is found by chance
during a biopsy or the examination of the removed tissue samples obtained in a surgical
procedure. This type of prostatitis is thought to be linked to the early stages of PCa.
2.3 Benign prostatic hyperplasia
2.3.1 Description
BPH consists of the pathological enlargement of the prostate with age, with a prevalence
increasing from 50% in men in their fifties to about 70% in men in their seventies
[26, 259, 265]. BPH may arise in the transition zone or the periurethral glands of the
prostate. This condition is caused by an imbalance between proliferation and programmed
cell death, which leads to an increase in cell number. The growing tissue constricts the
urethra and may obstruct urinary flow, hence causing bothersome lower-urinary tract
symptoms. The difference between a healthy prostate and and BPH is depicted in Fig. 2.5.
2.3.2 Origin
There is not a clear origin for the BPH [259, 265]. This condition has been associated with
the imbalance of androgens and estrogens that comes with aging, due to the empowering
effects of estrogens on testosterone and a decrease only in testosterone in older men.
Alternatively, growth factors have been also thought to be the cause of this disorder,
possibly those produced by the stromal cells in the prostate. These growth factors may
alter the normal life span of the prostatic cells. This results in a decrease in the cell
death rate with no variation in cell births, hence breaking the natural homeostatic balance
between both rates and provoking the abnormal growth.
Additionally, around 7% of men are prone to BPH due to certain inherited genes. Plus, a
series of genes seems to be altered both in BPH and PCa, so maybe there is a connection
between both diseases which worths investigating in order to shed light on the origin and
development of both disorders [4, 191, 259, 265].
2.3.3 Development
BPH is a different disease in every man depending on the shape of the abnormal growth,
the particular rate of participation of the tissues involved (epithelial and muscular), and
how these variables affect the bladder and even the kidneys [259, 265]. Initially, BPH
might be invisible because the powerful contractions of the bladder compensate the
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Figure 2.5. Benign prostatic hyperplasia. This pathology provokes the enlargement of the prostate,
which presses on the bladder and the urethra hence obstructing the flow of urine. Provided by the National
Cancer Institute of the USA at https://visualsonline.cancer.gov/.
urethral obstruction. As the disease develops, it may cause initial irritating but still
tolerable symptoms. However, when it progresses beyond a certain point of nuisance,
when the bladder is never empty or when the bladder and the kidneys become damaged,
it needs to be treated.
During BPH, the affected tissue grows developing bulbous nodules that form character-
istic clusters or lobes. The muscular tissue grows organizing its spatial configuration
according to the lobe growth. These lobes arrange themselves in three main configura-
tions: lateral lobe enlargement, which takes place at both sides of the urethra and causes
mild obstruction; middle lobe enlargement, which occurs around the bladder neck and
causes a great difficulty in urination; and trilobar enlargement, which is a combination of
both, i.e., obstruction takes place both around the urethra and the bladder neck.
Therefore, the common symptoms of BPH are related with obstruction of the urine
flow, namely: frequent urination, hesitancy, urgency, nocturia, unsteady urine flow and a
constant feeling of fullness in the bladder. Problems in urine flow may end up affecting
the bladder and, in the long run, even the kidneys. In particular, BPH forces the bladder
muscular tissue to exert more vigorous contractions in order to compensate the obstruction
of urine flow. This provokes the thickening and a loss of elasticity of the bladder muscle
tissue. Consequently, the bladder experiments a reduction in allowable liquid volume and
17
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becomes unstable and overly reactive, what usually leads to incontinence and nocturia.
2.3.4 Clinical management
2.3.4.1 Detection and diagnosis
The detection of BPH is based on digital rectal examination (DRE) and a PSA test [259,
265]. Because these two tests are the baseline of PCa screening, we will discuss them
in Section 2.4. The DRE relies on the experience of the physician performing it. False
negatives may be caused by the inner growth of the lobes, when they can’t be felt
by the doctor. The prostate size can also be measured more accurately with medical
imaging, such as ultrasounds (US) or MR. However, the degree of symptoms does not
only depend on the size of the prostate, but also on the particular type of BPH growth
(see Section 2.3.3).
As BPH does not develop in the PZ, the glandular prostate is segmented into two zones
in radiological studies: the PZ and the central gland (CG), which contains the central,
transition, and periurethral zones [62, 252, 265]. The PZ appears as an hyperintense
region in T2-weighted MR imaging due to the abundance of glandular components with
sparsely interwoven smooth muscle. As BPH develops, the central zone is increasingly
compressed until it becomes an almost imperceptible dark border that separates the PZ
and the CG. The CG has a larger and denser stromal component that becomes more
compact during BPH, what results in an overall lower signal intensity in T2-weighted
MR images. However, the signal intensity of the CG is usually rather heterogeneous due
to the varying proportions of stromal and glandular hyperplasia [62, 75, 186, 252, 265].
Additionally, the International Prostate Symptom Score (IPPS) aims at describing to
what extent BPH bothers each patient and helps in the choice of the best treatment. The
IPPS is comprised of eight questions that are graded by the patient. In particular, seven
questions describe the symptoms and one question about the quality of life due to urinary
symptoms. The patient’s medical history is also of major importance in the diagnosis of
BPH because many symptoms of this disease might be caused by other disorders, for
instance: an urethral stricture due to previous surgical procedures, urinary infections,
bladder cancer or even some neurological disorders.
Further tests for the diagnosis of BPH include uroflowmetry or urodynamic studies to
evaluate the urine flow, an analysis of the composition of the urine eliminated (conven-
tional urine test) or remaining in the bladder after urination (residual urine measurement),
and the evaluation of the organs of the urinary tract via US or cytoscopy. However,
any test involving the use of catheters or the cytosocope may be the source of urinary
infections.
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2.3.4.2 Treatment
There are three options for treating BPH [259, 265]:
• Watchful waiting: This option is only recommended for patients showing mild
symptoms of the disease. It consists of closely monitoring the evolution of BPH
and postpone treatment until the symptoms aggravate.
• Drug-based treatments: Patients with small prostates and moderate symptoms
are recommended alpha-blockers. These drugs act by relaxing the muscular tissue
in the prostate to relieve urinary obstruction. Patients with larger prostates are
normally treated with 5-α reductase inhibitors, which prevent testosterone from
converting into dihydrotestosterone. These drugs shrink the prostate and decrease
the obstructive symptoms, halting the progression of BPH. 5-α reductase inhibitors
do not alter the testosterone levels, so the patient’s libido is unaffected. However,
their effect is slow and gradual, they are mostly effective in large prostates, and
they may lower the PSA level artificially, hence causing a potential delay in the
detection of PCa. There exist combined approaches using both alpha blockers and
5-α reductase inhibitors, but they have been reported to alter PSA too and to have
controversial efficiency and accuracy.
• Surgery: Patients showing severe symptoms or no response to drug-based therapies
are recommended a transurethral resection of the prostate (TURP). This procedure
is performed under anesthesia and consists of the removal of excess tissue in the




Approximately 95% of PCa cases are adenocarcinomas, which originate in the glandular
cells that configure the prostate. Thus, we will only consider this kind of tumors in this
thesis. The remaining 5% of cases correspond to more rare variants of PCa, namely:
small-cell carcinoma, transitional-cell carcinoma, and sarcoma of the prostate [259, 265].
Prostatic adenocarcinomas mostly arise in the PZ and the transition zone, which account
for 70% and 20% of prostatic tumors, respectively. The remainder 10% of PCa cases
originate in the central zone. Transition zone tumors have been shown to have more




PCa is most likely caused by oxidative damage, i.e., the incremental damage to cell’s DNA
caused by a combination of inflammation and certain carcinogens and cancer-promoting
substances [259, 265]. Some of these substances are present directly in our diet or lifestyle,
while others may originate within our organism, for instance, free radicals resulting from
metabolism. Free radicals are highly reactive, unstable and electrically charged molecules
that can destroy tissue, melt membranes, and kill cells in an instant. Their role is to
eliminate bacteria and other foreign invaders of our organism but their levels are kept
low thanks to neutralization by scavenger enzymes and antioxidant nutrients within cells.
However, an overload of free radicals may overtake the scavenger enzymes abilities and
hence cause oxidative damage.
Inflammation can cause many types of cancer because it damages both cells and their
DNA. Inflammatory cells act in two ways: they produce harmful forms of oxygen and
nitrogen, which can mutate DNA directly, and they can injure healthy cells. This urges
the body to replace them quickly, thus contributing to initiate an event of rapid cell
proliferation during which replication mistakes may lead to the rising and propagation
of mutations and epigenetic changes. Hence, these events may lead to precancerous
stages. Scavenger enzymes also protect cells from the oxidative damage produced by
inflammation.
One of the most important beneficial enzymes against oxidative damage is called
glutathion-S-transferase-π (GST-π), whose job is to render free radicals into harm-
less, water-soluble products and provide toxic clean-up on a cellular level. This enzyme
is present in normal prostatic cells but not in precancerous or cancerous cells. Thus,
these cells are prone to experimenting further oxidative damage, which promotes cancer
progression.
Before PCa is effectively originated, the action of oxidative damage over time may lead
to precancerous stages that share a common feature: an abnormal proliferation of cells.
The specific precursor lesion of PCa is proliferative inflammatory atrophy (PIA), which
consists of hot spots of inflammation surrounded by areas of atrophy, that is, there are
cells that appear to be dying but they are actually proliferating rapidly. PIA lesions pave
the way for next precancerous stage: prostatic intraepithelial neoplasia (PIN), in which
the prostatic glands show a disorderly appearance but are not cancerous yet. Indeed, PIN
is the previous stage to PCa.
2.4.3 Development
Prostatic adenocarcinomas follow an evolution as outlined in Section 2.1. In brief, PCa
begins as a tiny highly proliferative mass of cells that grows in volume and competes for
space and nutrients with healthy cells. As the tumor grows, it progressively invades the
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healthy tissue in the prostate, normally within the anatomical zone where it originated.
Should the tumor grow close to the urethra it might cause lower-urinary tract symptoms
similar to those created by BPH. During tumor growth, new mutations and epigenetic
changes are accumulated in the cancerous tissue. This genetic drift increases the malig-
nancy of tumor cells, promoting their ability to conquer other tissues and conferring them
competing advantages over other cancerous species and healthy tissue. Aggressive PCa
can distort the internal tissue architecture of the prostate and invade other anatomical
zones and structures. As the prostate is poorly insulated, advanced PCa cells may escape
the organ and invade the capsule and the prostate bed, including the seminal vesicles,
the bladder, and local lymph nodes. The last stage of PCa involves the generation of
metastases typically in bones, lungs, lymph nodes, the liver, and the brain.
2.4.4 Risk factors
The main risk factors of PCa can be classified in five categories:
• Age: Oxidative damage is a gradual process. Additionally, mutations and epige-
netic changes must originate and propagate for a cancer to develop. It has been
estimated that 7 or 8 mutations are required for the onset and development of PCa,
an then, 10 to 12 years are needed from initiation to clinical presentation. Thus,
PCa is usually more frequent among older men.
• Family history: Approximately 25% men with PCa present family history of the
disease, which may be associated to environmental causes or the inheritance of
some genetic alterations. However, only 3-4% of them actually have hereditary
PCa, which involves a set of mutated genes that can be passed on by either parent.
Consequently, these men may develop PCa earlier, but it is as curable as regular
PCa.
• Diet: In general, diet can help preventing PCa by incrementing body’s defenses.
Additionally, an appropriate balance between calorie intake and exercise prevents
overweight and obesity, which have been proven to increase the risk of developing
PCa chiefly because of the larger amount of cells proliferating, the production
of fake low PSA levels, and more difficulty to correctly perform DRE. Some
elements of diet have been proven to contribute to PCa origin and evolution, such
as saturated fats (e.g.: meat, dairies) and hydrogenated or trans fats (e.g.: industrial
food). Conversely, polyunsaturated (e.g.: vegetable and fish oils, margarine, nuts
and seeds) and monounsaturated fats (e.g.: olive and canola oils) are beneficial for
the organism in general and for protection against PCa in particular. Low levels of
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• Race: Asian men present lower rates of PCa mostly due to their diet, which is rich
in vegetables, fruits, and natural antioxidants (soy, green tea). They also consume
less animal fats and do more exercise than western men. Additionally, Asian men
have been reported to be genetically protected against PCa. Conversely, black men
tend to develop more severe forms of PCa, experiment cancer recurrence, and die
from PCa. Several reasons have been pointed for this. We may highlight their
genetic susceptibility to PCa, the increased sensitivity of their prostate to hormones,
and their lower levels of vitamin D.
• Hormones: Hormonal supplements used to compensate the natural drop in a
man’s hormonal levels associated with age may boost PCa. Healthy men willing to
use them are recommended a previous complete examination for PCa and close
monitoring afterwards. These measures aim at preventing the early progression of
an undetected tumor and to closely follow these men, whose PSA levels may be
altered by some of these hormonal supplements.
2.4.5 Clinical management
A large body of research work is aimed at studying the biological mechanisms of PCa
growth and developing new strategies for detecting and eliminating prostatic tumors in a
more accurate and efficient manner [259, 265]. Due to the variety of factors that affect
the onset and development of PCa, statistical methods are leveraged to quantitatively
determine which of them have a significant role. Our current knowledge on PCa is based
on the experimental results and the statistical patterns that result from these investigations
as well as on the accumulated experience of the physicians treating the disease. Clinical
protocols translate this knowledge on the pathology to medical practice [63, 177, 181, 259,
260, 265]. These protocols include recommendations about PCa prevention, screening
strategies, a set of diagnostic variables, and recommendations for treatment and follow-up.
Patients are classified in risk groups according to certain clinical variables and each group
is assigned more specific protocols for treatment and follow-up. Fig. 2.6 summarizes the
current approach for the clinical management of PCa.
2.4.5.1 Prevention
Prevention of PCa is still a developing clinical strategy, with numerous ongoing research
projects. There are two basic approaches: chemoprevention and dietary prevention
[259, 265]. Chemoprevention consists of adding a drug or a dietary agent to our usual
regime in order to hinder cancer initiation or progression. Some examples are 5-α
reductase inhibitors (e.g.: finasteride, dutasteride), selenium, vitamin E, nonsteroidal
anti-inflammatory drugs (e.g.: aspirin, ibuprofen), statins, and zinc. Similarly, dietary
prevention consists of incorporating to our diet some food and drinks that are rich in
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substances that mitigate oxidative damage and strengthen the body’s defenses to obstruct
the development of cancer. In general, both balance and moderation are the key to dietary
prevention: excessive concentrations of some nutrients may be hazardous for other
organs in our body and a balanced diet avoids the lack of beneficial nurients, promotes
a synergistic effect from several cancer-fighting substances, and lowers the intake of
cancer-promoting nutrients. Reducing animal fat intake and increasing the consumption
of fruits and vegetables are widely accepted guidelines to prevent cancer. Soy, green
tea, red wine, carotenoids (e.g.: lycopene, vitamin A), cruciferous vegetables (e.g.: kale,
cauliflower, cabbage), and pomegranate juice have also been shown to prevent the onset
and progression of PCa. Nonetheless, research in dietary prevention is full of difficulties
because it does not only require determining the singular nutrient of interest in a certain
food, but also the appropriate dose and the frequency for an individual to benefit from it.
Additionally, regular exercise and reducing or avoiding the consumption of alcohol,
tobacco, and certain drugs contributes to minimize the risk of developing PCa. This way,
the presence of toxic substances in the organism is reduced and the defenses can focus on
other potential threats that may lead to developing cancer.
2.4.5.2 Screening and detection
PCa is easier to cure in its lower stages, before it gets excessively aggressive and spreads
out of the prostate. However, this disease hardly ever produces any symptom until the
tumor reaches such advance stage. The symptoms of PCa include urinary problems as
in BPH, less rigid erection, blood in urine or the ejaculate, impotence, decrease in the
volume of ejaculate, and pain in the back, pelvis, rectum, hips or thighs. However, some
of these symptoms can also be attributed to other pathologies in aging men, such as BPH,
prostatitis, arthritis, fybromialgia, or aging itself.
Nowadays, the best way to combat PCa is a combination of prevention and regular
screening for early detection [259, 260, 265]. This strategy facilitates the diagnosis
and treatment of PCa when it is localized in the prostate. Indeed, a wide variety of
treatments have been developed to effectively target and eliminate PCa in this stage.
Regular screening for PCa usually consists of a PSA test and a DRE, which are usually
performed periodically in men over age fifty.
Digital rectal examination
The DRE is a physical test in which the doctor palpates the rectal wall nearby the prostate
searching for unusual firm masses, as healthy prostates are normally compliant. The
accuracy of DRE largely depends on experience of the doctor performing it. Should the
DRE be inconclusive, physicians may recommend a complementary transrectal ultrasound
(TRUS).
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A DRE informs about the location and extension of PCa. This test can also tell if cancer
has spread out of the prostate into the pelvic side wall or the seminal vesicles. However,
the DRE misses the tumors out of the doctor’s finger reach, e.g., in the CG or anterior PZ,
tumors growing in naturally firmer prostates, and smaller tumors that may be aggressive.
Additionally, multifocal tumors are typical in PCa and they are also difficult to detect
with a DRE because the prostate feels uniformly firm, which may be confused with its
natural compliance.
PSA test
The PSA test is a blood test for measuring the serum level of this prostate activity
biomarker. The rationale for this test is that PSA usually rises during PCa growth because
the tumor blocks some parts of the prostatic ductal system and leaves glandular areas
unconnected with the urethra, so that prostatic secretions are leaked to the bloodstream.
A PSA test normally covers the array of tumor types that cannot be detected with a DRE.
The worldwide accepted threshold for the PSA level to begin further investigation for
potential PCa is 4.0 ng/mL. Some studies and clinical protocols recommend specific
thresholds according to patient age or race in order to focus on the diagnosis and effective
treatment of relevant PCa cases more efficiently [175, 189, 201].
However, PSA testing is a controversial issue in the urologic community [259, 265]. First,
PSA is prostate-specific, not cancer-specific: a higher level of PCa can be attributed to
other causes, such as BPH, a vigorous rectal exam, trauma to the prostate, a cytoscopy,
recent surgery for BPH, sexual activity, prostate biopsy, prostatitis, prostate infarction,
or even a mistake in the laboratory. Additionally, fake low PSA levels may come from
the treatment with 5-α reductase inhibitors, obesity or TURP, because of the removal of
prostatic glandular tissue during the surgery.
During the last three decades, alternative serum tests and PSA-based measurements have
been proposed with the aim to reduce overdetection and overtreatment of nonaggressive
PCa [63, 177, 181, 259, 265]. The most common ones are:
• Free and bound PSA: If PSA circulated in the blood in its native form, it could
be devastating every tissue it touched. However, once PSA leaves the prostate it
is bounded to a protective chemical case (bound PSA) or it can inactivate itself
(free PSA), so that it becomes chemically passive. The free PSA test is commonly
used to complement PCa screening, especially in men with PSA between 4 and 10
ng/mL. Low values of free PSA (<25% of total PSA) indicate that PSA is likely
to come from a significant and potentially aggressive PCa case [50, 190]. The
complexed PSA test measures bound PSA instead, but it is not common because it
does not provide the free PSA percentage directly.
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• PSA velocity: It is the rate of change from year to year in PSA. It normally requires
at least three PSA measurements obtained during a two-year period in order to
avoid the natural fluctuations of PSA. The rationale for this measurement is that
PCa cells double and produce PSA at a much faster rate than in BPH, so that the
yearly rate of increase in PSA is likely to be larger in PCa than in BPH. A consistent
increase greater than 0.75 ng/mL/y in patients with PSA>4 ng/mL or greater than
0.2-0.4 ng/mL/y in patients with PSA level 1-4 ng/mL might be attributed to PCa.
Similarly, the PSA doubling time provides the exponential increase in PSA over
time. While PSA velocity and doubling time may have a prognostic role in PCa
treatment, their diagnostic use is limited because of the background noise (prostate
volume and BPH), different intervals between the PSA tests, and acceleration and
deceleration effects over time [117, 187, 247].
• PSA density: It is the PSA score divided by the volume of the prostate, measured
on medical images (e.g.: US, MR). This measurement helps to differentiate between
BPH and PCa because in BPH the PSA level takes values between 10% and 15%
of the prostate volume, while PSA levels in PCa are much higher. Therefore, a
greater PSA density is likely to be associated with clinically relevant PCa [114].
2.4.5.3 Diagnosis and staging
Biopsy
If either the DRE or the PSA test is positive, the patient will be asked to undergo a biopsy,
an invasive procedure performed with a hollow needle guided by TRUS to obtain an
average of 8 to 12 tissue cores. This procedure entails a very reduced risk of complications,
which include mild to moderate pain and presence of blood in urine or semen. In rare
cases, a biopsy may provoke an infection, rectal bleeding, or temporary impotence.
A prostatic biopsy may have four possible results: benign cells (negative biopsy), atypical,
PIN, and cancerous cells (positive biopsy). In the case of an atypical result or PIN the
biopsy is said to be inconclusive. Sometimes it is difficult to indubitably label an odd
cellular architecture as cancerous in biopsy samples. An atypical or dubious result should
be reviewed by an expert and a second biopsy is usually performed. A biopsy may reveal
three possible patterns of PIN: mild, moderate, and severe. Mild PIN, also known as
low-grade PIN, is insignificant and does not need further investigation. Moderate and
severe PIN are also called high-grade PIN and involve premalignant cells. A second
biopsy is usually performed if high-grade PIN is found in more than 3 or 4 biopsy cores.
A second biopsy is also justified after an initial negative biopsy because false negatives
are common in PCa: the needle may miss cancer or may glance off its edge, as tumors are
usually harder than healthy prostatic tissue. Unless there exists a sound suspicion of PCa,
further biopsies are not recommended because they may increase the risk of side-effects
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Figure 2.7. The Gleason scale. The histopathologic patterns corresponding to Gleason grades 1 to 5 to
determine the aggressiveness of prostatic adenocarcinoma. Reproduced from [240].
during and after the procedure. Repeated biopsies usually involve more samples taken
and a broadened search including the transition zone and the prostate base.
Gleason score
If cancerous cells are found in the biopsy, the structure and organization of the aberrant
cells will be analyzed by a pathologist to determine the aggressiveness of the tumor,
which is measured by an heuristic histopathological indicator known as the Gleason score
(GS). The Gleason scale consists of five possible grades numbered 1 to 5 with decreasing
cell differentation, as shown in Fig. 2.7. The GS is computed as the sum of the number of
the most common grade and the number of the second most common one.
Prostate tumors with a GS of 2, 3, or 4 are slowly-growing, non-aggressive, and they
are not likely to metastasize. These tumors are normally found in the transition zone as
a result of examining the tissue samples from TURP. If the GS is 5 or 6, the tumor is
usually growing. Treatment can be delayed under close monitoring of the patient until
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the tumor becomes more clinically relevant, but it is also recommended to start devising
the treatment strategy to optimize the chances of cure. A GS of 7 is considered the
threshold for aggressive PCa. In fact, for these tumors it is also important to know which
Gleason grade is predominant, 3 or 4, because in the latter case the tumor tends to be
far more aggressive. Prostate tumors with GS of 8, 9, and 10 are very aggressive and
likely to have escaped the prostate and invaded the seminal vesicles, the pelvic walls, the
bladder, the urethra, or the surrounding lymph nodes. They are also likely to produce
distant metastases, chiefly in the lungs or bones. Tumors with GS≥ 8 normally defy most
treatments and high-intensity radiotherapy, a combination of chemotherapy techniques,
or the sum of both are often the only options to fight them.
The stages of prostate cancer
With the results of the DRE, the biopsy and some possible medical images, such as MR or
CT images, PCa guidelines [63, 177, 181, 259, 260] are used to establish a clinical stage,
that is, an estimation of how far cancer has progressed. Further information contributing
to determine the clinical stage include the evaluation of TURP samples or assessment
of the lymph nodes. The clinical stage of prostatic tumors is determined with the TNM
system, as follows:
• T: description of the local extent of the tumor.
– T1: the tumor is not found during DRE or seen with imaging such as TRUS.
◦ T1a: cancer is found incidentally during TURP that was done for BPH
and it does not appear in more than 5% of the tissue removed.
◦ T1b: cancer is found during a TURP, as in the previous case, but it is
more than 5% of the tissue removed.
◦ T1c: cancer is found by needle biopsy that was done because of an
increased PSA level.
– T2: the tumor is detected during DRE or seen with imaging such as TRUS,
but it still appears to be confined to the prostate.
◦ T2a: the cancer is in one half or less of only one side, right or left, of the
prostate.
◦ T2b: the cancer is in more than half of only one side, right or left, of the
prostate.
◦ T2c: the cancer is found in both sides of the prostate.
– T3: The cancer has begun to grow and spread outside the prostate and may
have reached the seminal vesicles.
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◦ T3a: the cancer extends outside the prostate but not to the seminal
vesicles.
◦ T3b: the cancer has spread to the seminal vesicles.
– T4: the cancer has grown into tissues next to the prostate other than the
seminal vesicles, such as the urethral sphincter, the rectum, the bladder and/or
the wall of the pelvis.
• N: state of assessment of whether cancer has reached the regional lymph nodes.
– NX: nearby lymph nodes were not assessed.
– N0: cancer has not spread to the nearby lymph nodes.
– N1: cancer has spread to one or more nearby lymph nodes in the pelvis.
• M: state of assessment of whether cancer has metastasized and thus spread to
distant parts of the body.
– M0: cancer has not spread past nearby lymph nodes.
– M1: cancer has spread beyond the pelvic lymph nodes.
◦ M1a: cancer has spread to distant lymph nodes, outside the pelvis.
◦ M1b: cancer has spread to the bones.
◦ M1c: cancer has spread to other organs, such as lungs, liver or the brain,
with or without spread to the bones.
Fig. 2.8 depicts some examples to illustrate these stages. It is important to take into
account that the DRE tends to underestimate the stage of PCa because it only provides
superficial information on tumor location and extension and relies on the the doctor’s
expertise. PSA can also offer information about PCa stage but with limitations. In lower-
GS tumors, the production of PSA by the cancerous tissue shows a certain correspondence
to tumor volume. However, poorly differentiated cancer cells in higher-GS tumors make
less PSA per gram of tissue than well-differentiated cells so, as the tumor progresses
toward a higher GS, PSA becomes less representative of tumoral stage.
The pathologic stage arises from the examination of the actual prostate specimen obtained
after surgery. Though the pathologic stage cannot be used to assess the tumor stage before
treatment, it can be employed to predict the likelihood of cure after surgery. Additionally,
the estimated pathologic stage helps to predict what would be found if the prostate were
removed surgically and examined by a pathologist. It is determined by correlating the
clinical stage, the data used to determine the clinical stage, the GS, and the PSA level
on the basis of large datasets of clinical data accumulated during the last decades and
typically sorted on tables. The Partin tables provides the likelihood and 95% confidence




Figure 2.8. The TNM system. A: Examples of T1, T2 and T3 tumors. B: Example of a T4 tumor. C:
Example of a M1 tumor. Provided by Cancer Research UK / Wikimedia Commons.
seminal vesicles, or cancer in the lymph nodes. Additionally, the Han tables allow to
estimate the likelihood that a man’s PSA level will be undetectable ten years after surgery
with 95% confidence.
Risk groups
Taking the clinical stage, the PSA level, and the GS together, protocols are utilized to
define the risk group for a patient and associate a series of alternative treatments and
strategies to manage the disease more specifically. A common classification in risk groups
is provided by the National Comprehensive Cancer Network (NCCN) [181]:
• Very low risk: T1cN0M0 tumor, PSA<10 ng/mL, GS≤6, PSA density less than
0.15 and less than 3 positive biopsy cores and in half or less of any core.
• Low risk: T1aN0M0 to T2aN0M0, PSA<10 ng/mL and GS≤6.
• Intermediate risk: T2bN0M0 or T2cN0M0 tumor, PSA level between 10 ng/mL
and 20 ng/mL or a GS of 7. If a patient meets more than one criterion, his risk is
high.
• High risk: T3aN0M0 tumor, PSA≥20 ng/mL or a GS≥8. If a patient meets more
than one criterion, his risk is very high.
• Very high risk: T3bN0M0 or T4N0M0 tumors, primary Gleaon grade 5, or more
than 4 biopsy cores with GS between 8 and 10. Only one of these conditions
suffices to classify a patient in this group.
• Regional cancer: Any T, N1 and M0 tumors.
• Metastatic cancer: M1 tumors.
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In order to carry out research on PCa treatments, very low-risk patients are usually
considered to be low-risk and very high-risk patients are summed up with high-risk
patients. Men with regional or metastatic disease are normally set aside for specific
studies on very advanced PCa.
2.4.5.4 Treatment
The selection of the treatment takes into account all the available clinical and pathological
information on the patient’s tumor, but also the age, life expectancy, other aspects of the
clinical history, and the personal preferences of individual patients. The chosen treatment
may be of a curative or palliative nature, the former being the standard for localized PCa
and the latter the common practice for advanced PCa. In general, curative treatments
are usually delivered to younger patients with more than 15 years of life expectancy and
with a nice overall health status, for which hypertension, smoking, diabetes, more than
four daily servings of alcohol, and sedentarism are negative factors. Older patients tend
to be less resilient and more prone to develop side-effects after a curative treatment. In
particular, surgery and radiation are two excellent options to cure localized PCa. The
main purpose in the treatment of advanced PCa or cancer recurrence is that the patient
dies with cancer, not of cancer, and preserves a good quality of life, which is always
subjected to the extent of disease.
Active surveillance and watchful waiting
In some cases, if the tumor is in its very early stages and shows a favorable pathology
or if the risk is judged to be very low, a curative treatment may be delayed while the
patient is monitored until the appropriate moment for treatment. This strategy is called
active surveillance. Patients that are not eligible for local curative treatment, or those
with a short life expectancy, may benefit from a deferred palliative treatment, aimed at
tackling specific symptoms of the disease, while they continue on regular screening. This
approach is known as watchful waiting.
Surgery
The surgical option to treat PCa consists of the removal of the entire prostate and it is de-
nominated radical prostatectomy. Apart from temporary pain, the two main potential side
effects are incontinence and impotence. Currently, radical prostatectomy is considered
the gold standard of PCa treatment, showing high rates of success with minimum and
only temporary side effects.
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The ideal candidates for radical prostatectomy are men whose cancer is clearly curable:
organ-confined (T1-T2) or with certain capsular penetration (T3) and well to moderately
well differentiated. These patients are more likely to leave clear surgical margins, that is,
no cancerous tissue is left in the prostatic bed and surrounding tissues once the prostate
has been removed. Men undergoing surgery must also have a nice overall health, to avoid
complications during the intervention and to minimize the risk of side effects, and should
have an estimated life expectancy of more than 10-15 years. Older patients are not ideal
candidates because they may suffer more problems during and after radical prostatectomy
and their cancer might be more advanced that the clinical findings suggest (e.g: BPH
causing stage underestimation during DRE).
PSA is controlled after surgery because it is sensitive enough to monitor the eventual
recurrence of cancer. After radical prostatectomy, PSA level should fall to an undetectable
level of less than 0.20 ng/mL. The first test should be done after 8-12 weeks because PSA
has a half life of 2 to 3 days in the bloodstream, and then once a year. In average, PCa
recurrence after surgery may take place 10 years after the intervention. The later it comes
back, the more likely it will be to respond to a second round of treatment, either radiation,
hormonal therapy, chemotherapy, or a combination of them. However, not all patients
need an aggressive treatment: some of them can be followed with watchful waiting or
active surveillance. The most common situation of PCa recurrence after surgery is a
micrometastatic spread of cancer. Other possible but rare causes are remaining benign
tissue or cancerous cells left in the prostate bed, either because the surgeon could not
remove them or because their removal endangered other neighboring tissues.
Radiation therapy
In this form of treatment, radiation is aimed at disrupting the DNA in the cells’ nuclei
so that they are forced to undergo apoptosis. This is very harmful for a rapid cell-
proliferating tissue featuring cells with already altered DNA because, after cell division,
DNA is checked and a cell suicides if the damage to its genetic material is excessive.
Healthy cells are affected by radiation too, but they are not as easily damaged because
of their unaltered DNA. Additionally, radiotherapy also hinders the development of
angiogenesis.
Nowadays, radiotherapy is a viable treatment option for patients with 10-15 years of life
expectancy, acceptable overall health, who are not too old to suffer from a high risk of
side effects, and whose cancer has not entered a metastatic stage. Thus, it is a suitable
option for patients in low to high risk groups meeting the previous criteria. Advanced
PCa is normally immune to radiation because the apoptosis pathways have been silenced
or the involved genes have been mutated. Neoadjuvant and adjuvant hormonal therapy
improve the results of radiotherapy and may reduce the risk of side effects by adding an
hormonal supplement before or during radiotherapy, respectively. However, these options
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are only prescribed to ensure the cure of high-risk patients or intermediate-risk patients
with doubtful stage. The combination with hormonal therapy leads to volume shrinkage,
apoptosis boost, and a reduction of the activity of PCa.
There are two main approaches in radiation therapy for PCa: external beam radiotherapy
and brachytherapy. In external beam radiotherapy, radiation comes from an outside
beam in the form of electromagnetic waves. Brachytherapy consists of the implantation
of a certain number of tiny radioactive seeds within the prostate with a image-guided
procedure through the perineum and with the aid of a template. Both approaches require
a precise planning of the dosage and may involve different techniques. Dose fractionation
consists of delivering the dose in multiple sessions in order to avoid damage to healthy
structures and a high risk of side effects due to an excessive dose. Dosage escalation
consists of defining a precise area coverage of the prostate, hence determining which
areas will receive more dose and controlling minimum coverage too. Dosage to the
urethra and rectal wall are also monitored in order to control potential harm to these
structures. It is also crucial to deliver radiation on a certain margin beyond the prostate
to cover the possibility that the tumor might have escaped the organ. Major side effects
of radiotherapy are: fatigue, incontinence, impotence, rectal bleeding, strictures, and
prostatitis. These side effects may appear shortly after the procedure or may be late
symptoms and they may disappear gradually or be permanent. This mostly depends on
the patient’s overall health status and age.
PSA tends to decrease after radiotherapy because cancerous cells die as a consequence
of the treatment. Hence, the trend of PSA during the following months after radiation
therapy is closely monitored because a continued rise may be indicative of surviving
tumoral cells. However, sudden rises of PSA can be produced by ceasing adjuvant
hormonal therapy or the so-called PSA bounce, consisting of a transient rise of more
than 0.5 ng/mL which is quickly dropped to prebounce levels. This phenomenon is more
common in younger patients around the twelfth month after treatment and is linked to a
better disease survival.
If the PSA level rises after radiation therapy, it can be either because cancer has reacti-
vated locally, within the prostate or the surrounding tissue, or due to distant metastases.
Watchful therapy is initially recommended if the patient has local reactivation and no
symptoms apart from a gradual elevation of PSA. Salvage radical prostatectomy entails
an important risk of side effects and the procedure might be more complicated. Salvage
cryoablation involves less risk of side effects than surgery but provides inferior cancer
control. Alternatively, salvage brachytherapy may be effective in men with PSA<10
ng/mL but the risk of side effects is increased and the treatment plan must be very precise.
Metastatic disease is normally addressed with hormonal therapy or chemotherapy.
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Cryoablation and thermal ablation
Cryoablation and thermal ablation consist of cooling or heating the prostate to extreme
temperatures causing all the cancerous cells to die, respectively. The prostatic urethra
must be protected during these treatments using a catheter with a circulating saline
solution at an adequate temperature. As PCa can be multifocal, a certain amount of
cancerous cells may be near the urethra and would not be killed by these treatments.
These treatment options are recommended for high-risk patients with clinically localized
PCa, as salvage therapy after radiation, and to men that are not eligible for surgery or
radiation. Patients who have undergone a TURP are not candidates for these treatments,
as they may develop sloughing of the urethra and urinary retention, nor are eligible those
with large prostates because the pubic bone may interfere in the procedure.
Cryoablation technology consists in a TRUS-guided procedure. Typically, 8 to 25 needles
are placed into the prostate through the perineum with the aid of a template. Pressurized
argon gas is passed through the needles to freeze the prostate down to -40◦C for a few
minutes. Then, helium is used to thaw the prostatic tissue. Multiple thermocouples are
also placed into the prostate, at the sphincter, over the rectum and near the neurovascular
bundles to control the temperature and avoid damage to other structures. The doctor will
normally administrate two consecutive rounds of freezing and thawing.
Many techniques of thermal ablation are still investigational but there is one that has met a
quite widespread use: high-intensity focused ultrasound (HIFU). It is also a TRUS-guided
procedure in which the ultrasound probe is placed in the rectum inside a balloon-shaped
latex cooling device to maintain the rectal wall at less than 37◦C. During the procedure, a
beam of focused ultrasound waves is emitted intermittently targeting each layer of the
prostate until the entire treatment area is covered.
Hormonal therapy
Hormonal therapy is the standard approach for advanced PCa. This approach aims at
interfering in the production of the hormones that regulate the prostate function and
sustain cancer, so that hormonal therapy is a setback rather than radical treatment to PCa.
The early results of this form of treatment are usually encouraging: the tumor shrinks,
the PSA levels fall, and the patient feels better. However, PCa is not gone, the more
malignant cancerous cells do not make much PSA, and the tumor might contain cancerous
cells that are not affected by hormonal therapy. They are called androgen-independent
or androgen-insensitive cancer cells, while a tumor that defies hormonal therapy is said
to be an hormone refractory disease. These androgen-independent cells result from the
accumulation of mutations (genetic drift) and their survival and competing behavior
with respect to other less malignant cancerous species (clonal selection). In general,
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the efficacy of hormonal therapy depends on the ratio of hormone-resistant cells to
hormone-dependent cells and the doubling time of cancer volume.
Nowadays, hormonal therapy has two main approaches:
• Surgical castration: it consists of the surgical removal of a man’s testicles (or-
chiectomy) or the parts of the testes that make testosterone (sucapsular orchiec-
tomy). This choice of treatment is relatively inexpensive, effective almost imme-
diately, the results are permanent, and it does not mean a lifetime of medication.
A man’s testosterone level falls a 95% to the so-called castrate range, a cutoff
that is used to measure the success of this sort of hormonal therapy. The main
disadvantages are psychological and cosmetic.
• Medical castration: it consists of the administration of one or several types
of drugs, which can be classified in three groups: drugs that shut down the
hypothalamic-pituitary connection, such as estrogens and luteinizing-hormone
releasing hormone agonists and antagonists; drugs that block the effect of hor-
mones in the prostate, such as antiandrogens and 5-α reductase inhibitors; and
drugs that inhibit the production of testosterone, such as ketoconazole. The latter
has become obsolete against antiandrogens. A combined androgen blockade aims
at obstructing all sources androgens, both testes and adrenal glands, by combining
an antiandrogen and a procedure to achieve castrate range of testosterone, such as
surgical castration, luteinizing-hormone releasing hormone agonists, or estrogens.
Hormonal therapy is normally prescribed to patients with metastases to bone, bone pain,
or a large mass of cancer that is actually obstructing the bladder or the kidneys. the most
common approaches are luteinizing-hormone releasing hormone antagonists or surgical
castration. When a man should start hormonal therapy is one of the most controversial
issues in PCa treatment. The advocates of hormonal therapy recommend an immediate
onset of the treatment believing that the less androgen-independent cells at that moment,
the more a patient’s life expectancy will be increased. The detractors of hormonal therapy
neglect any benefit and consider that it only adds side effects and a worse quality of life.
Intermittent hormonal therapy is an intermediate approach and consists of start and stop
hormonal therapy when necessary in view of decreasing side-effects and enhancing the
quality of life. Likewise, in step-up treatments, men start with innocuous therapies and
then the intensity of the treatment is increased as the cancer progresses.
The fall in testosterone levels produced by hormonal therapy comes with a host of side
effects, ranging from the loss of manhood to cardiovascular problems, osteoporosis
and depression, but also including loss of verbal fluency, visual memory and visual




Chemotherapy is a treatment approach for advanced PCa that encompasses a host of
drugs aimed at killing or hindering the development of cancerous cells both in the prostate
area or in metastases. These drugs are classified in the following categories:
• Conventional cytotoxic chemotherapy: these drugs work by affecting the vital
mechanisms of growing cells and can affect normal cells along with cancer cells.
For instance, Taxotere interrupts cell division thus hindering cell replication.
• Bone-targeted treatments: these drugs make bones a place less habitable for
cancer to develop. There are several approaches, such as: bisphosphonates, radio-
pharmaceuticals, endothelin blockers, and interleukin-6 antibodies.
• Immunotherapy: The general idea behind this form of treatment is to help the
body to become strong enough to battle cancer by its own means. There are two
main approaches: active immunity, which consists of activating T cells to focus
on tumor cells in order to eliminate them, and passive immunity, which involves
the production of monoclonal antibodies that are specifically designed to attack
cancer cells directly or some growth factor receptors on them. Radioimmunotherapy
entails the combination of these monoclonal antibodies with radioisotopes, enabling
the delivery of tiny bursts of radiation wherever the cancerous cells might be.
• Gene therapy: it is the use of DNA as a pharmaceutical agent to treat the disease
by supplementing or altering the genes within an individual’s cells. A common
form of gene therapy involves using DNA encoding a functional therapeutic gene
to either replace a mutated gene or correct a mutation. Another usual strategy
leverages DNA encoding a therapeutic protein drug, rather than a natural human
gene. This DNA is packed into a vector, which is then used to get to the DNA of
the cells inside the patient’s body so that the encoded substance is produced by the
cells naturally afterwards. Some gene therapy approaches leverage adenoviruses
that have been remodeled so that they are activated by the PSA promoter, a small
stretch of DNA near the PSA gene in the DNA chain that acts as a chemical switch
that governs how PSA is produced. This makes this treatment highly focused on
prostatic cells. The combination of virotherapy and radiation has been found to
be nearly seven times more effective in reducing tumors than the predicted sum of
both therapies separately. Other PSA-targeted approaches in gene therapy aim at
activating apoptosis only in prostate cells.
• Drugs that block tumor invasion and metastasis: the most important and used
are angiogenesis inhibitors. These drugs block the formation of new blood vessels,
destroy the recent ones and, thus, cut off the supply of nutrients to the tumor.
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Their main advantages are that they do not damage fully developed blood vessels
supplying other organs and that cancer will not become resistant to its requirement
of blood vessels. However, they must be taken continuously and they may hinder
the formation of new blood vessels in the heart, which is a constant process in this
organ. They are more effective in men with micrometastases, rather than those with
widely extended disease. One example is Avastin, which is a monoclonal antibody
that targets VEGF, a growth factor and a major stimulus for angiogenesis.
• Differentiating agents: these drugs keep cancer in check by slowing down the
elevated birth date, giving the death rate a chance to catch up so that cancer growth
is slowed down. Some differentiating agents that show promise are: vitamin D
derivatives, because of the ability of vitamin D to inhibit cancer growth; HDAC
inhibitors, which can turn on again some genes that cancer has already switched
off so that cancer growth is checked; and phenylbutyrates, which slow down
cancer growth by turning on a set of genes that had been silenced by the cancer.
Phenylbutyrates work better in combination with other agents, such as retinoids
(vitamin A), which also slow down cancer growth.
• Inhibitors of signal transduction and cell-to-cell interaction mechanisms:
cells communicate with each other through a host of signaling mechanisms involv-
ing highly specific receptors and these drugs act by blocking such transmission of
messages or altering them. This approach is similar to that of inhibiting growth
factors.
• Small-cell carcinoma drugs: this is not an adenocarcinoma of the prostate but it
can be confused with it. A man may undergo surgery or radiation to treat it, but it
usually comes back very aggressively as a rapidly growing soft tissue mass often in
the prostate bed and provoking metastases in bones, liver, lungs and brain. It also
shows a low PSA. Nevertheless, the same drugs that work on small-cell carcinoma
elsewhere in the body work in the prostate as well, but it has to be detected quickly.
2.5 Mathematical modeling of cancer growth
Mathematical oncology has been a rich area of research in the recent decades. The advent
of more precise technologies for medical imaging and their progressive integration in
clinical protocols to manage cancer, such as mpMR, have been of paramount importance
for the development of the field. Additionally, the advances in scientific computing
and computational mechanics have enabled the simulation of cancer growth in larger
domains and shorter times, opening the door for tissue-scale patient-scientific simulation
of tumor growth in clinically relevant times, in the order of hours or days. Extensive
reviews on the advances in mathematical oncology to date can be found in references
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[7, 9, 42, 52, 53, 97, 160, 167, 170, 174, 188, 206, 211, 212, 236, 251, 274]. In the
following, we will provide a succinct description of the types of mathematical models to
study tumor growth.
2.5.1 General concepts
The conception of a tumor growth model begins establishing which phenomena or
processes explain the advancement of the particular type of cancer under study. This
decision emanates from the current knowledge on the disease and the recent experimental
and clinical results that intend to broaden and deepen it. The inclusion of all the available
data would render an exceedingly complex model, which would be computationally
prohibitive and would lack clinical applicability. Instead, it is necessary to single out the
key mechanisms that explain tumor growth, define the variables that participate in them,
and write their corresponding mathematical description.
Furthermore, cancer models usually describe cancer in the organ harboring the disease
or a tissue patch including the tumor because incorporating the whole organism in
simulations would be computationally prohibitive. Hence, another important decision
is the selection of the boundary conditions, which model the behavior of the tissues and
structures surrounding the considered organ or tissue patch. Initial conditions are usually
extracted from medical images, such as the initial geometry of the organ and tumor, and
the clinical data in the patient’s medical history, such as biomarker levels.
Tumor growth models include a variable that enable the distinction between healthy and
cancerous tissue. The model may also include several tumoral species, commonly termed
phases or compartments, which may be classified according to numerous criteria, for
instance: their status (e.g.: viable, necrotic), their genetic profile, their principal role
in tumor growth (e.g.: proliferative, invasive, quiescent), the type of metabolism (e.g.:
normoxic, hypoxic), or their resistance to a certain type of treatment (e.g.: radiotherapy,
hormonal therapy). In this case, models also include a mathematical description for the in-
teraction between tumoral species, which can categorized into competence, collaboration,
or transference from one phase to another. Some models also feature additional phases to
describe different types of healthy tissue, the extracellular matrix, and interstitial water.
In general, net proliferation and invasion are considered the key mechanisms driving
tumor growth in these models. Some of them further differentiate between proliferation
and cellular death. The model may also include the dynamics of key substances for tumor
growth, such as nutrients, biomarkers, metabolites, and proangiogenic factors. In this case,
the model mathematically describes how the concentrations of these substances affect
tumor growth, typically in terms of net proliferation and invasion, and, conversely, how the
tumor alter the dynamics of these substances. In particular, it is common to include taxis
phenomena in the model, i.e., cellular migration motivated by the presence of gradients,
for example, in the concentration of certain substances in interstitial water (chemotaxis), in
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the concentration of of certain compounds adhered to the extracellular matrix (haptotaxis),
or in the mechanical properties of the extracellular matrix (mechanotaxis).
2.5.2 Classification of tumor growth models according to mathematical
description
The study of cancer phenomena at a subcellular or cellular scale is usually carried out
by means of a discrete formulation [2, 99, 174, 188, 206]. These models enable the
integration of a wide array of experimental results to investigate, e.g., proliferation,
apoptosis, the cell cycle, protein production, cellular metabolism, mutational events, the
dynamics of tissue architecture and organization, or communication pathways. In this
framework, tumor growth is typically studied in a tissue patch that includes a group of
cancerous cells circumvented by healthy cells. There exist several subtypes of discrete
models of tumor growth. Agent-based models are composed by single units that represent
cells interacting in a lattice-free space. Cellular automata and cellular Potts models divide
the considered tissue region with a fine lattice that defines the positions the cells may
take. In cellular automata models, each position of the lattice can be only occupied by
one cell, while in cellular Potts models a single cell might span several lattice positions.
Hence, cellular automata models do not account for cellular shape but permit simulation
over slightly larger scales. Alternatively, cellular Potts models enable a deeper insight
into cellular morphology, polarity, elasticity, and tisular arrangement. Discrete models
feature a set of rules that govern tumor growth on each time step. These rules specify,
for example, how each cellular type moves, feeds, produces or consumes substances,
divides, and dies. Additionally, the concentrations of key substances can be included
in the model with a continuous description, such that their dynamics are captured by
partial differential equations. However, discrete models are spatially limited because the
computational power required to model a whole organ within this framework would be
prohibitive. Besides, cellular and subcellular phenomena occur in shorter time scales than
global tumor growth, as assessed in a clinical scenario. Thus, these simulations are also
limited to times ranging from hours to a couple of months.
Alternatively, continuous models of tumor growth enable simulation over larger domains
and longer times with a significant reduction in the computational cost. These models
leverage continuous functions to describe the dynamics of cellular densities or cellular
volume fractions of healthy and tumoral tissue. We can use these fields to determine the
regions of the harboring organ affected by the tumor, compute the volume of cancerous tis-
sue, and contour the tumor but we can no longer track cells individually. Therefore, some
phenomena taking place at cellular and subcellular scale cannot be directly transferred
to a continuous model. Instead, a mathematical adaptation to the continuous framework
involving the volumetric averaging of cell species is usually required. These models




Continuous models consist of a set of partial derivative equations that describe the dy-
namics of each cellular phase and substance in the model. The terms participating in
these equations can be typically classified in four categories: diffusion, convection, re-
action, and taxis. Global cellular migration is typically described using diffusive and
convective terms. Reactive terms are mathematical functions involving some variables
of the model and a set of parameters to represent cellular phenomena at a greater scale,
such as proliferation, apoptosis, metabolism, and interaction between cellular phases.
The terms modeling taxis can adopt a similar form to diffusive, convective, or reactive
terms depending on the type of cellular migration to be modeled. From a methodological
perspective, we can highlight the successful efforts in modeling tumoral dynamics accom-
plished with Fisher-Kolgomorov equations [64, 202, 261, 266–268], the mixture theory
[41, 197], multiphase porous media mechanics [216, 217], and the phase-field method
[68, 115, 159, 160, 236, 271].
The dynamics of the substances participating in a continuous model are usually modeled
with reaction-diffusion equations, as convection is usually neglected. The effect of treat-
ments such as radiation therapy, chemotherapy, and hormonal therapy can be included by
adjusting the parameters of the equations of the affected cellular phases or adding new
reactive terms in those equations [64, 94, 133, 135, 136, 149, 176, 202, 223]. Addition-
ally, chemotherapy and hormonal therapy might require an ancillary reaction-diffusion
equation to model the dynamics of the specific drugs [94, 223].
Hybrid models benefit from a combination of discrete and continuous formulations
for the phases in the model [8, 93, 95, 272, 273]. In this framework, a single phase
may even have both formulations to capture different phenomena occurring at cellular
and tisular scale. The major challenge of these models is precisely coupling these
processes across the scales considered in the model. When each phase in the model has
a single mathematical description, these models are also called composite or discrete-
continuous models. Hybrid models have been successfully leveraged to model tumor-
induced angiogenesis [93, 95, 248–250].
2.5.3 The tumor mass effect
The rapid overproliferation of cancerous cells leads to high cell densities in their confined
microenvironment within the harboring tissue. As a result, tumors develop a high
compressive hydrostatic stress state in their interior and exert outward forces as they grow.
These forces deform the neighboring tissues, generating stress fields aimed at resisting
the mechanical load imposed by tumor growth. This phenomenon is known as the tumor
mass effect [57, 109, 118, 137, 205, 228, 256]. In turn, these mechanical stress fields
are known to exert an inhibitory effect on tumor growth both directly, by slowing down
tumor dynamics, and indirectly, by deforming and collapsing the local vasculature in the
tumor region. Therefore, the tumor-induced deformation and its effect on tumor dynamics
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are also key phenomena that are usually incorporated to mathematical models of tumor
growth.
The modeling of the tumor mass effect requires the definition of the constitutive equations
for the mechanical behavior of healthy and cancerous tissue, as well as the coupling of the
tumor growth model with the equations of mechanical equilibrium. Discrete formulations
enable a very precise definition of the exerted forces on a cell-to-cell basis. However, the
tumor mass effect has been mostly explored within a continuous modeling framework,
in which tissue-scale patient-specific simulation in clinically relevant times is feasible
[56, 61, 125, 160, 163, 266–268]. In this context, the forces induced by the tumor are
usually modeled as an outward force perpendicular to the boundaries of the tumor or as a
pressure acting on the volume occupied by the cancerous tissue. Mechanical inhibition of
tumor growth is usually modeled via a coefficient that slows down tumor invasion, net
proliferation, or both [160, 266–268]. This coefficient is usually defined as a measure of
the stress state and loading conditions.
In most cases, tumor growth is assumed to develop at a sufficiently slow rate so as to
neglect the inertial effects during the deformation, which is thus considered to be a
quasistatic process. Linear elasticity has been widely accepted to model mechanical
equilibrium in living tissue subjected to slow processes over short time scales (t ∼ 1
year) [56, 61, 125, 134, 160, 163, 267, 268]. The rationale for this is that, under these
conditions, the tumor produces small strains and rotations, which are acceptable within the
limits of linear elasticity. Hence, this paradigm provides a simple mechanical framework
to study the tumor mass effect and mechanotransductive effects that can be easily coupled
to a preexisting model of tumor growth.
2.6 The phase-field method
The phase-field method is an advantageous mathematical framework to address phase
transition problems featuring an evolving interface [34, 54, 81, 104, 199, 200, 226]. This
approach arose in the field of Thermodynamics in order to solve, for instance, precip-
itations, crystallization, and solidification. These problems feature several substances
in contact, the same material in different states, and the same material with different
chemical compositions or arrangements, respectively. In this context, each of the sub-
stances, material states, or chemical species in contact is called a phase and the separating
surface between them is called the interface. Traditionally, the equations that govern the
dynamics of each phase are solved simultaneously with the boundary conditions modeling
the evolving interface between the phases, which is unkwown a priori. This approach is
termed a sharp-interface model because the interface is modeled as a surface with zero
width whose dynamics is consistent with the mechanism of phase transformation.
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Figure 2.9. Sharp interface versus diffuse interface models. In the sharp interface model on the
right, a certain variable or property field φ is discontinuous at the interface between the regions of the domain
in which it takes different values. On the right, the phase-field method enables a continuous description of φ ,
which varies smoothly between the bulk values across the diffuse interface.
the interface might be unknown for certain problems, the number of equations may
increase with the number of phases due to the increasing number of interfaces, the
interface requires an explicit geometric parameterization that can be difficult to obtain and
manipulate, the interface may have a complex topological description requiring ancillary
equations to model its actual behavior (e.g.: in terms of curvature), and the interface
may undergo complex geometrical transformations (e.g.: merging, separation, pinch-off).
Additionally, the computational cost of performing simulations with high accuracy and in
mildly complex domains can be almost prohibitive.
Alternatively, phase-field models introduce a variable termed order parameter or phase
field φ to continuously represent the different phases in contact across the computational
domain, as shown in Fig. 2.9. For instance, within a problem of precipitation, φ = 0
may represent the matrix and φ = 1, the precipitate. The interface is represented by
a rapid and smooth transition of the phase field in the region where 0 < φ < 1. This
signature assumption is the reason why this approach is also termed a diffuse-interface
method. Now, the location of the interface has no longer to be tracked explicitly because
it can be inferred from the values of the phase field, for example, by means of the
isosurface φ = 0.5. The phase-field method addresses some of the problems arising in
sharp-interface approaches. In particular, the governing equations can be directly solved
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on the entire computational domain and the boundary conditions on the interface are
now replaced with an equation modeling the dynamics of the phase field. The initial
conditions need to account for the diffuse interface. Hyperbolic tangents are very versatile
functions to serve this purpose and they usually represent the phase field naturally in this
framework.
The phase-field method also enables the use of both conserved or non-conserved order
parameters, depending on the requirements of the problem to solve. The order parameter
is usually a scalar field, but there exist some examples of vectorial descriptions too. For
the general case of Nφ interacting phases, multiphase-field methods [183, 271] involve a




φi = 1. (2.1)
Then, each region of the domain where a single phase φk exists will be defined by φk = 1
and φi = 0 for the remainder phases. The bounding interfaces of phase k with the other
phases in the problem will be represented by the regions where 0 < φk < 1.
In the last decades, phase-field models have gained increased interest in many fields of
science and engineering to solve problems featuring evolving interfaces, for example,
complex fluids [38], crack propagation [30, 144], water infiltration in porous media [69,
107], foams [91], boiling [162], dendritic growth [139, 147], cell migration [178, 179],
elastocapillarity [39, 243], and angiogenesis [248–250]. In particular, cancer growth has
also been successfully addressed by exploiting the advantages of phase-field methods to
describe the underlying physical phenomena and capture the evolution of the tumoral
morphologies [20, 68, 93, 95, 115, 159, 160, 236, 271].
Phase-field models are usually derived within a thermodynamical framework from free-
energy functionals, but they can also be obtained by smoothing a sharp-interface problem.
While the phase field may correspond to a known physical variable in some applications
(e.g.: concentration, fraction of tissue), in many others it has a physical meaning but
does not represent a physical variable of the problem (e.g.: a crack, cancer malignancy).
The unphysical nature of the phase field may hamper a direct comparison with reality,
which is usually limited to the correlation of shape. Besides, some assumptions that are
introduced in the definition of the free energy functionals might result arguable, either
because of the lack of physical justification for the adopted forms or due to the extent to
which the validity of the involved expressions holds. Still, it is usually possible to find a
physical interpretation for those terms and define sufficiently wide limits for the validity
of the model.
Phase-field models also constitute a computationally challenging subject that attracts
much research interest [103, 105, 108, 161]. Capturing the dynamics of thin interfaces
usually requires fine computational meshes, renders stiff equations, and limits time
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stepping, what may hamper simulating over realistic spatial and time scales. Adaptive
time stepping and local dynamic mesh adaptivity have been proven to successfully tackle
these computational challenges to a great extent. Defining a broader interface usually
reduces the required computational resources too, but it entails an increased risk of
losing detail in the representation of the interface or even obtaining unphysical results.
Additionally, phase-field models normally involve higher-order operators. This feature
limits the use of classical FEA because it would require a basis with high global continuity,
which would pose a great difficulty especially in complex 3D domains. A mixed FEA
formulation with additional degrees of freedom would be more appropriate instead.
Alternatively, IGA naturally leverages basis functions with higher global continuity for
both spatial discretization and analysis, making it an appealing approach to solve phase-
field models in intricate geometries. For a more thorough review of phase-field methods,
the interested reader is referred to references [34, 54, 81, 104, 199, 200, 226].
2.7 Isogeometric analysis
IGA is an emergent and cutting-edge technology that tightly connects computer aided
design (CAD) and FEA, hence opening the door for integrated design-through-analysis
frameworks [66, 130]. The central idea of IGA is to leverage the smooth function basis
used to define the CAD geometry as a basis for analysis. Thus, for properly constituted
CAD models, isogeometric methods bypass the mesh generation step of classic FEA,
which rendered an approximation of the original CAD geometry and may represent up
to 80% of the required time to perform the analysis of complex engineering designs or
scientific models. CAD descriptions which are suitable for analysis are called analysis-
suitable geometries (ASG). The higher-order smooth ASG bases that are used in IGA have
been shown to produce superior results when compared to standard C0 discretizations.
The advantages of IGA have been demonstrated in a wide variety of fields of science and
engineering, including structural analysis [23, 49, 65, 74, 146], fluids [13, 15, 19], fluid-
structure interaction [16, 38, 46, 47], fracture and damage [30, 244, 245], phase-field
analysis [30, 105, 106], shape optimization [258], electromagnetics [40], and biomedicine
[14, 17, 129, 248, 249, 272]. Additionally, several research groups have been actively
developing powerful software packages for IGA, such as PetIGA [70], igatools [193] and
GeoPDEs [72].
B-splines and NURBS [84, 195, 204] were the first functional spaces employed to perform
IGA and are still extensively used nowadays. They are ubiquitous in CAD and can be
handled with relative simplicity to perform analysis. In particular, isogeometric methods
based on these functional spaces are geometrically exact, provide enhanced accuracy
per degree of freedom, and enable higher global continuity (Cp−1 for spline spaces with
polynomial degree p) [1, 66]. Methodologies such as Bézier extraction [29, 220] simplify
the implementation of isogeometric basis function technology into existing finite element
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frameworks.
Standard Galerkin discretizations and Gaussian quadrature are commonly used in IGA
[66]. Recent developments have provided promising quadrature strategies to improve the
efficiency of isogemetric methods [11, 43, 131]. However, there are alternative numerical
methods that are compatible with IGA, such as collocation, least-squares FEA, and
meshless methods [66]. Another important property of IGA that has been recently proven
is that Galerkin solutions can be obtained with only one evaluation per degree of freedom
using the concept of variational collocation [104].
Mesh adaptivity is a rich subject in IGA. The possibilities include element subdivision or
merging (h-adaptivity), degree elevation or reduction (p-adaptivity), basis roughening or
smoothing (k-adaptivity), and reparameterization (r-adaptivity). These operations can be
combined to produce sophisticated hpkr-adaptive schemes. These methodologies have
been recently cast into a unified framework based on Bézier projection [234].
Local adaptivity is extremely useful to address those problems whose solution presents
highly localized features that call for a finer mesh, while coarser elements can be used
elsewhere. The most common examples are internal and boundary layers in advection-
dominated flows, interfaces between the phases of a heterogeneous mixture, or stress
concentrations in structural analysis. However, traditional approaches to isogeometric
mesh adaptivity based on B-splines and NURBS suffer from global propagation of refine-
ment due to the rigid tensor-product definition of these functional spaces. Coarsening is
much more difficult to apply accurately and efficiently and it is rarely considered.
In order to accommodate local adaptivity in IGA, several ASG descriptions have been
proposed. Hierarchical B-splines [121, 151, 214, 215, 257] are constructed in a multi-
level fashion where higher levels are composed of finer B-spline bases. A selection
mechanism is used to construct a global basis from functions in the hierarchy. Due
to interactions between coarse and fine basis functions the conditioning of the basis
can deteriorate. Truncated hierarchical B-splines (THB-splines) address this issue to
a certain degree [100–102, 119, 124, 148]. Spline forests [219] are an extension of
hierarchical B-splines and NURBS to complex surfaces and solids of arbitrary topological
genus. T-splines [221] are a generalization of NURBS that are locally refinable and
capable of modeling complicated designs as a single, watertight geometry. Analysis-
suitable T-splines [21, 22, 48, 154, 156, 218] are a subset of T-splines with the same
mathematical properties as NURBS. Recently, hierarchical analysis-suitable T-splines
[83] have been shown to combine the local refinement properties of T-splines, which
can be used to precisely design the geometry, with the power of the hierarchical concept,
which accommodates efficient local adaptivity for analysis. Polynomial splines over
hierarchical T-meshes (PHT-splines) [76, 155, 262], modified T-splines [142], locally
refined splines (LR-splines) [35, 79, 140], truncated T-splines [264], and generalized


























Figure 2.10. Bernstein basis functions. The Bernstein basis for polynomial degrees p = 1,2,3. Repro-
duced from [166].
2.8 Bernstein bases
2.8.1 Univariate Bernstein basis
The univariate Bernstein basis functions are defined as







(1−ξ )p−(i−1)(1+ξ )i−1, (2.2)






(i−1)!(p+1−i)! , 1 ≤ i ≤ p+ 1. We choose to define the Bernstein basis over the biunit
interval to facilitate Gaussian quadrature in FEA rather than use the convention of the
computer-aided geometric design (CAGD) community where the Bernstein polynomials
are defined over the unit interval [0,1]. The Bernstein basis functions for polynomial
degrees p = 1,2,3 are shown in Fig. 2.10.
It is often useful to define a vector of Bernstein basis functions Bp(ξ ) = {Bpi (ξ )}
p+1
i=1 .
The degree superscript is suppressed when unnecessary. We denote the space of functions
over the biunit interval spanned by the Bernstein basis of degree p by Bp. From an
analysis perspective, Bernstein bases enjoy interesting properties, such as partition of
unity, pointwise nonnegativity, endpoint interpolation, and symmetry. A useful review of
Bernstein polynomials and their properties is provided in [85].
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2.8.2 Multivariate Bernstein basis
We define a multivariate Bernstein basis over the box of dimension dp, [−1,1]dp , by the
tensor product. The polynomial degree may be different in each direction and so we
define the vector of degrees p = {p`}
dp
`=1. The vector of multivariate Bernstein basis
functions is defined by the Kronecker product
Bp =Bpdp (ξdp)⊗·· ·⊗B
p1(ξ1). (2.3)
Thus, there are ∏
dp
`=1(p`+1) basis functions in the vector. All of the properties of the
univariate Bernstein basis are inherited by the multivariate Bernstein basis.
2.8.3 Relations between Bernstein polynomials over different intervals


















A polynomial function f of degree p can be represented by a linear combination of the















As shown by [86], the coefficient vectors c= {ci}p+1i=1 and c̃= {c̃i}
p+1
i=1 can be related by
the transformation matrix A
c̃=Ac (2.7)









k−i (ã) for j,k = 1,2, . . . , p+1. (2.8)
This can be extended to multiple dimensions by a tensor product. The elements of the







k−i (a) for j,k = 1,2, . . . , p+1. (2.9)
The inverse matrix provides a relationship between the basis functions over each interval
B̃p =A−TBp. (2.10)
Both Eqs. (2.8) and (2.9) are defined using one-based indexing for both the matrix entries
and the Bernstein basis as opposed to the zero-based indexing used in [86].
2.8.4 The Gramian of the Bernstein basis and its inverse
When computing the projection of an arbitrary function onto the Bernstein polynomials,
an expression for the Gramian matrix Gp for the basis of degree p is required. The entries






k (ξ )dξ for j,k = 1,2, . . . , p+1. (2.11)
Expressions for products and integrals of the Bernstein polynomials in [78, 85] permit














The Gramian matrix for a multivariate Bernstein basis of dimension dp and with the
vector of polynomial degrees p=
{
p1, . . . , pdp
}
is obtained from a Kronecker product
Gp =Gpdp ⊗·· ·⊗Gp1 . (2.13)
An expression for the inverse of the Gramian of the Bernstein basis can be obtained by
considering the Bernstein-Bézier representation of the dual basis in [141]. The Bézier
48
2.9 · B-splines and NURBS
coefficients of the dual basis are precisely the entries in the inverse of the Gramian and so






























after modification to use one-based indexing and the Bernstein basis over the biunit
interval. The inverse of a Kronecker product of matrices is given by the Kronecker
product of the inverses and so Eq. (2.14) can be used to compute the inverse of a
multivariate Gramian matrix
(Gp)−1 = (Gpdp )−1⊗·· ·⊗ (Gp1)−1. (2.15)
2.9 B-splines and NURBS
2.9.1 B-splines
A univariate B-spline is defined by the polynomial degree of the spline p and the knot
vector G, a set of non-decreasing parametric coordinates G = {sA}n+p+1A=1 , sA ≤ sA+1
where n is the number of B-spline basis functions [84, 195, 204]. The multiplicity of
a knot value sA ∈ G is 0 ≤ µ (G,sA) ≤ p+ 1 and it will be zero for any sA 6∈ G. We
require that the knot vector be open, that is, µ (G,s1) = µ (G,sn+p+1) = p+1. We call
Ω̂ = [s1,sn+p+1] the parameter space, which is partitioned into knot spans [sA,sA+1] by
the knots in G. The Ath spline basis function over the knot vector can be defined using
the Cox-de Boor recursion formula [67, 71]:
N0A(s) =
{

















































Figure 2.11. B-spline basis functions. This figure depicts the set of B-spline quadratic basis functions













The B-spline space spanned by the spline basis is denoted by N p. We denote the set of
functions in the basis by N. From an analysis perspective, B-spline bases enjoy several
interesting properties, such as partition of unity, pointwise nonnegativity, global and local
linear independence, and compact support (p+1 knot spans for B-spline functions of
polynomial order p). Additionally, if µ(G,si) = k, then the basis functions are Cp−k-
continuous at si. When k = p, the basis is C0 and interpolatory at that location. Within
the knot spans, the basis functions are C∞. Fig. 2.11 depicts an example of a quadratic
B-spline basis.
A B-spline curve of dimension ds is a function mapping Ω̂⊂ R to Rds . The curve x(s) is








An alternate form of Eq. (2.18) can be obtained by defining the vector of control points







P is a matrix of dimension n× ds. Due to the variation diminishing property of the
B-spline basis, the curve will generally only interpolate the control points at the ends of
the curve or at locations where the spline basis is C0. A multivariate B-spline basis is
defined from a tensor product of univariate B-spline bases [84, 195, 204]. The properties
of multivariate B-spline basis functions follow from the corresponding properties of their
univariate counterparts. We can build B-spline surfaces and solids using a bivariate or
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trivariate spline basis in Eq. (2.18), respectively. For a profound review on splines, the
interested reader is referred to [84, 195, 204].
2.9.2 Non-uniform rational B-splines (NURBS)
The spline basis defined in the previous section provides a flexible means to represent
curves. However, this polynomial basis cannot represent certain curves of interest such as
circular arcs. A rational spline basis can be used to remedy this deficiency [84, 195, 204].
The rational basis is defined by associating a weight wA ∈ R+ with each basis function






























A=1. We can define multivariate rational
spline bases and describe multiparametric geometries with them following the same
approach as in Section 2.9.1. NURBS functions inherit most of the properties of B-
splines. Note also that if the weights are all equal, NURBS basis functions reduce to
B-spline basis functions. For a thorough review on rational splines, the interested reader




2.10.1 Hierarchical spline spaces
Hierarchical splines are an attractive adaptive technology to perform IGA for several
reasons:
• Simple and efficient.
• Preserves many of the mathematical properties of B-splines and NURBS.
• Generates smooth, localized, and geometrically exact discretizations.
• Enables design on the first level while higher levels can be leveraged for analysis.
• Compatible with quadrilateral and hexahedral meshing technology.
A hierarchical spline space is constructed from a finite sequence of nh nested spline spaces,
N α ⊂N α+1, α = 1, . . . ,nh−1, and nh open bounded subdomains of the parametric space
Ω̂ such that Ω̂nh ⊆ Ω̂nh−1 ⊆ . . . ⊆ Ω̂1 [257]. We denote by Nα the spline basis at each
hierarchical level. To ensure nestedness of the spline spaces N α ⊂N α+1 we impose the
following restrictions:
• pα+1` ≥ p
α
` , `= 1, . . . ,dp, α = 1, . . . ,nh−1
• Gα` ⊂ G
α+1







` , ∀s ∈ Ω̂, `= 1, . . . ,dp, α = 1, . . . ,nh−1
We will set Ω̂1 = Ω̂ and require that the boundaries ∂ Ω̂α , α = 1, . . . ,nh, are aligned with
knot lines in N α−1. This is called a strong boundary condition [257]. In the remainder
of this thesis, we will drop the polynomial degree p from our notation as introduced in
Section 2.9.
The hierarchical spline basis H is constructed recursively:
1. Initialize H1 = N1.
2. Recursively construct Hα+1 from Hα by setting
Hα+1 = Hα+1coarse∪Hα+1f ine , α = 1, . . . ,nh−1
where
Hα+1coarse = {N ∈ Hα : supp(N) 6⊆ Ω̂α+1}
and
Hα+1f ine = {N ∈ N
α+1 : supp(N)⊆ Ω̂α+1}
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3. Set H= Hnh .
We denote the number of hierarchical basis functions in H by n f , which span a hierarchical
spline space H. During each step of the previous algorithm, we first build Hα+1coarse by
dropping from Hα those functions whose support is contained in Ω̂α+1. Then, we add to
the hierarchical basis through Hα+1f ine all the functions from N
α+1 that are fully supported
by Ω̂α+1. The rationale for excluding functions from Hα when building Hα+1coarse is that
those functions can be represented by a linear combination of the functions in Hα+1f ine .
Consequently, the functions in the resulting hierarchical basis H are linearly independent.
Fig. 2.12 shows an example of a univariate quadratic hierarchical spline basis. Notice also
that given H1, . . . ,HN , a sequence of hierarchical spline bases, span Hα ⊆ span Hα+1.
For a thorough exposition of the these and other properties of hierarchical spline bases,
the interested reader is referred to [257].
By construction,N 1 ⊆H, thus the approximation properties of B-splines and NURBS are
inherited by their hierarchical counterparts. In particular, constants are exactly represented
and all patch tests are satisfied [132, 219].
2.10.2 The geometric map for hierarchical splines
The geometric map x : Ω̂⊂ Rdp 7→Ω⊂ Rds for hierarchical splines can be constructed
in various ways. Let ng denote the number of geometric blending functions. In this paper
we will associate a ds dimensional control point PA to each function N1A ∈ N1 and write















A=1. We can also use the functions in N
1 to
represent the weight function w(s) if we are working with a rational basis [66, 219].
2.10.3 Bézier extraction
It is not immediately obvious how to integrate hierarchical splines into existing finite
element tools. A primary challenge is converting the hierarchy into a finite element
mesh. A simple and elegant solution to this problem is based on Bézier extraction. This
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Figure 2.12. Basis functions for a univariate quadratic hierarchical spline space. Functions
in H are represented with solid lines and a different color for each level. Functions in Nα dependent on
higher-level functions are depicted with dashed lines in the corresponding color for each level. Functions that
are not fully supported by the hierarchy of subdomains Ω̂α are represented in gray dotted lines. In each level,
the Bézier elements in Eα (see Section 2.10.3) that are contained in the subdomain Ω̂α are shown in black and
the remainder in dark gray. Bézier elements in HE (see Section 2.10.3) are highlighted in green across the
hierarchy. Note that the functions in H are supported entirely by Bézier elements. Reproduced from [166].
technique was initially introduced in [29] for NURBS and in [220] for T-splines. Then it
was extended for hierarchical splines [219] and hierarchical analysis-suitable T-splines
[83]. Bézier extraction collapses the spline hierarchy onto a single level finite element
mesh. Both the hierarchical basis H and geometry are described with the same set of
Bernstein basis functions.
2.10.3.1 Bézier elements
We denote a Bézier element by e and the set of all Bézier elements on each hierarchical
level by Eα . The set of Bézier elements HE corresponding to a spline hierarchy can be
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determined recursively by selecting specific Bézier elements from each Eα , α = 1, . . . ,nh.
We will use the index e to enumerate the elements in HE and we denote by ne the number
of elements in HE. The parametric domain of an element e is denoted by Ω̂e and we use
Ωe to denote the physical domain corresponding to Ω̂e under the geometric map (2.24).
The set of all Bézier elements is also called the Bézier mesh. We build HE as follows:
1. Initialize HE1 = E1.
2. Recursively construct HEα+1 from HEα and Eα by setting
HEα+1 = HEα+1coarse∪HEα+1f ine , α = 1, . . . ,nh−1
where
HEα+1coarse = {e ∈ HEα : Ω̂e 6⊆ Ω̂α+1}
and
HEα+1f ine = {e ∈ E
α+1 : Ω̂e ⊆ Ω̂α+1}
3. Set HE= HEnh .
The previous algorithm bears much in common with the selection mechanism to build the
hierarchical basis. We exclude from HEαcoarse the elements e ∈ HEα whose parametric
domain is also contained in Ω̂α+1 because there exists a union of finer elements in that
subdomain that represents Ω̂e. Indeed, HEα+1f ine brings in those finer elements. Notice
that only the elements contained in the subdomains Ω̂α , α = 1, . . . ,N, are eligible to be
part of the Bézier mesh. In Fig. 2.12, the elements in HE are colored in green across the
hierarchy. Fig. 2.13 shows the Bézier mesh HE for a two-dimensional hierarchical spline
space together with the Bézier meshes Eα corresponding to each hierarchical level.
2.10.3.2 Hierarchical extraction operator
Over each Bézier element it is possible to determine the Bernstein-Bézier representation
of the hierarchical basis functions. This relationship can be written as
He =CeB (2.26)
where He is the vector containing the hierarchical basis functions with support over the
element, Ce is the element extraction operator whose entries are computed using standard




















































































































































































































































A computational approach for the tissue-
scale, patient-specific prediction of PCa
growth
3.1 Introduction
In this Chapter, we present a phenomenological model for PCa that qualitatively re-
produces in vitro experiments and the actual growth patterns of PCa during the early
to mid-late stages of the disease, when PCa is usually diagnosed and treated. We also
describe how the mathematical modeling and simulation of PCa could be integrated in
the clinical management of the disease on a tissue-scale, patient-specific basis within the
context of mathematical oncology. Although the potential of PSA as a PCa biomarker
remains unclear, PCa diagnosis and monitoring in clinical practice relies heavily on PSA
time evolution. Thus, we also propose an equation that models the PSA dynamics within
the prostatic tissue. Under certain assumptions, the integration of this equation leads
to another one governing the dynamics of serum PSA, whose solution can be directly
interpreted by a urologist. In addition, our PSA model may shed light on the role of
PSA as a biomarker for PCa, which is currently one of the most contentious debates in
the urology community. Our modeling and simulation technology also addresses new
challenges posed by the tissue-scale problem. Traditional smaller-scale modeling usually
ignores the geometry of the host tissue. Yet, experimental evidence shows that tissue
geometry determines sites of branching morphogenesis and plays a key role in tissue
growth [182], and, consequently, in cancer development. Accounting for tissue geometry
might be especially relevant in PCa because prostate anatomy varies significantly from
one person to another, and PCa normally develops in the PZ, close to the prostatic cap-
sule. Thus, we propose the use of patient-specific anatomy in PCa modeling. We utilize
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techniques of computational geometry to extract the precise anatomy of the prostate from
medical images, as well as the initial location and shape of the tumor for a patient. Then,
we perform fully three-dimensional computer simulations that predict the growth of the
tumor, including the first patient-specific simulation of PCa evolution based on prostatic
anatomy obtained from CT images.
3.2 A mathematical oncology framework for PCa
Based on the current standards of clinical practice for PCa, the inclusion of the methods
of predictive medicine require diagnostic medical imaging, such as mpMR imaging
[51, 64, 75, 87, 111, 116, 123, 153, 202, 227, 238, 261, 266–268, 274]. In the future,
imaging might replace the biopsy, thus eliminating an invasive procedure and introducing
a more powerful tool to determine the presence of cancer. Imaging also makes it possible
to construct a precise virtual anatomic model of the prostate and tumors for a given
patient [90, 278–280]. A mathematical tissue-scale, patient-specific anatomic model for
PCa will enable the prediction of the progress of the disease. This information, along
with factors like age, life expectancy, overall health status, and patient preferences, will
enable a urologist to make a more informed diagnosis and treatment plan. Moreover, the
mathematical model may be used to simulate, compare and contrast alternative treatments,
and then define and prescribe optimal treatment plans for individual patients. The follow-
up in this context consists of a dialogue between current techniques, based on PSA
monitoring and medical imaging, and the computer modeling and simulation of treatment
response. Fig. 3.1 depicts the approach for the clinical management of PCa within the
context of mathematical oncology that we have described in this section.
3.3 Mathematical model
Localized PCa growth can be interpreted as a moving interface problem aimed at deter-
mining the evolution of the interface that separates healthy and cancerous tissue. From
this standpoint, we use the phase-field method to account for the healthy-to-tumoral
transition and the coupled dynamics of both the host tissue and the cancerous cells,
resulting in the diffusion-reaction model in Eq. (3.1). We define an order parameter φ ,
which is a measure of cellular microstructure. This order parameter varies between 0 and
1. Lower values represent healthy tissue while higher values represent an aberrant cell
organization, typical of PCa. The level set φ = 0.5 implicitly defines the interface.
The growth of PCa is driven by a host of hormones, growth factors and vital nutrients,
but for the sake of simplicity, we will assume that tumor growth chiefly depends on
nutrients, in particular, glucose. The model could also incorporate other substances,
but their regulatory effect on PCa growth can be interpreted equivalently in terms of
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3 · A computational approach for the tissue-scale, patient-specific prediction of PCa growth
glucose. Hence, if we modify the baseline glucose dynamics, we can also account
for these ancillary substances affecting tumor growth. Therefore, we will consider the
evolution of a nutrient η , mainly composed of glucose. We will assume that convection
has a negligible contribution to the transport of glucose, a fact that is consistent with
experimental observations [59]. This assumption leads to the diffusion-reaction model in
Eq. (3.2). The complete model reads as
∂φ
∂ t








= Dη ∆η +S−δφ − γη η (3.2)
In Eq. (3.1), F(φ) is a double-well potential, a typical function within the phase-field
method, that makes possible the stable coexistence of healthy and cancerous cells in the
prostate, and takes on the explicit form
F(φ) = 16φ 2(1−φ)2 (3.3)
The last two terms in Eq. (3.1) account for nutrient-driven growth and apoptosis (i.e.,
programmed cell death), respectively. We assume that the growth rate depends linearly
on the local nutrient concentration [80] with the growth rate coefficient χ . We further
assume that apoptosis follows a linear relation with the population of tumoral cells, A
being its rate, as this is the natural response in the prostatic tissue. In Eq. (3.2), S is
the nutrient supply. On the right-hand side of the equation, the third term represents
the consumption of nutrient by the tumoral cells, while the fourth term accounts for the
natural decay of nutrient.
The values for the model parameters can be obtained from numerous studies [6, 25, 68,
80, 180, 216] on nutrient transport within tissues and tumor growth. We will always
take τ = 0.01 year, δ = 2.75 g/(L·day) and γη = 1000 1/year. However, we consider
several values for the growth rate χ and the apoptosis rate A, ranging from χ =400
L/(g·year) to χ =700 L/(g·year) and from A =100 1/year to A =700 1/year, in order to
recreate the different morphologies of PCa growth during its first stages. To make the
problem computationally tractable, we take Dφ ∼ h2/T , where h is the characteristic
length scale of the computational mesh and T is the characteristic time scale, which we
have considered to be 1 year (see [105] for rationale). In accordance with other models of
tumor growth, we will take Dη ∼10Dφ to Dη ∼100Dφ , which manifests the experimental
observation that tumor dynamics is slower than nutrient dynamics.
We will introduce the nutrient supply in two different fashions in order to simulate
the experimental results regarding the tumor morphology change. Beginning with a
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Figure 3.2. Vasculature allows to define a mild heterogeneity for the nutrient supply. A: Capil-
lary network used in order to introduce a more realistic distribution in the nutrient supply for a tissue domain
of 2000×2000 µm; taken from [98]. B: Values of the nutrient supply in g/(L·day) according to the previous
vascular network, which are higher in the vicinity of the blood vessels and get lower as we consider a point at a
sufficient distance from them. The nutrient supply is obtained by filtering the color map in the vascular-network
image and building a matrix that holds the values of the nutrient supply at an even interval along each direction.
For 3D simulations, we use an average of the three values obtained from reading the nutrient supply as though
it were placed on the three coordinated planes. Reproduced from [165].
homogeneous supply with a value S1 = 2.75 g/(L·day), we will perform a series of
simulations which already show the shape instability that makes an initially rounded
tiny mass of aberrant cells grow with a fingered pattern invading the surrounding tissue.
Afterwards, we will set the previous value to be the base S0 upon which we will add a
mild heterogeneity Sc, which takes values between −0.2 g/(L·day) and 0.2 g/(l·day). In
this case the nutrient supply will be S2 = S0 +Sc. Making use of an experimental image
from [98], we add the previous value Sc according to the vascular network depicted in
the image, so that the nutrient supply will be maximum, S = 2.95 g/(L·day), near the
blood vessels and minimum, S = 2.55 g/(L·day), at a point sufficiently far from them
(see Fig. 3.2). Both S1 and S2 attempt to represent in vitro conditions, but the latter aims
at reproducing a more realistic scenario. However, for the tissue-scale, patient-specific
simulations we have considered a more appropriate constant value of S3 = 2.70 g/(l·day).
We introduce an additional equation that models PSA dynamics within the prostate tissue
based on a novel measure for PSA: the tissue PSA ρ , or serum PSA concentration leaked
to the bloodstream per unit volume of prostatic tissue. Hence, tissue PSA will allow us to
study the spatial distribution of the sources of serum PSA concentration within the gland.
Both healthy and cancerous cells secrete PSA, but the latter generally produce PSA at a
much higher rate than healthy cells [259, 265]. We will denote cancerous and healthy
rates of PSA production per unit volume of prostatic tissue by αc and αh, respectively.
Similarly to other substances within the prostate, such as the nutrient, we also assume that
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the concentration of tissue PSA ρ diffuses over the prostatic tissue and decays naturally
with a rate γρ , following Eq. (3.4).
∂ρ
∂ t
= Dρ ∆ρ +αh(1−φ)+αcφ − γρ ρ (3.4)
Considering that ρ represents the concentration of serum PSA that leaks to the blood-
stream per unit volume, then we can define serum PSA Ps as the integral of the tissue





If we integrate Eq. (3.4) over the tissue region that we are simulating and assume free-flux
boundary conditions, we obtain the following ordinary differential equation
dPs
dt
= αhVh +αcVc− γρ Ps (3.6)
where Vh and Vc denote, respectively, the volumes of healthy and cancerous tissue. This
equation has been already proposed in [229] as a model for serum PSA dynamics. A
similar, yet simplified, version also appears in [253]. References [31] and [201] provide
data of prostate gland volumes and age-related PSA scores for a cohort of healthy men,
respectively. We used these data to estimate αh and γρ by means of Eq. (3.6), choosing the
values αh = 6.25 (ng/mL)/(cc·year) and γρ = 100 1/year, respectively, which correlated
well, as it can be seen in Fig. 3.3. Indeed, this value of γρ corresponds to a PSA half-life
of 2.5 days, which is consistent with the values reported in [37, 169, 259, 265]. As
PSA is produced in higher levels in cancerous cells, we decided to take αc = 15αh, yet
this proportion can be modified to represent different real cases for each patient, also
introducing different levels of PCa malignancy. Finally, as both cancerous cells and a
higher production of PSA are linked features in PCa, we will assume that Dφ = Dρ .
Because we are focusing on localized PCa, we imposed zero-valued Dirichlet conditions
for φ all over the prostate boundary. We set natural boundary conditions for η and ρ .
3.4 Patient data
The Austin Radiological Association provided us with a series of axial and coronal CT
images of a small cohort of patients with PCa, with and without contrast (institutional
review board approval and informed consent were not required for this study). CT is a
not a suitable technique for the detection of localized PCa due to its reduced contrast
between healthy and cancerous tissue within this gland. However, it is implemented in
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Figure 3.3. Estimation of tissue PSA parameters. Correlation of the serum PSA time history between
our model and the average values of prostate volumes and PSA scores of healthy men presented in [31] and
[201], respectively. Reproduced from [165].
PCa protocols primarily in order to scan for metastasis or as a resource to initially analyze
the prostate anatomy and the pelvic region with more detail than ultrasound.
We have chosen one of these patients in order to predict the evolution of his prostatic
tumor with our model and assess the performance of the simulation on the basis of the
current knowledge of PCa evolution. This patient showed a small cancerous lesion of
0.03 cm3, previously detected by US, in the posterior part of the PZ at the middle region
of the prostatic gland. The volume of the prostate gland is considered constant along the
simulation and has a value of 71.67 cc.
3.5 Numerical methods
The nonlinearity of the set of equations that comprise the model in Section 3.3 and
the complex geometry of both the prostate and the initial tumor in the patient-specific
simulations call for very efficient methods of resolution in terms of memory and time
of computation. To perform the numerical simulations, we introduce new algorithms
based on the concept of IGA [66, 130]. To speed up the calculations and create a
technology that facilitates obtaining solutions in a clinically relevant time, we also
advocate dynamic mesh-adaptivity techniques based on the concept of hierarchical
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refinement and coarsening [215, 219, 234, 257]. The details on our numerical algorithms
will be presented as a central contribution in Chapter 4.
To extract geometric models of the prostate and the initial tumor, several methods have
been proposed to construct solid anatomic NURBS models [90, 278–280]. Since the
geometry of a prostate is topologically equivalent to that of torus, we employ a parametric
mapping method to deform a torus NURBS model to match with the patient-specific
prostate surface obtained from CT data, as depicted in Fig. 3.4. Finally, we can hier-
archically refine the computational mesh that represents the anatomy of the prostate to
perform precise patient-specific simulations. For further information on our methodology
to generate patient-specific prostate meshes from medical images, the interested reader is
referred to Section B.1.
CT imaging is not sufficiently accurate to detect localized PCa, so we resorted to the
prior reported TRUS data to get the location and estimated shape of the tumor. Hence,
in order to introduce the initial tumor in the model, we approximated its geometry as an
ellipsoid. In particular, we L2-projected a three-dimensional hyperbolic tangent field onto
the spline space that defines the anatomy of the patient’s prostate in order to approximate
the initial tumor with the phase field, hence obtaining an ellipsoidal cancerous mass in
terms of the order parameter φ (see Fig. 3.9(A)).
3.6 Simulation of PCa growth
3.6.1 Growth patterns of localized PCa
The morphology of PCa may vary from spheroidal tumors to tubular or fingered struc-
tures that invade the prostatic epithelium forming branches, as demonstrated by clinical
practice and in vitro experimental studies involving cultures of prostate epithelial cells
[128]. Large-scale, two-dimensional and three-dimensional simulations of Eq. (3.1) and
Eq. (3.2) show that the model can predict both growth types, as depicted in Fig. 3.5, and
hence qualitatively reproduces the associated clinical and experimental results for both
morphologies in references [128, 194].
It has been suggested that this change in tumor morphology is promoted by a series of
chemical signals, also motivated by specific mutations or epigenetic changes. However, a
conclusive explanation of the mechanisms of this shift in cancer growth remains largely
unknown. We have been able to activate the shape instability using two mechanisms
previously suggested in the literature: first, increasing the parameters χ and A in Eq. (3.1),
which represents a more aggressive cancer with larger apoptosis [6, 68], and second,
reducing the value of the nutrient supply S, which may be understood as a situation in
which the tumor is surrounded by a harsh microenvironment [7, 194].
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Figure 3.4. Extraction of the geometry of the prostate and the initial tumor from CT data. The
process to perform tissue-scale, patient-specific simulations begins by extracting in vivo data of the patient
from medical images, such as his prostate anatomy, the tumor location, and its shape. A: Axial CT image of
the patient’s abdomen at the height of the middle prostatic gland. B: We generate a NURBS model of a torus,
which is topologically identical to a prostate. C: Using computer graphics techniques we map the torus to the
actual geometry of the patient’s prostate (posterior view). D: Finally, we use hierarchical refinement to generate
the computational mesh (anterior view). Reproduced from [165].
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Figure 3.5. Different growth morphologies adopted by initially spheroidal prostatic tumors.
Large-scale, two-dimensional and three-dimensional simulations of our model reproduce the spheroidal and
fingered tumor growth patterns as seen in clinical practice and experiments (Dφ = 5 ·10−11 cm2/s, Dη = 2 ·10−9
cm2/s ). We have used the heterogeneous nutrient supply S2 in these simulations to produce more realistic
patterns of growth. A: In vitro three dimensional Matrigel culture of PC-3 cells growing with a spherical or
rounded pattern (taken from [128]). Large-scale, two-dimensional (B) and three-dimensional (C) simulations of
our model reproducing spheroidal growth (χ = 400 L/(g·year), A = 300 1/year). D: In vitro three dimensional
Matrigel culture of RWPE-1 cells showing a fingered morphology (taken from [128]). Large-scale, two-
dimensional (E) and three-dimensional (F) simulations of our model reproducing fingered growth (χ = 600
L/(g·year), A = 600 1/year). Reproduced from [165].
66









Figure 3.6. Nutrient distribution in PCa morphologies. The white line corresponds to the tumor
contour. A: For the spheroidal morphology, the nutrient concentration is ∼0.85 g/L out of the cancerous mass
and ∼0.10 g/L in its interior. B: Stable fingered growth shows concentrations of ∼0.30 g/L where the tumor is
developing and ∼0.70 g/L in the remainder healthy tissue. These subfigures correspond to simulations on a
2000×2000 µm computational domain using the homogeneous nutrient supply and the parameters cited in
Fig. 3.5. Reproduced from [165].
Spheroidal or ellipsoidal growth takes place in the very first stages of PCa, when it
is not excessively malignant. We conjecture that at these early stages the tumor will
feature low values for the growth rate χ and the apoptosis rate A. In particular, taking the
aforementioned default values for all the parameters in the model, χ = 400 L/(g·year) and
A = 300 1/year, leads to a spheroidal pattern of growth, as it can be seen in Fig. 3.5(B)-
(C). Conversely, the fingered morphology corresponds to a more advanced cancer in
comparison to the spheroidal pattern, still within the scope of localized PCa. This tubular
growth can be reproduced by our model with higher values of these two parameters,
which must also be balanced, that is, they must take similar values. In order to perform
the simulations depicted in Fig. 3.5(E)-(F), we have taken χ=600 L/(g·year) and A=600
1/year, which appear to yield a characteristic fingered morphology.
Interestingly, with this latter selection of parameters we initially observe spheroidal
growth. Should the tumor continue to develop with this morphology, the nutrient con-
centration in its central region would drop to values promoting hypoxia, starvation and
necrosis (see Fig. 3.6). However, once the tumor reaches a volume that would lead to
this inner harmful environment, the shift towards the fingered morphology takes place.
With this growth pattern, the nutrient concentration within the tumor is not critical any
longer (see Fig. 3.6). In particular, Fig. 3.7 shows this evolution in a simple experimen-
tal scenario. Whether we consider the homogeneous or the heterogeneous definition
for the nutrient supply, as long as S1 = S0, the shape instability will occur at a similar
time. However, the spatial distribution will be different, as the homogeneous nutrient
supply produces symmetrical patterns of fingered growth and the introduction of a mild
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Figure 3.7. Details on the onset and evolution of the shape instability. In each subfigure, the left
image corresponds to the tumor geometry and the right image shows the nutrient field. We have also plotted the
tumor contour in white over the nutrient field to represent the differences between healthy and tumoral tissue.
A-B: The initial tumor initially develops with the spheroidal pattern but the shape instability takes place to
avoid the formation of a central necrotic core, owing to hypoxia and starvation of the most inner cells in the
tumor. C-D: Then, the evolution of the fingered morphology begins with two areas of preferential growth which
will get thinner as their shape develops. E-H: Secondary and thinner branches develop until the tumor occupies
the whole computational domain. These subfigures correspond to instants 0.1 years apart of a simulation on a
2000×2000 µm computational domain, from t = 0 to t = 0.7 years. We used the homogeneous nutrient supply
and the parameters cited in Fig. 3.5. Reproduced from [165].
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heterogeneity promotes growth along the gradients of η .
If we reduce the value of the nutrient supply, that is, S1 for the homogeneous version,
and S0 for the heterogeneous one, then fingered growth may take place for a selection of
χ and A which would produce spheroidal growth otherwise. Furthermore, in the range
of values for χ and A typical of fingered growth, reducing S accelerates the onset of the
shape instability. We also observe that a drop in the values of S leads to slower tumor
growth, while increasing the nutrient supply makes the tumor grow at a faster rate. In the
case of the fingered morphology, the higher the value of S, the thicker the branches of
the tumor (see Fig. 3.8), as the resulting higher concentrations of the nutrient within the
tissue support larger tumoral structures.
3.6.2 Patient-specific simulation
Fig. 3.9 represents the prediction of the growth of a prostatic adenocarcinoma according
to our model at tissue scale and on a patient-specific basis, that is, we ran our model on
the actual geometry of the prostate of the patient under consideration (see Section 3.4),
after extracting it and the initial tumoral volume from the CT output files. This simulation
represents tumor growth during 1 year and at the end the tumor volume is 2.66 cc.
Initially, the tumor grows following an ellipsoidal pattern but it soon starts to develop
preferential directions of growth, defining finger-like structures. As the tumor expands
within the prostate, its geometry evolves toward a structure consisting of thickened layers
of cancerous tissue with fingered protrusions along the main directions of growth. The
axial section at the mid-gland shows an evolution from the spheroidal pattern of growth to
the fingered morphology similar to that observed in large-scale, 2D and 3D simulations.
The tumoral area in these sections qualitatively matches some delineations of PCa made
on actual histopathologic specimens [185] in terms of size and shape. As the delineations
of [185], Fig. 3.9(D)-(F) shows axial sections with disjoint cancerous regions. In the
absence of the 3D representation of both the prostate and the tumor, this situation might
be classified as a multifocal tumor, rather than a single tumor with fingered shape.
We observed that if we changed the position of the tumor within the prostate, but conserved
its original shape, the tumoral pattern of growth was different. These results suggest that
cancer growth morphology is dependent on the particular geometry of the tumor as well
as on the specific anatomy of the prostate. Consequently, this observation supports the
major importance of considering patient-specific anatomies for both the prostate and the
tumor to accurately predict tumor growth.
The simulation presented in Fig. 3.9 shows an important and typical feature of PCa,
namely, why some biopsies are falsely negative or apparently yield a lower tumoral stage.
As the tumor grows, it develops finger-like structures after the morphology shift that,
in a three-dimensional, patient-specific scenario, evolve not only as branches but also
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Figure 3.8. Fingered morphology of PCa growth in the presence of decreased and increased
nutrient supply. In each subfigure, the left image corresponds to the tumor geometry and the right image
shows the nutrient field. We have also plotted the tumor contour in white over the nutrient field to represent the
differences between healthy and tumoral tissue. A: The fingered morphology develops with less and thinner
branches with a reduced nutrient supply of 2.60 g/(L·day). B: Fingered tumoral geometry of reference using a
nutrient supply of 2.75 g/(L·day). C: An increased nutrient supply of 2.80 g/(L·day) produces wider branches.
These subfigures correspond to simulations on a 2000×2000 µm computational domain using the homogeneous
nutrient supply and the parameters cited in Fig. 3.5. Reproduced from [165].
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Figure 3.9. Tissue-scale, patient-specific simulation of PCa growth. These images show the
predicted evolution of a prostatic tumor on the actual anatomy of the prostate of an individual patient (Dφ = 0.24
mm2/day, Dη = 7.5 mm2/day ). The axial section depicted is at z=25.5 mm, with the origin of the coordinate
z set at the prostate base (A: anterior, P: posterior, L: patient’s left, R: patient’s right). The position of this
section has been shaded in dark blue in the anterior and posterior views for t = 0. A: Initial tumor as identified
in the patient’s CT images. B-F: Predicted growth according to our model during 1 year, with each subfigure
corresponding to an instant 0.2 years apart. Reproduced from [165].
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as thickened layers of cancerous cells. Likewise, there are other layers and regions of
healthy tissue surrounding and in between these cancerous layers, which are required in
order to provide an adequate distribution of the nutrient. When a biopsy is performed
following the current standards, a number of tissue samples are obtained in prescribed
positions trying to map the whole prostatic gland. However, the tumor might be out of the
reach of the needle used in the biopsy, resulting in a false negative, or it may target one
of these tumoral thickened layers orthogonally, what may produce a low percentage of
tumor in the tissue sample, leading to further biopsies or/and an erroneous stage of PCa
that may compromise the patient quality of life and survival. One might conclude that the
pathology analysis of a prostatic tumor biopsy would always provide a lower bound to
the severity of the cancer, creating a dangerous predictive scenario.
3.6.3 Tissue and serum PSA
In our simulations tissue PSA evolution is obtained from Eq. (3.4), and serum PSA
evolution is then obtained from Eq. (3.6). The field of tissue PSA typically shows higher
values in the central areas of the tumor and lower values as we move away from the
lesion, as depicted in Fig. 3.10. The difference in the values of ρ in healthy and cancerous
tissue is due to the fact that the initial tumor starts producing PSA at a higher rate from
the first moment and, as the tumor grows, higher tissue PSA values are found in the
areas occupied by cancerous cells and following the preferential directions of growth. In
general, tissue PSA values do not differ greatly between healthy and tumoral tissue in
our 2D and 3D experimental simulations. However, in the tissue-scale, patient-specific
simulations, the values of ρ in the tumor, around 0.70 (ng/mL)/cc, were an average of 3
times higher than in the healthy regions, around 0.24 (ng/mL)/cc; as seen in Fig. 3.10.
Taking lower values for αc, but greater than αh, the field of tissue PSA becomes more
homogeneous, meaning that the peak values are lower too, due to the reduced difference
between the rates of production of PSA in healthy and cancerous cells. The evolution
of serum PSA is linked to the velocity of tumor growth. The faster the tumor grows, the
faster serum PSA increases because there are more tumoral cells, producing PSA at a
higher rate. Taking lower values for αc also induces lower PSA scores in blood and the
PSA velocity is also slowed down.
We obtain the serum PSA by integrating the values of ρ over the entire prostate anatomy.
We lacked the biochemical data for the patients on our cohort, so we had to estimate
the baseline serum PSA according to the tumor stage and the dynamics imposed by our
model. Beginning with the minimum value of 4.0 ng/ml, beyond which a physician would
recommend a TRUS-guided biopsy, we observed a steep jump towards a higher value in
the first time steps and then serum PSA followed exponential dynamics, as observed in
clinical practice [229, 253, 254, 259, 265]. Therefore, in order to produce more realistic
simulations, we restarted our model once this readjustment of serum PSA was completed,
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Figure 3.10. Tissue PSA distribution across the prostate gland at t = 0.5 years, tumor volume
evolution and serum PSA history. Tissue PSA takes higher values on the tumoral tissue because it is
produced by cancerous cells at a higher rate. A: Anterior view of the prostate and tumor at t = 0.5 years with
the location of the axial sections depicted in this figure as black contours on the tumor. B: Predicted serum PSA
and tumor volume time histories. C-F: Evenly-spaced axial sections of the prostate representing the distribution
of tissue PSA ρ at time t = 0.5 years and height z = 18.3 mm, z = 21.6 mm, z = 24.9 mm, and z = 28.2 mm,
respectively, with the origin of the coordinate z set at the prostate base. The white line is the contour of the
tumor (A: anterior, P: posterior, L: patient’s left, R: patient’s right).
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correcting the initial condition for ρ so that it corresponded to the value of serum PSA
reached just after the rising branch. Hence, serum PSA readjustment was eliminated and
it followed exponential dynamics from the beginning of the simulations. In particular, we
have estimated an initial serum PSA level of 17.3 ng/mL and, at the end of the simulation,
PSA reaches 18.9 ng/mL. Fig. 3.10 shows the predicted serum PSA history for our patient
taking into account all these considerations together with the time history for tumor
volume. Indeed, we have observed a parallelism between both dynamics, as it has been
previously reported in literature [229, 253, 259, 265].
3.7 Conclusions
In this Chapter, we describe a computational framework to contribute to the clinical
management of PCa within the context of mathematical oncology. We introduce a
mathematical model for the growth of localized PCa, which constitutes the baseline
theory for the work presented in this thesis. This model is derived using the phase-
field method to account for the coupled dynamics of healthy and cancerous tissue. The
model is completed with two reaction-diffusion equations to capture the dynamics of a
generic nutrient and tissue PSA, which measures serum PSA production per unit volume
of prostatic tissue. We propose the use of IGA methods to accurately and efficiently
address the nonlinerarity of our model, the complex geometry of the prostate, and
the intricate growth patterns of prostatic tumors. In addition, we advocate the use of
dynamic mesh adaptivity techniques based on hierarchical refinement and coarsening
to accelerate the simulations of tumor growth and obtain results in a clinically relevant
time. The description and analysis of these computational methods are addressed in
Chapter 4. We also propose a methodology to obtain patient-specific prostate meshes
from medical images by means of a parametric mapping method (see Section B.1 for
further information).
Our simulations show that our model is able to reproduce the typical features of prostatic
adenocarcinoma growth from the first to the mid-late stages of the disease as seen in
experimental results and clinical practice. Our model reproduces a known shape instability
from a spheroidal pattern to fingered growth. Our computations suggest that such shift is
a tumor response to avoid starvation, hypoxia, and eventually, necrosis. The branching
morphology enables the tumor to minimize the distance from inner cells to external
nutrients. Therefore, this mechanism contributes to the survival of PCa and supports
its development. We have also leveraged our model to perform the first tissue-scale,
patient-specific simulation of PCa growth based on prostatic anatomy extracted from




Hierarchical adaptivity strategies for the
resolution of phase-field models of PCa
growth
4.1 Introduction
In the context of phase-field models, local adaptivity is essential to accurately and
efficiently resolve evolving interfaces. In particular, hierarchical splines are an attractive
adaptive technology, for the reasons outlined in Section 2.10. In this Chapter, we present a
set of algorithms for coupled local hierarchical h-refinement and h-coarsening and apply it
in the context of adaptive IGA. Our algorithms are capable of handling evolving interfaces
efficiently. The framework is based on an extension of Bézier extraction and projection
to the hierarchical setting. The coarsening projection is local and quadrature-free. We
introduce a balance parameter to control the overlap of hierarchical basis functions
resulting in superior conditioning of the resulting linear systems. Coupling the localized
projection and the balance parameter enables fine-grain control over the behavior of the
adaptive algorithms.
In order to illustrate our methods we address the simulation of localized PCa growth using
the phase-field model that we introduced in Chapter 3. This problem has an evolving
interface which separates the tumor from the surrounding healthy tissue. To resolve
this interface we use our local adaptivity approach. First, we describe and analyze the
behavior of our adaptive algorithms in simple 2D and 3D settings. Then, we apply them to
a tissue-scale, patient-specific simulation, where we solve our equations of tumor growth
over the patient’s prostate anatomy extracted from CT images. Finally, we demonstrate
that our algorithms for local adaptivity are a cornerstone in the successful implementation
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of our model for localized PCa growth as a predictive tool for the clinical management of
the disease.
4.2 Hierarchical reconstruction operator
The element extraction operator Ce for single-level spline representations like B-splines,
NURBS and analysis-suitable T-splines is invertible. The inverse of Ce is called the
reconstruction operator [234] and is denoted by Re. For hierarchical splines there are
elements where Ce is not invertible since the hierarchical basis, restricted to the element
domain, is not linearly independent (see Section 2.10). To overcome this limitation we
define the element reconstruction operator as
Re = (LeCe)−1Le (4.1)
where Le is called a transmission refinement operator and it is computed following
Algorithm 4.2.1. Fig. 4.1 illustrates the action of Le.
Algorithm 4.2.1. Computation of the transmission refinement operator Le and the
reconstruction operator Re for an element e.
1. Compute He and Ce over element e.
2. Search through the functions in He finding the function from the coarsest level αc.
3. Find ec in Eαc such that Ω̂ec ⊃ Ω̂e.
4. Construct a vector Nec of all the functions in Nαc that have support over the
element ec. These functions form a complete, locally linearly independent basis at
level αc over ec.
5. Build the transmission refinement operator Le from element e to element ec mapping
from the functions in He to Nec , that is
Nec = LeHe. (4.2)
This can be done using standard knot insertion techniques [66, 130, 195].
6. Build the reconstruction operator Re using Le and Ce in Eq. (4.1).
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Figure 4.1. Bézier extraction operator Ce and reconstruction operator Re for a bilinear hi-













, which we represent throughout their support. However, the bilinear Bernstein
basis contains only 4 functions, so Ce is not invertible. Le maps the functions in He to a local independent










. The functions in Nec are also represented
throughout their support. Now, we can map the functions in Nec to the Bernstein basis throughout the spline
reconstruction operator (LeCe)−1. Then, the hierarchical reconstruction operator over the element is given by
Re = (LeCe)−1Le. Reproduced from [166].
4.3 Hierarchical refinement
Local refinement for hierarchical splines is straightforward due to the multilevel construc-
tion of the basis.
Algorithm 4.3.1. Refinement of a hierarchical B-spline.
1. Create the refined hierarchical destination mesh from a hierarchical source mesh
by defining the refined subdomains Ω̂αr such that Ω̂
α ⊆ Ω̂αr , α = 1, . . . ,nh.
2. Build the refinement operator Ma,b using knot insertion [66, 130, 195] such that
Nb =Ma,bNa (4.3)
3. Construct the destination spline coefficients Pb from the source spline coefficients
Pa as
Pb = (Ma,b)TPa (4.4)
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4.4 Hierarchical coarsening
Bézier projection will be used to perform local coarsening. For a complete exposition on
the subject the interested reader is referred to [234], which also addresses Bézier projec-
tion onto and between analysis-suitable T-spline spaces, shows the optimal convergence
rates of the methodology, and demonstrates its applicability to hpkr-adaptivity in IGA. Of
particular importance is the possibility to use Bézier projection to develop quadrature-free
coarsening algorithms.
Using Eq. (4.1) as the reconstruction operator we can employ Bézier projection to
coarsen hierarchical splines spaces and to project fields defined over a source mesh onto
a coarsened destination mesh.
Algorithm 4.4.1. Projection of the control values from m source elements {ei} onto the
control values for a single coarse element ē in the destination mesh.
1. Use the element extraction operators for the elements {ei} to convert the control
values on each element to Bézier form
Qei = (Cei)TPei . (4.5)








where φi = vol(Ω̂ei)/vol(Ω̂ē) .
3. Compute the element reconstruction operator for ē using Algorithm 4.2.1 to convert
the Bézier control values to spline control values
Pē = (Rē)TQē. (4.7)
Algorithm 4.4.2. Coarsening of a hierarchical B-spline.
1. Create the coarsened hierarchical destination mesh from a hierarchical source
mesh by defining the coarsened subdomains Ω̂αc such that Ω̂
α ⊇ Ω̂αc , α = 1, . . . ,nh.
2. Perform the Bézier projection in Algorithm 4.4.1 to obtain the set of local control
values for each element in the destination mesh.












4.5 · Function support balancing
where EA = HE∩ supp(NA), to compute the new global control values for the Ath








4.5 Function support balancing
Balancing controls the overlap of functions across the hierarchy. In other words, it
prevents the elements in level α from supporting hierarchical basis functions from level β
where α  β . In the context of IGA, such a situation would result in poorly conditioned
system matrices. Balancing is performed every time the hierarchical mesh HE changes.
The balancing behavior is controlled by a parameter called the balance parameter.
To simplify the exposition, we introduce the concept of parent element, grandparent
element, and child element. Given an element e ∈ Eα , we say that the parent element of e
is another element p ∈ Eα−1 such that Ω̂p ⊃ Ω̂e. Likewise, the greatk−1 grandparent of
element e is an element g ∈ Eα−k−1 such that Ω̂g ⊃ Ω̂e. The children of element e are
the set of elements {ei} ∈ Eα+1 such that Ω̂ei ⊂ Ω̂e.
Algorithm 4.5.1 outlines ring balancing, a simple strategy which was introduced in [219].
Algorithm 4.5.1. Balancing of a hierarchical spline for a given value of the ring balance
parameter, nrb ∈ N.
1. Partition HE by sorting the elements according to their hierarchical level, hence
building the subsets pHEα = Eα ∩HE
2. For α = nh,nh−1, . . . ,1, do the following for each element e ∈ pHEα :
(a) Construct a set P1 ⊂ Eα−1 consisting of the parent of element e, p, and nrb
rings of neighbors of p that lie immediately around p.
(b) Construct a set P2 ⊂ Eα−2 consisting of the parents of the elements in P1.
(c) Update P1 including all the children elements of the elements in P2.
(d) Define the new subdomain Ω̂α−1b = P1∪ Ω̂
α−1.
(e) Define the new subdomain Ω̂α−2b = P2∪ Ω̂
α−2.
As depicted in Fig. 4.2, a reduction in basis overlap is achieved with higher values of
the ring balance parameter. However, some elements might still support hierarchical
basis functions from distant levels after balancing. For instance, in Fig. 4.2(e), element e
supports a function from level 1 after balancing with either nrb = 1 or nrb = 2.
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To overcome this limitation, we developed function support balancing. Function support
balancing is an elementwise balancing procedure that specifically accounts for the level
of each element e, the levels of the hierarchical basis functions in He, and the extent of
the support of these functions. Algorithm 4.5.2 outlines this new balancing strategy.
Algorithm 4.5.2. Balancing of a hierarchical spline for a given value of the function
support balance parameter, n f sb ∈ N.
1. Partition HE by sorting the elements according to their hierarchical level, hence
building the subsets pHEα = Eα ∩HE
2. For α = nh,nh−1, . . . ,1, do the following for each element e ∈ pHEα :
(a) Construct a set P ∈ Eα−n f sb−1 consisting of the greatn f sb−1 grandparent of
element e, g, and the neighbors of g that support e’s hierarchical basis
functions.
(b) Construct a set C ∈ Eα−n f sb consisting of the children of the elements in P.
(c) Define the new subdomain Ω̂
α−n f sb−1
b = P∪ Ω̂
α−n f sb−1.
(d) Define the new subdomain Ω̂
α−n f sb
b = C∪ Ω̂
α−n f sb .
(e) If n f sb > 1, ring balance the current element with nrb = 1.
The function support balance parameter enables us to set a maximum level for the
hierarchical basis functions with support over an element as follows: an element in level
α can only support functions in levels α,α−1 . . .α−n f sb. Should a function from level
β < α−n f sb be nonzero over this element, Algorithm 4.5.2 will refine its support until
the balancing constraint is satisfied. Thus, function support balancing sets an explicit
limit to the overlapping of functions over the elements in HE that we can control directly.
The performance of n f sb is illustrated in Fig. 4.3 on a simple two-dimensional scenario.
Additional analysis of function support balancing will be presented in Section 4.6.5.
Notice that function support balancing also brings an improved control over the compu-
tation of Le: n f sb enables us to explicitly define the distance from the level α of each
element to the coarse level αc in Algorithm 4.2.1. This also implies an enhanced control
of the computation of the reconstruction operator Re and the performance of coarsening
as described in Algorithms 4.4.1 and 4.4.2.
4.6 Application to a phase-field model of PCa growth
In this Section, we present a series of numerical examples that highlight the advantages of
hierarchical adaptivity over uniform meshes in the modeling and simulation of localized
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(a) HE (b) E3 (c) E2 (d) E3 (e) HE
Figure 4.2. Ring balancing of a bilinear hierarchical mesh over an element e for nrb = 1 and
nrb = 2. The considered element e is marked with a circled cross. (a) Original hierarchical mesh. (b)
Construction of P1 over E3 with the parent of element e, p (shaded in darker gray), and nrb rings of elements
surrounding p. (c) Construction of P2 over E2 with the parents of the elements in P1. (d) Update of P1 over
E3 with all the children of the elements in P2. The new elements added to P1 are shown in darker gray. (e)
Final mesh, after redefining the subdomains Ω̂3b = P1 ∪ Ω̂
3 and Ω̂2b = P2 ∪ Ω̂2. In subfigures (b)-(d), elements






















(b) He (c) n f sb = 1 (d) n f sb = 2
Figure 4.3. Function support balancing of a bilinear hierarchical mesh over an element e for
n f sb = 1 and n f sb = 2. The considered element e is marked with a circled cross. (a) Original hierarchical
mesh. (b) Hierarchical basis functions in He, represented throughout their support with lighter shades for each
level. The support of the only hierarchical basis function in He from level 1 covers Ω̂ completely. (c) Resulting
hierarchical mesh after balancing with n f sb = 1 over e. Following Algorithm 4.5.2, P= E2 and, then, C= E3.
Consequently, Ω̂2b = E
2 and Ω̂3b = E
3, so that no function from any level α < 3 enters in He. (d) Resulting
hierarchical mesh after balancing with n f sb = 2 over e. Now, Algorithm 4.5.2 renders P = E1 and C = E2.
Hence, the balancing constraint only applies to hierarchical basis functions in level 1. Finally, we ring balance
the element e with nrb = 1. Reproduced from [166].
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PCa growth. We will leverage the mathematical model presented in Chapter 3, which
develops steep layers representing the interface between the tumor and the host tissue. In
order to capture the interface accurately we require very fine meshes. However, within
healthy tissue (φ = 0) or the tumor (φ = 1) we could use a much coarser mesh to represent
the constant value of the phase field over these regions. Consequently, localized PCa
growth is a paradigmatic problem that can benefit from our local adaptive techniques.
We will show that the use of the techniques described in Sections 4.3, 4.4 and 4.5 are
fundamental in order to perform patient-specific tissue-scale simulations in an accurate
and efficient way – a requisite for the implementation of predictive models of tumor
progression on a clinical scenario.
4.6.1 Spatial discretization
The strong form of our cancer growth problem is composed of Eqs. (3.1)-(3.4). We will
approximate its solution by means of IGA based on a Bubnov-Galerkin approach that
leverages a C1 quadratic hierarchical spline basis H, as introduced in Section 2.10. Let us
denote by V the trial solution and the weighting function spaces, which are assumed to be
identical. The space V is a subset of H1, the Sobolev space of square integrable functions
with square integrable first derivatives. We will only work with free-flux, periodic or
zero-valued Dirichlet boundary conditions. Let us define the discrete space Vh = H,
which is a subset of V . Hence, the corresponding variational problem to Eqs. (3.1)-(3.4)
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where the coefficients φA, ηA and ρA are the so-called control variables in the context of
IGA. The weighting functions wh
φ
, whη , and w
h
ρ are defined analogously [66, 132].
4.6.2 Time integration
We have chosen the generalized-α method [58, 138] in order to perform time integration.
This technique is second-order accurate and A-stable. The generalized-α method leads to
a nonlinear problem at each time step, which we linearize using the Newton-Raphson
method. We used the linear solvers available in the Trilinos open-source package for all
the simulations in this paper [120]. In particular, we have used the GMRES algorithm
[209] with a basic block diagonal preconditioner to solve the linear system during each
corrector step. We also implemented a local update for the consistent tangent matrix
during each corrector step because only the entries corresponding to the double-well
potential in Eq. (3.1) change during the corrector phases. Hence, we take the tangent
matrix from the previous corrector step and update these entries to obtain the new tangent
matrix. We set the parameters of the generalized-α method as in [105]. We chose a
constant time step ∆t = 0.001 years.
4.6.3 Automatic adaptivity
We have automated the operations of refinement and coarsening in an adaptive solver that
we present in Algorithm 4.6.1. To do so, we have introduced two basic features: first, an
indicator to determine which elements must undergo an adaptive procedure, and second,
a time-step offset for each operation.
4.6.3.1 Indicator







| ∇φ |2 dΩe, (4.16)
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where we compute the squared L2-norm of the gradient of the phase field over each
element Ωe and normalize it with respect to its corresponding volume vol(Ωe). During
a refinement step, we compare re to its average over all elements and proceed to flag
for refinement those elements that exceed an arbitrary threshold. Likewise, during a
coarsening step, if re is smaller than a certain preset value dependent on the average re,
we mark the element for coarsening. As shown in Algorithm 4.6.1, we also use two
constant parameters CR and CC to control the intensity of refinement and coarsening,
respectively.
4.6.3.2 Time step offsets
We refine the mesh every ∆T SR = 5 time steps in order to keep track of the moving
interface. However, coarsening is performed every ∆T SC = 10 time steps to clean up
the finer elements left in the rear of the moving interface and that are no longer required.
This means that every 10 time steps we refine and then we coarsen the mesh.
4.6.3.3 Adaptive solver
Algorithm 4.6.1 shows how we coupled time integration and automatic adaptivity into an
adaptive solver. All our simulations were performed in a parallel environment provided
by MPI.
Algorithm 4.6.1. Adaptive solver to perform time integration at time step i and locally
adapt the mesh to the solution fields automatically.
1. Compute the solution fields at the current time step i using the generalized-α
method as indicated in Section 4.6.2.
2. If i is a multiple of ∆T SR, then we perform refinement.
(a) Compute the value of the gradient-based indicator re in each element e of the
hierarchical mesh HE.
(b) Flag for refinement the elements that verify re > CRne ∑
ne
e=1 re .
(c) Call Algorithm 4.3.1 to refine the hierarchical mesh and compute the new
control variables. Once we have created the refined destination mesh at step 1
of this algorithm, call Algorithm 4.5.2 to perform function support balancing.
3. If i is a multiple of ∆T SC, then we perform coarsening.
(a) Compute the value of the gradient-based indicator re in each element e of the
hierarchical mesh HE.
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(c) Call Algorithm 4.4.2 to coarsen the hierarchical mesh and compute the new
control variables. Once we have created the coarsened destination mesh at
step 1 of this algorithm, call Algorithm 4.5.2 to perform function support
balancing.
4.6.4 Initial conditions
The initial condition for the phase field φ0 is an elliptic (2D) or ellipsoidal (3D) tumor
that we model with a hyperbolic tangent field. The initial conditions for the nutrient
η and the tissue PSA ρ are approximations based on φ0 given by η0 = c0η + c
1
η φ0 and
ρ0 = c0ρ +c
1






ρ , and c
1
ρ are computed
so that η0 and ρ0 reproduce the constant value of the nutrient and the tissue PSA within
the tumor and the host tissue, respectively.
We use an adaptive L2-projection procedure in order to tailor an appropriate initial mesh
that fits the initial condition for the tumor phase field. Beginning with a Bézier mesh only
composed of elements on level 1, we perform nh rounds of refinement to progressively
enlarge HE with elements in higher levels. During each step k of this procedure we
L2-project φ0 over an initial Bézier mesh composed of elements in levels α = 1, . . . ,k.
Then we use the gradient-based indicator in Eq. (4.16) to flag the elements to refine.
Finally we refine and balance the resulting Bézier mesh now having elements from levels
α = 1, . . . ,k+ 1. In the last refinement round the initial Bézier mesh already includes
elements across the whole hierarchy, but we perform one last round of refinement to
fine-tune the mesh.
4.6.5 PCa growth in a square domain
We begin investigating the behavior of our adaptive methods on a basic 2D scenario for
PCa growth: a 2000×2000 µm square with periodic boundaries. The initial tumor is
placed in the center of the computational domain and the lengths of its semiaxes are 100
µm and 150 µm. We used a quadratic hierarchical B-spline space with 5 levels, going
from 32×32 elements in E1 to 512×512 elements in E5. Table 4.1 provides the values
of the model parameters that we have used in this simulation. We have set CR = 1 and
CC = 0.01.
The evolution of the tumor phase field and the supporting adaptive mesh using n f sb = 1 is
shown in Fig. 4.4. The same results for n f sb = 2 are shown in Fig. 4.5. The phenomenon
of PCa growth is perfectly captured in both simulations (cf. Chapter 3). Initially, the
elliptic tumor grows spheroidally but this pattern of growth leads to very low levels of the
nutrient inside the tumor. Should the tumor continue to develop with this morphology, it
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Table 4.1. Parameters in the PCa growth model: square and cubic domain simulations.
Parameter Notation Value
Diffusivity of the phase field Dφ 1.6 ·105 µm2/year
Time scale for the phase field τ 0.01 years
Nutrient-induced tumor growth rate χ 600 L/(g·year)
Apoptosis rate A 600 1/year
Nutrient diffusivity Dη 5.0 ·106 µm2/year
Nutrient supply S 2.70 g/(L·day)
Nutrient consumption rate δ 2.75 g/(L·day)
Nutrient natural decay rate γη 1000 1/year
Tissue PSA diffusivity Dρ 1.6 ·105 µm2/year
Tissue PSA production rate in healthy tissue αh 6.25 (ng/mL)/(cc·year)
Tissue PSA production rate in cancerous tissue αc αc = 15αh
Tissue PSA natural decay rate γρ 100 1/year
would suffer from starvation, hypoxia, and, eventually, necrosis, which would hamper
cancer growth. Alternatively, the tumor undergoes a shape instability towards a fingered
pattern of growth. This shift in morphology begins with a sort of bottleneck, as shown
in Fig. 4.4(b) and Fig. 4.5(b). Then, in the evolving geometries in Fig. 4.4(c)-(d) and
Fig. 4.5(c)-(d), the distance from the inner areas of the tumor to the surrounding healthy
tissue is much shorter that in an spheroidal morphology, thus preventing the tumoral cells
from starving.
The design of the hierarchy is not trivial. For this problem of PCa growth, we knew that a
quadratic uniform B-spline mesh of 512×512 elements produced an accurate solution.
Then, we started to add levels on top of this original mesh, each consisting of a uniform
B-spline mesh with half the elements per parametric direction than the last added. This
strategy enabled us to study the benefits of using hierarchical spaces with increasing
number of levels, but such that the interface would always be supported by the elements
in the original 512×512 mesh. Increasing the number of levels contributed to improve
efficiency, but it also carried more overlapping of functions across the hierarchy. Very
coarse levels, for instance, with 16×16 or 8×8 elements, were not useful because their
elements disappeared shortly after the onset of the simulation. To solve this tumor growth
problem, our initial tests showed that it suffices to add 3 or 4 levels on top of the finer
reference level with 512×512 elements.
Leveraging a 5-level hierarchy, the resulting finite element meshes depicted in Fig. 4.4
and Fig. 4.5 accomplish our expectation: finer elements to support the interface and
coarser elements within the tumor and in healthy tissue regions, where the phase field
is constant. The main difference between the meshes in Fig. 4.4 and Fig. 4.5 is the
distribution of the elements in HE across the hierarchy during the simulation. Fig. 4.6
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Figure 4.4. Tumor phase field and adaptive mesh for a simulation of 2D PCa growth using a
quadratic hierarchical B-spline space with 5 levels and balance parameter n f sb = 1. Level 1 is
the coarsest level, with 32×32 elements in E1, and level 5 is the finest, with 512×512 elements in E5. The
size of the tissue domain is 2000×2000 µm. Reproduced from [166].
portrays the subdomains Ω̂α , α = 1, . . . ,nh, and the elements in HE that belong to each
of these subdomains for the balance parameter values n f sb = 1 and n f sb = 2. In Fig. 4.6,
we can also observe how the elements in HE∩Eα , α = 1, . . . ,nh, can be collapsed from a
multilevel topology onto the single-level finite element representation provided by the
Bézier mesh HE. The balance parameter n f sb affects how adaptivity is performed beyond
refinement and coarsening, limiting the overlapping of the basis functions in H across the
hierarchy on each element. Hence, the differences in the hierarchical meshes depicted
in Fig. 4.4, Fig. 4.5, and Fig. 4.6 are a direct consequence of the selected value for the
balance parameter.
When n f sb = 1, an element in level α can only support hierarchical basis functions in
level α or level α−1. Consequently, after refinement or coarsening, balancing enforces
a considerable amount of further refinement to enforce the overlapping constraint. Let
us illustrate this with an example of the operation of balancing after refinement and
coarsening. Consider the elements in an intermediate level α . If a sufficient amount
of elements in level α are refined to level α + 1, some hierarchical basis functions in
level α − 1, which originally had some support on those refined elements in level α ,
may have support in level α +1 now. During balancing, these functions will be flagged
for refinement and their entire support will be refined to level α . Let us consider an
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Figure 4.5. Tumor phase field and adaptive mesh for a simulation of 2D PCa growth using a
quadratic hierarchical B-spline space with 5 levels and balance parameter n f sb = 2. Level 1 is
the coarsest level, with 32×32 elements in E1, and level 5 is the finest, with 512×512 elements in E5. The
size of the tissue domain is 2000×2000 µm. Reproduced from [166].
alternative example. After performing coarsening in level α , we might eliminate enough
elements in this level so that some functions in level α−1 enter in the hierarchical basis.
However, functions in level α − 1 have a larger support and part of it may lie in level
α +1 or even deeper. Balancing will flag these new functions in level α−1 and their
whole support will be refined to level α . Hence, when n f sb = 1 the borders between the
subdomains Ω̂α are very distant from one another in order to prevent the hierarchical
basis functions in levels above α − 1 and below α + 1 from overlapping. As a result,
this constraint produces a smooth transition between the levels of the hierarchy, whose
elements are disposed in wide rings for each level, as shown in Fig. 4.4 and Fig. 4.6(a)-(b).
The previous examples considered a situation close to the threshold level to perform
balancing, that is, a global function in level α−1 that has support in level α+1. However,
balancing propagates across the hierarchy and it also prevents the overlapping of basis
functions in HE in more distant levels. For example, consider hierarchical basis functions
in a shallow level α −m, m >> n f sb, that after an adaptive operation have support on
elements in level α . In this case, balancing refinement is triggered in an element in level
α and it will affect functions from level α−m downwards until all the hierarchical basis
functions with support in that element meet the balancing constraint.
If we set n f sb = 2, the elements in level α can now support hierarchical basis functions
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1 2 3 4 5
HE







(a) Bézier mesh HE, n f sb=1 (b) Bézier meshes Eα at each hierarchical level α , n f sb=1
(c) Bézier mesh HE, n f sb=2 (d) Bézier meshes Eα at each hierarchical level α , n f sb=2
Figure 4.6. The distribution of elements across the hierarchical levels and the corresponding
Bézier meshes for n f sb = 1 and n f sb = 2 at t = 0.4 years. Reproduced from [166].
in levels α , α−1 and α−2. The overlapping between the functions of different levels
of the hierarchy is stronger than for n f sb = 1. Hence, the refinement operation caused
by balancing is significantly reduced: to trigger refinement to balance the mesh when
n f sb = 2 it is necessary that an element in level α supports a hierarchical basis function
in level α−3 or above. Consequently, the transition between levels in the hierarchical
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(c)
Figure 4.7. Analysis of the number of hierarchical basis functions (HBF) and elements along
the simulations in Fig. 4.4 (n f sb = 1) and Fig. 4.5 (n f sb = 2). (a) Time history of the parameters that
describe the distribution of the number of HBF per element during the simulation in Fig. 4.4, including the
mean, the median, and the standard deviation (StdDev). (b) Time history of the parameters that describe the
distribution of the number of HBF per element during the simulation in Fig. 4.5, including the mean, the median,
and the standard deviation (StdDev). (c) Time history of the minimum and maximum number of HBF per
element during the simulations in Fig. 4.4 and Fig. 4.5. The minimum number of HBF over an element is
exactly (p+1)2 = 9. Reproduced from [166].
mesh is sharper for n f sb = 2, with the elements describing thinner rings, as shown in
Fig. 4.5and Fig. 4.6(c)-(d).
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Figure 4.7. (Continued) Analysis of the number of hierarchical basis functions (HBF) and
elements along the simulations in Fig. 4.4 and Fig. 4.5. (d) Time history of the total number of
HBF. (e) Time history of the total number of elements and the number of elements with minimal number of
hierarchical basis functions (MinHBF). (f) Time history of the ratio of the number of MinHBF elements to the
total number of elements. Reproduced from [166].
Fig. 4.6 shows that the coarsest elements in the hierarchy, belonging to level 1, only
appear sufficiently far from the interface. In these areas, the gradient is small and the
hierarchical basis functions in level 1 do not overlap with basis functions in much deeper
levels. However, the gradient is also approximately zero in the inner tumor but only
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(b) n f sb = 2
Figure 4.8. Time history of the distribution of the number of hierarchical basis functions per
element. Reproduced from [166].
elements in level 2 appear there. This is caused by balancing: the vicinity of the interface
requires the finest elements and the fingered morphology does not have enough space in
the internal areas of the tumor to enable the transition from elements in level 5 to level
1 satisfying the balancing constraint. A similar situation takes place with the elements
in level 2 between the branches of the tumor, chiefly when n f sb = 2, as depicted in
Fig. 4.6(c)-(d). When n f sb = 1, most of those elements in level 2 are refined to level 3
near the interface (see Fig. 4.6).
The plots in Fig. 4.7 offer a deeper insight in the differences between a mesh balanced
with n f sb = 1 and n f sb = 2. The parameters that describe the distribution of the number
of basis functions per element take higher values when we select n f sb = 2 in Fig. 4.7(a)-
(c). This feature is caused by the increased overlapping of hierarchical basis functions
that is inherent to higher values of the balance parameter. However, the total number
of hierarchical basis functions is lower for n f sb = 2 than for n f sb = 1, as shown in
see Fig. 4.7(d). This is due to the more localized effect of the adaptive operations for
n f sb = 2. The number of elements is also lower for n f sb = 2 than for n f sb = 1, as depicted
in Fig. 4.7(e). However, notice that the difference between both choices of balance
parameter is mild in Fig. 4.7(d)-(e) and both led to a significant decrease in ne with
respect to the 512×512 element mesh. For instance, at t = 0.4 years, the total number of
elements is reduced to a 15.1% with n f sb = 1 and a 12.2% with n f sb = 2.
The minimal number of hierarchical basis functions over a 2D element is exactly (p+1)2,
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Figure 4.9. Accuracy of the hierarchical solution. Comparison between a detail of the reference
solution (white contour) for the interface (φ = 0.5) at t = 0.4 years and a hierarchical solution (green contour)
computed with a quadratic 5-level B-spline space. Reproduced from [166].
as in the corresponding single-level B-spline mesh that configures each hierarchical level.
We consider the ratio of the number of elements with minimal number of hierarchical
basis functions to the total number of elements. Higher values of this ratio reflect minimal
overlapping of functions. In the context of our adaptive algorithms, this means that there
is a smooth transition between the regions of the mesh corresponding to each hierarchical
level, Ω̂α . Superior accuracy is expected from these meshes because they are composed
of broad regions of finer elements near the interface and coarser elements sufficiently
far from it (see Fig. 4.6); not to mention that reduced overlapping improves numerical
conditioning. In Fig. 4.7(e) the number of elements supporting a minimal number of
hierarchical basis functions is considerably superior for n f sb = 1 than for n f sb = 2. Indeed,
such difference is of greater magnitude than in terms of the total number of elements.
Hence, the ratio of elements with minimal number of hierarchical basis functions to total
elements is higher when we choose n f sb = 1, as shown in Fig. 4.7(f).
The cumulative histograms in Fig. 4.8 show the distribution of the number of hierarchical
basis functions per element along the simulations corresponding to Fig. 4.4 and Fig. 4.5.
Notice the increased dispersion and higher variability for the case n f sb = 2, which is
caused by the increased overlapping of functions for this choice of balance parameter.
In order to test the accuracy of the solutions computed with a hierarchical basis, in
Fig. 4.9 we provide a comparison between these and a reference solution obtained on a
quadratic single-level B-spline mesh of 1024×1024 elements. When we select n f sb = 1
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(d) p = 3 (e) p = 4 (f) p = 5
Figure 4.10. Our adaptive algorithms are compatible with global k-refinement. (a) Tumor phase
field at t = 0.4 years computed with a quadratic hierarchical B-spline basis with 5 levels as in Fig. 4.4. (b)-(f)
Two-dimensional meshes at t = 0.4 years using a 5-level hierarchical B-spline space with increasing polynomial
degrees from p = 1 to p = 5 in both parametric directions. The white contour depicts the level set φ = 0.5,
which represents the interface between the tumor and the healthy tissue. We set the balance parameter value to
n f sb = 1. Reproduced from [166].
the reference and hierarchical solutions are practically indistinguishable, as depicted in
Fig. 4.9(a). If we set n f sb = 2, some slight differences between the reference and the
hierarchical solution appear, as seen in Fig. 4.9(b). However, the overall quality of the
hierarchical solution is still acceptable. The decrease in the accuracy for n f sb = 2 is
caused by the increased overlapping of hierarchical basis functions. Consequently, the
mesh presents coarser elements closer to the interface, which reduce the accuracy of the
overall hierarchical solution. The balance parameter value n f sb = 2 does not bring major
savings in the number of elements or functions in the hierarchy (see Fig. 4.7) and the
solution is not more accurate. Hence, we conclude that n f sb = 1 suffices to balance the
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mesh accurately while preserving all the advantages of local adaptivity.
Our adaptive algorithms are fully compatible with global k-refinement, as shown in
Fig. 4.10. Increasing the degree of the polynomial functions that build the hierarchical
basis enriches the space of functions that can be represented with that basis. Consequently,
the accuracy of the solution also improves. However, global k-refinement also carries
some disadvantages, which are mostly manifested for high polynomial degrees, such as
p = 4 or p = 5. First, increasing the polynomial order increments the number of functions
on every element in every level of the hierarchy. Second, elevating the polynomial degree
leads to an adaptive mesh where refinement and coarsening are less and less local. As
the support of each basis function N ∈ Nα is (p+ 1)2 elements in Eα , the refinement
operation induced by balancing will affect a larger domain. Hence, the extent of the
subdomains Ω̂α is larger and those corresponding to coarser levels might become void.
As a result, a substantial amount of memory is required to store the tangent matrix and
the residual and the simulations run more slowly.
4.6.6 PCa growth in a cubic domain
We tested our adaptive algorithms in a cubic domain with periodic boundaries and side
length 2000 µm to study their performance in a simple 3D scenario. The initial tumor
is placed in the center of the cube and has two semiaxes of length 100 µm and one
with length 150 µm. We have set CR = 1 and CC = 0.01 for this simulation. The model
parameters take the values indicated in Table 4.1.
We designed the hierarchy following the same approach as for the previous 2D examples,
but reducing the mesh size to keep simulations tractable. Our cancer growth problem
can be solved with sufficient accuracy by means of a single-level B-spline mesh with
256 elements per parametric direction. Hence, we used a quadratic hierarchical B-spline
space with 5 levels, ranging from 16 to 256 elements per parametric direction in E1 and
E5, respectively. According to the analysis of the effect of the function support balance in
the previous subsection, we chose n f sb = 1 to attain higher accuracy with a reasonable
distribution of elements across the levels in HE.
Fig. 4.11 shows the evolution of the tumor and the adaptive mesh along several time
steps. Similar to the 2D scenario, tumor morphology evolves from an initial ellipsoid
developing branches to gain better access to the nutrient. The main feature that emerges
in this 3D simulation is that some of the finger-like structures turn into curved layers
of tumoral tissue. However, if we take a cross section of the tumor we obtain again the
characteristic branches that we observed in the 2D scenario. Interestingly, at t = 0.6 years,
Fig. 4.11(d), the tumor has divided into three independent tumoral regions: a central
ellipsoidal mass surrounded by two opposing concave shell-like structures with a satellite
directed outwards. These satellites eventually detach, hence defining two additional
cancerous regions.
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Figure 4.11. Tumor phase field and adaptive mesh for a simulation of 3D PCa growth using a
quadratic hierarchical B-spline space with 5 levels and balance parameter n f sb = 1. Level 1 is
the coarsest level, with 16×16×16 elements in E1, and level 5 is the finest, with 256×256×256 elements in
E5. The size of the tissue domain is 2000×2000×2000 µm. See the tumor at later times in the continuation of
Fig. 4.11 to follow. Reproduced from [166].
The adaptive mesh follows the evolution of the interface between healthy and tumoral
tissue efficiently along the simulation. Our algorithms to implement local adaptivity
dramatically lower the total number of elements with respect to an uniform mesh with
256 elements per parametric direction. For example, at t = 0.4 years ne is reduced to
6.9%, and it stays below 15% until t = 0.56 years. These rates reveal the promising
potential of our algorithms to efficiently resolve local features with IGA in 3D scenarios.
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Figure 4.11. (Continued) Tumor phase field and adaptive mesh for a simulation of 3D PCa
growth using a quadratic hierarchical B-spline space with 5 levels and balance parameter
n f sb = 1. Level 1 is the coarsest level, with 16× 16× 16 elements in E1, and level 5 is the finest, with
256×256×256 elements in E5. The size of the tissue domain is 2000×2000×2000 µm. Reproduced from
[166].
4.6.7 Tissue-scale, patient-specific simulation of PCa growth
Our final example consists of a simulation of prostatic tumor growth over the geometry of
a patient’s prostate, which we extracted from CT image dataset described in Section 3.4
(institutional review board approval and informed consent were not required for this study).
As outlined in Section 3.5, we leverage a parametric mapping method that deforms a
torus NURBS model to match the surface of the prostate obtained from the patient’s
CT data. The original torus and the resulting prostate mesh are both discretized with 32
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Table 4.2. Parameters in the PCa growth model: patient-specific, tissue-scale simulation.
Parameter Notation Value
Diffusivity of the phase field Dφ 175 mm2/year
Time scale for the phase field τ 0.01 years
Nutrient-induced tumor growth rate χ 550 L/(g·year)
Apoptosis rate A 600 1/year
Nutrient diffusivity Dη 5.47 ·103 mm2/year
Nutrient supply S 2.70 g/(L·day)
Nutrient consumption rate δ 2.75 g/(L·day)
Nutrient natural decay rate γη 1000 1/year
Tissue PSA diffusivity Dρ 175 mm2/year
Tissue PSA production rate in healthy tissue αh 6.25 (ng/mL)/(cc·year)
Tissue PSA production rate in cancerous tissue αc αc = 15αh
Tissue PSA natural decay rate γρ 100 1/year
elements along the toroidal direction, 32 elements along the cross-section circumferential
direction, and 8 elements along the cross-section radial direction.
We have approximated the initial tumor geometry to an ellipsoidal mass placed in the left
posterior region of the prostate. We recursively refine the extracted prostate mesh in order
to adapt to this initial tumor by following the approach described in Section 4.6.4. The
values of the model parameters for this simulation are summarized in Table 4.2. Because
we are focusing on localized PCa, we imposed zero-valued Dirichlet conditions for φ all
over the prostate boundary. We set natural boundary conditions for η and ρ .
Patient-specific, tissue scale PCa growth can be solved using a single-level NURBS with
256 elements in the toroidal direction, 256 elements in the cross-section circumferential
direction, and 64 elements in the cross-section radial direction. Therefore, we chose a
quadratic hierarchical NURBS space with 4 levels. We place the previous single-level
discretization in the highest level and the prostate mesh extracted from CT in level α = 1.
We set n f sb = 1 again to attain higher accuracy with a reasonable distribution of elements
across HE. We set CR = 0.1 and CC = 0.0005 for this simulation.
Fig. 4.12 shows the evolution of the tumor within the prostate and the adaptive mesh from
an anterior view. Fig. 4.13 provides the same results but observed from a posterior view.
The initial tumor starts growing as a mass but, eventually, it undergoes a shape instability
towards a fingered morphology that grows surrounding the urethra. With this new pattern
of development, the tumor reaches more nutrients and escapes hypoxia, starvation, and,
eventually, necrosis, which would hamper tumor growth.
The mesh efficiently adapts to the evolution of the tumor in a similar fashion as we
described for the square and cubic domains in Section 4.6.5 and Section 4.6.6, respectively.
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The finest elements from level α = 4 are localized to the surroundings of the interface
between tumoral and healthy tissue to accurately capture its evolution. The operation
of balancing ensures a distribution of elements in coarser levels that guarantees reduced
overlapping of basis functions. These features can be observed in the adaptive meshes
depicted in Fig. 4.12 and Fig. 4.13. Notice also that during the simulation coarser
elements from levels α = 1 and α = 2 cover the majority of the volume of the prostate.
As a result, we dramatically reduce the number of elements with respect to the reference
single-level NURBS mesh. For instance, at t = 0.3 years ne is reduced to 6.6%, and
it stays below 15% until t = 0.55 years. Consequently, our adaptive algorithms also
reduce the computational resources and time required to run patient-specific, tissue-scale
simulations of PCa growth.
These advantages are of much interest in view of implementing our model for PCa growth
in the clinic, within the computational framework for the medical management of PCa
presented in Section 3.2. Physicians could use our model to predict the personalized
prognosis of a patient and hence determine the best course of clinical management, from
scheduling new revisions to starting a radical treatment. Our adaptive algorithms offer an
efficient and accurate way to solve the cancer growth problem in a reasonable time.
4.7 Conclusions
In this Chapter, we present a set of algorithms for local h-adaptivity of hierarchical splines
to be utilized in IGA. We extend Bézier projection, an efficient quadrature-free local
projection technique, to the hierarchical setting. In this case, extraction operators may
not be invertible. To address this issue we develop a multi-level reconstruction operator
which maintains the locality properties of the projection. We also introduce a balance
parameter to control the overlap of hierarchical functions leading to improved numerical
conditioning.
We apply our algorithms to the simulation of localized PCa growth using the model
described in Chapter 3. Our results include examples on simple 2D and 3D domains and
a more compelling tissue-scale, patient-specific simulation, which is run over a prostate
anatomy extracted from CT images. Our methods for local h-adaptivity efficiently
capture the evolving interface between the tumor and the neighboring healthy tissue with
remarkable accuracy in all cases. The number of elements required by our hierarchical
methods is shown to be considerably lower than that of the uniform mesh that we would
need to run the same simulation.
We believe that the adaptive technologies described in this Chapter are an important
enabling technology for the implementation of predictive models of PCa growth in
clinical software in an accurate and efficient manner. In addition, our methods can be
adopted to address other moving interface problems, which are ubiquitous in science and
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(a) Tumor, t = 0 years
1 2 3 4
Hierarchy Levels
(b) HE, t = 0 years
(c) Tumor, t = 0.3 years
1 2 3 4
Hierarchy Levels
(d) HE, t = 0.3 years
(e) Tumor, t = 0.6 years
1 2 3 4
Hierarchy Levels
(f) HE, t = 0.6 years
Figure 4.12. Patient-specific, tissue scale simulation of PCa growth (anterior view). We used a
quadratic hierarchical NURBS space with 4 levels and balance parameter n f sb = 1. The volume of the prostate
is 35.8 cc. Reproduced from [166].
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(a) Tumor, t = 0 years
1 2 3 4
Hierarchy Levels
(b) HE, t = 0 years
(c) Tumor, t = 0.3 years
1 2 3 4
Hierarchy Levels
(d) HE, t = 0.3 years
(e) Tumor, t = 0.6 years
1 2 3 4
Hierarchy Levels
(f) HE, t = 0.6 years
Figure 4.13. Patient-specific, tissue scale simulation of PCa growth (posterior view). We used a
quadratic hierarchical NURBS space with 4 levels and balance parameter n f sb = 1. The volume of the prostate
is 35.8 cc. Reproduced from [166].
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engineering, as well as problems involving fine-scale features. Some examples are droplet
motion, cell motion, angiogenesis, internal and boundary layers in advection-dominated
flows, stress concentration, and accurate geometric definitions.
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CHAPTER 5
A mechanically-coupled model for PCa
growth and interaction with BPH
5.1 Introduction
Beyond anatomical location, BPH and PCa possess other similarities [4, 191, 265]. At
the epidemiological level, both diseases affect older men, have increasing incidence
with age, and frequently coexist in the same patient. These pathologies may induce
lower urinary tract symptoms and increase serum levels of PSA. Additionally, PCa and
BPH share some genetic alterations, are hormone-dependent, have been correlated with
prior inflammation, and might be part of the metabolic syndrome. Despite the evidence
suggesting links between PCa and BPH, the relationship between these diseases has been
under continuous debate in the medical community due to the existence of contradictory
studies and the scarcity of research thoroughly confirming the proposed hypothetical
links [4, 191]. Gaining knowledge about the connection between PCa and BPH would
challenge the current clinical standards and potentially enhance treatment and prevention
of both diseases.
The biopsy detection rate of PCa in large prostates is known to be lower than in small
prostates [55, 73, 269]. This low detection rate has been attributed to various artifacts,
such as sampling errors and a biopsy selection bias in patients with increasing PSA,
possibly caused by BPH [55, 150, 241]. However, it appears that neither increasing
sampling nor using more advanced medical imaging to perform biopsy has leveled the
detection rate across prostate volume groups [73, 77, 213, 269]. Recent studies on large
series of radical prostatectomy specimens show that tumors arising in larger prostates
present favorable pathological features, such as lower aggressiveness measured with the
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GS [265], smaller tumor volume, and lower risk of extraprostatic extension or seminal
vesicle invasion [36, 55, 92, 126, 145, 184]. These studies provide solid evidence to
suggest that large prostates may exert a protective effect against PCa, but the underlying
mechanisms are not known.
In this Chapter, we propose a mechanical explanation for this phenomenon: BPH exerts
an inhibitory effect on PCa growth due to the accumulation of mechanical stress. BPH
creates a compressive hydrostatic stress state within the CG and outward forces that
deform the PZ [62, 252, 265]. We will show that, as the CG enlarges over time, the
mechanical stress fields created by BPH intensify and reach larger values than those
created by the tumor mass effect. Hence, BPH may also exert an inhibitory effect on PCa
growth but its impact has been overlooked. Additionally, the confinement of the prostate
in the pelvic area further contributes to the internal mechanical stress fields because the
surrounding tissues resist the pathological deformation of this organ.
To analyze whether enlarged prostates may provide protection against PCa growth, we
need to determine whether the stress induced by BPH is enough to significantly produce
an inhibitory effect on PCa. This fundamentally requires a 3D, anatomically faithful,
mechanical model of the prostate. The amount by which the growth rate of the tumor
decreases with stress may be estimated from experiments in the literature. To perform
this study, we derive a tissue-scale, patient-specific mechanically-coupled mathematical
model for PCa growth and perform a series of computer simulations.
5.2 Patient data
Anonymized patient data were obtained from the public repository for PCa imag-
ing data at the Initiative for Collaborative Computer Vision Benchmarking website
(http://i2cvb.github.io/) [153]. Institutional review board approval and informed consent
were not required for this study. We used the mpMR image dataset obtained with a
3.0 Tesla Siemens Magnetom Trio TIM scanner (Erlangen, Germany). Patient cohort
description and details on data acquisition have been previously described [152]. For
each biopsy-confirmed patient, this database includes T2-weighted MR images, dynamic
contrast enhanced MR images, diffusion weighted MR images, MR spectroscopic images,
apparent diffusion coefficient maps, and the segmentations of the prostate, the PZ, the
CG, and the tumor by an experienced radiologist. For this research, we selected a patient
aged 54 years at MR date who had a large prostate of 52.81 cc harboring a localized
tumor in the PZ. Fig. 5.1 depicts the anatomy of his prostate.
5.3 Mathematical model
Our mechanically-coupled model is described by the following equations:
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Figure 5.1. Patient-specific local anatomy of the prostate. From a radiological perspective, the
prostate is divided in central gland (CG) and peripheral zone (PZ). BPH takes place in the CG and most cases
of PCa arise in the PZ. We extracted the geometry of the patient’s prostate and CG from their corresponding
segmentations provided on axial T2-weighted MR images. The volumes of the prostate, CG, and PZ at MR
imaging date are 52.81 cc, 33.15 cc, and 19.66 cc, respectively. The major diameters of the prostate at MR
















= Dη ∆η +S−δφ − γη η (5.2)
∂ρ
∂ t
= Dρ ∆ρ +αh(1−φ)+αcφ − γρ ρ (5.3)
∇ ·σ = 0 (5.4)
Eq. (5.1)- Eq. (5.3) come from our previous theory of PCa growth, presented in Chapter 3
and also leveraged in Chapter 4 [165, 166]. The mechanical stress fields generated by a
growing tumor have been shown to slow down its dynamics [57, 118, 137, 205, 228, 256].
This inhibitory effect is modeled with coefficient M in Eq. (5.1). Following previous
mechanically-coupled models [160, 267, 268], we define M in Eq. (5.5) with a decaying
exponential function that depends on a certain measure of the strain energy and the
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loading conditions. Mechanical stress can be decomposed as the sum of hydrostatic stress
σh (defined in Eq. (5.6)), which tends to change the volume of the stressed body, and
deviatoric stress, which tends to distort it [134]. The Von Mises stress σv (defined in
Eq. (5.7)) [134] is a good measure of the distortional strain energy around the tumor that
has been widely adopted in mechanically-coupled models [160, 267, 268]. However, σv
is insensitive to hydrostatic stress, which better describes the natural stress state within
a growing region of tissue, such as a tumor or the CG developing BPH [137, 205, 228].
Hydrostatic stress is also bound to increase globally during these growth processes
because the prostate is a confined organ [265]. Therefore, we propose to combine σv
and the hydrostatic stress σh[134] in the definition of M following a similar approach to
multiaxial stress-based failure criteria:
























σi j with i, j = 1,2,3 are the components of the stress tensor σ , I is the second order
identity tensor, and β1 and β2 are constants that were adjusted to match the experimental
and clinical results of previous studies on tumor growth [57, 118, 137, 160, 205, 228,
256, 267, 268]. We use the absolute value of the hydrostatic stress because both growth-
induced compressive and tensile solid stress have been shown to hamper tumor dynamics
at tissue scale in vivo [137, 228].
We assume that PCa and BPH show sufficiently slow rates [265] to neglect the inertial
effects in the deformation of prostatic tissue. Hence, Eq. (5.4) describes mechanical
equilibrium as a quasistatic process. Linear elasticity has been widely accepted to
model mechanical equilibrium in living tissue subjected to slow processes over short
time scales (t ∼ 1 year) [56, 61, 125, 134, 160, 163, 267, 268]. Hence, this paradigm
provides a simple mechanical framework to compute the stresses in Eq. (5.5) and perform
our qualitative study on the mechanical influence of BPH on PCa. The prostate is
an histologically heterogeneous organ: while the CG has a higher and denser stromal
component, the PZ has more abundant glandular elements with sparsely interwoven
smooth muscle [75, 252, 265]. Benign enlargement of the prostate tends to make the
CG denser and more compact [186, 265]. Therefore, the CG is normally stiffer than PZ
in patients with PCa and/or BPH [27, 207, 263, 276]. The growing tumor induces an
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internal compressive hydrostatic stress and exerts outward forces acting on the tumor
border [109, 137, 228], so we modeled the tumor mass effect as
ptumor =−κφ . (5.8)
This assumes that κ is a constant compressive pressure, which is admissible over short
simulation times [61, 160, 163, 267, 268]. Volumetric growth due to BPH is usually
modeled with an exponential function, but the slow growth rates justify a linear approx-
imation over periods ∆t ∼ 1−10 years [157, 203, 270]. Hence, we modeled BPH as a




HCG (x) , (5.9)
where K is the bulk modulus, g is the estimated linear volumetric growth rate of the
prostate due to BPH at MR date, VMRI is the volume of the prostate as measured on
T2-weighted MR imaging, ∆t is the time passed since the MR date, and HCG (x) is a
Heaviside function with value 1 in the CG and 0 elsewhere. The parameter ζ adjusts
the value of the pressure pBPH to obtain the estimated CG growth rate. Taking all
the considerations above, we model prostatic tissue as a linear elastic, heterogeneous,
isotropic material whose constitutive equation is given by
σ = λ (∇ ·u)I+2µ∇su−κφI−Kζ g∆t
VMRI
HCG (x)I (5.10)
where σ is the stress tensor, λ and µ are the Lamé constants, u is the displacement vector,
and x is the position vector. The segmentation of CG and PZ was extracted from our
patient’s imaging data and mapped over the quadrature points to define heterogeneous
material properties (see Fig. 5.1).










where Ω is the prostate segmented on the patient’s MR images [165].
Because we are focusing on localized PCa, we imposed zero-valued Dirichlet conditions
for φ all over the prostate boundary ∂Ω. We set natural boundary conditions for η and ρ .
The confinement of the prostate within the pelvic area [265] was modeled with Winkler
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boundary conditions on the external surface of the prostate, while free-displacement was
enabled along the urethra, i.e.,
σn=−kwu in ∂Ω|exterior
σn= 0 in ∂Ω|urethra
(5.12)
where n is the outer normal vector to ∂Ω and kw is the Winkler constant.
The initial condition of the phase field, φ0, was an L2-projection of the tumor segmentation
extracted from the patient’s T2-weighted MR images and mapped over quadrature points
or was artificially modeled with an L2-projected hyperbolic tangent field. The initial
conditions for η and ρ were approximated with linear functions based on φ0, as we
did in Chapter 3 and Chapter 4. Linear elasticity allows us to apply the Principle of
Superposition and set zero-valued initial conditions for the displacements, i.e., u0 = 0.
This means that we are only computing the displacements produced since the MR date.
To study how BPH mechanically influences PCa growth, we estimated the stress state σ 0
caused by the history of BPH before the detection of PCa at MR date and leveraged it
as a prestress to compute M in Eq. (3.1). Hence, for this purpose, σ = σ 0 +σ 1, where
σ 1 are the stresses developed since the detection of PCa at MR date. To estimate σ 0,
we assumed that the volume of the patient’s prostate was 20 cc at age 40 [26, 265] and
leveraged Eq. (5.4) with a negative value for g and ∆t = 14 years to approximate the
undeformed, healthy state of our patient’s prostate according to the standard anatomical
features [265]. Because we are using linear elasticity, it suffices to reverse the sign of the










where g is now positive and ∆t0 = 14 years.
Parameter selection for Eq. (5.1)-(5.3) has been previously discussed in Chapter 3 and
it is provided in Table 5.1. We set the values of the Young modulus of PZ and CG to
EPZ = 3 KPa and ECG = 6 KPa, respectively [27, 207, 263, 276]. Because living soft
tissues have high content of water [27, 61, 268], we set the Poisson coefficients νPZ =
νCG = 0.40. We empirically calibrated β1 = 0.80 1/KPa and β2 = 1.50 in agreement with
the experimental and clinical observations reported in previous studies on tumor growth
[57, 118, 137, 160, 205, 228, 256, 267, 268]. We selected κ = 2.50 KPa to produce
displacements in the order of 1 mm. The analysis of BPH and PCa deformation and the
computation of the stress fields σ 0 rendered g = 2.34 cc/year, ζ = 2.78, and kw = 0.23
KPa/mm. These values for g and ζ reasonably agree with previous observations in the
literature for our patient characteristics [26, 44, 157, 203, 265, 270].
108
5.4 · Numerical methods
Table 5.1. List of parameters in the baseline PCa growth model.
Parameter Notation Value
Diffusivity of the phase field Dφ 200 mm2/year
Time scale for the phase field τ 0.01 years
Nutrient-induced tumor growth rate χ 600 L/(g·year)
Apoptosis rate A 600 1/year
Nutrient diffusivity Dη 5.47 ·103 mm2/year
Nutrient supply S 2.70 g/(L·day)
Nutrient consumption rate δ 2.75 g/(L·day)
Nutrient natural decay rate γη 1000 1/year
Tissue PSA diffusivity Dρ 200 mm2/year
Tissue PSA production rate in healthy tissue αh 6.25 (ng/mL)/(cc·year)
Tissue PSA production rate in cancerous tissue αc αc = 15αh
Tissue PSA natural decay rate γρ 100 1/year
5.4 Numerical methods
Since tumor growth and BPH are modeled as quasistatic processes, we adopted a staggered
approach to solve the equations in our mathematical model. We calculated tumor growth
at every time step, but we only updated the displacements every two time steps. We
performed spatial discretization by means of a standard isogeometric Bubnov-Galerkin
approach using a three-dimensional C1 quadratic NURBS space [66, 130, 195]. Temporal
integration in the tumor growth problem was carried out with the generalized-α method
[58, 138]. This technique led to a nonlinear problem in each time step, which we
linearized using the Newton-Raphson method. The resulting linear system was solved
utilizing the GMRES algorithm [209] with a diagonal preconditioner. We also used the
preconditioned GMRES to solve the quasistatic elastic problem. We chose a constant
time step of 0.002 years and the parameters in the generalized-α method were set as in
previous studies [105]. The simulations were performed using an in-house FORTRAN
code within a parallel environment provided by MPI.
We used the provided prostate segmentation as guidance to contour the organ on the
patient’s T2-weighted MR images. Then, we used the same parametric mapping method
described in Chapter 3 to obtain the mesh of our patient’s prostate (see also Section B.1
for further details). The original torus and prostate NURBS meshes were discretized with
32x32x8 elements along the toroidal direction, the cross-section circumferential direction,
and the cross-section radial direction, respectively. We globally refined the prostate mesh
to a 256x256x64 elements using standard knot insertion [66] to perform our simulations
with a good level of accuracy.
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Figure 5.2. Deformation of the prostate caused by BPH over 1 year. (a) Length of the displacement
field vector over original anatomy at t = 1 year. (b) Original and deformed geometries of the prostate at t = 1
year.
5.5 Deformation of the prostate due to BPH
Our model predicted that BPH produces the volumetric expansion of the prostate in the
perpendicular direction to the CG border, as depicted in Fig. 5.2 and Fig. 5.3. The PZ
was pushed outwards from the borders of the growing CG against the prostate external
surface and experimented a very slight shrinkage, as the Winkler boundary conditions
partially enabled outward displacement.
The extremal values of the displacements were attained at the CG borders that are closer
to the external surface of the prostate. The maximum total displacement was 0.74 mm.
The urethra was displaced posteriorly and its diameter was virtually unaltered.
The hydrostatic stress was compressive within the CG (-0.20 to -0.13 KPa) and negligible
within the PZ (see Fig. 5.3). Positive hydrostatic stress appeared in thin PZ regions
between the CG border and the prostate boundary, where tension accumulated as the CG
expanded. The Von Mises stress was negligible within the CG, except along the urethra
(0.27 to 0.53 KPa). Within the PZ, the Von Mises stress peaked near the borders of the
CG (0.20 to 0.33 KPa) and decreased towards the external surface of the prostate (0.07 to
0.17 KPa), depending on the distance between them (see Fig. 5.3).
5.6 Deformation of the prostate due to PCa
We considered three artificial tumors placed in characteristic locations within the prostate:
the basal PZ, the apical PZ, and the CG. Each tumor had ellipsoidal geometry with one
semiaxis measuring 4 mm and the others 3 mm. The largest dimension was oriented in
anteriorposterior direction. We selected the parameters that regulate tumor dynamics so
that these tumors were aggressive and showed the two typical morphologies of localized
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Figure 5.3. Detail of the deformation of the prostate caused by BPH over 1 year. (a) Displacement
field u1 over original anatomy at t = 1 year. (b) Displacement field u2 over original anatomy at t = 1 year. (c)
Displacement field u3 over original anatomy at t = 1 year. (d) Von Mises stress (VMS) and hydrostatic stress
(HDR) over original anatomy at t = 1 year.
PCa: spheroidal, or massive, and fingered [165]. Fig. 5.4 and Fig. 5.5 show the growth of
these artificial tumors and how they deformed our patient’s prostate.
All tumors started growing with the massive morphology, which is characteristic of small
prostatic cancers. The PZ tumors soon adjusted their geometry to the anatomy of the
patient’s prostate boundary (see Fig. 5.4(a1)-(a2) at t = 0.3 years). Due to the reduced
thickness of the PZ around the CG in our patient’s prostate, these PZ tumors invaded
the CG early (t < 0.1 years). The CG tumor took longer to reach the PZ and invade it
(t ≈ 0.3 years). As every tumor grew in size, the intratumoral nutrient concentration
decreased. This shortage cued a shape instability that progressively adjusted the tumors
to a fingered or lobular morphology, hence ensuring a spatial distribution of nutrient that
sustained tumor growth[165]. This phenomenon happened by t = 0.4 years for the tumor
in basal PZ, by t = 0.35 years for the tumor in apical PZ, and by t = 0.55 years for the
CG tumor. The shift in morphology arrested tumor growth momentarily (< 0.15 years)
and even reduced the CG tumor volume by 12.2%. However, tumors grew faster and
more extensively after this phenomenon.
The CG tumor grew faster and larger than the PZ tumors, whose growth rates and
initial volumes were similar. Because the tumor in apical PZ underwent the change in
morphology earlier, its volume was larger than the basal PZ tumor for the second half of
the simulation. The final volumes of the basal PZ tumor, the apical PZ tumor, and the CG
tumor were 5.43 cc, 6.82 cc, and 9.02 cc, respectively.
Tumors produced a local swelling deformation. The outermost tumoral structures pro-
duced the greatest displacements, which ranged between 0.65 and 1.15 mm and created
noticeable smooth lumps on the external prostatic boundary, especially in the PZ (see
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Figure 5.4. Analysis of prostate deformation caused by artificial tumors in different locations.
Deformation of the prostate over 1 year produced by a tumor originated on basal PZ (a1)-(c1), apical PZ
(a2)-(c2), and median CG (a3)-(c3). (a1)-(a3) Tumor growth over the original prostate geometry. (b1)-(b3)
Length of the displacement field vector over original anatomy at t = 1 year. The contour of the tumor is depicted
with black curves. (c1)-(c3) Original and deformed geometries of the prostate at t = 1 year.
Fig. 5.4(b1)-(b3), Fig. 5.4(c1)-(c3), and Fig. 5.5). The CG tumor barely deformed the
posterior aspect of the PZ. During the shift in tumor morphology, the displacement fields
redistributed and decreased globally between 23% and 31%, taking 0.3 to 0.6 years to
recover during fingered growth. The urethra was displaced away from the tumor and also
constricted (max. 0.44-0.75 mm), mainly in the segments circumvented by the fingered
tumors.
The hydrostatic stress was compressive within the tumors, with lower values in the
PZ (-0.75 to -0.33 KPa; see Fig. 5.5). Around the tumors, the hydrostatic stress was
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Figure 5.5. Details of prostate deformation caused by artificial tumors in different locations.
Detail of the deformation of the prostate over 1 year produced by a tumor originated on basal PZ (a1)-(d1),
apical PZ (a2)-(d2), and median CG (a3)-(d3). The contour of the tumor is depicted with black curves. (a1)-(a3)
Displacement field u1 over original anatomy at t = 1 year. (b1)-(b3) Displacement field u2 over original anatomy
at t = 1 year. (c1)-(c3) Displacement field u3 over original anatomy at t = 1 year. (d1)-(d3) Von Mises stress
(VMS) and hydrostatic stress (HDR) over original anatomy at t = 1 year.
113
5 · A mechanically-coupled model for PCa growth and interaction with BPH
compressive in the PZ, with a minimum of -0.08 KPa, and tensile in the CG, with a
maximum of 0.10 KPa. Maximal tensile hydrostatic stress between 0.67 and 0.88 KPa
was obtained on the most constricted contours of the urethra and was accompanied by
compressive values with minimum between -0.52 and -0.38 KPa on the urethral contours
in perpendicular direction to the constriction. High tensile hydrostatic stress was also
registered when tumors grew near the prostate external surface (up to 0.33 KPa in PZ and
0.48 KPa in CG). Far from the tumor, the hydrostatic stress was negligible.
The Von Mises stress ranged between 0.05 and 0.25 KPa inside the tumor and it was
higher around the convex side of the tumor borders, with values typically between 0.45
and 0.60 KPa (see Fig. 5.5). Maximal values of the Von Mises stress were obtained in
the healthy tissue between tumor branches (0.60 to 0.70 KPa), within intricate concave
regions of fingered tumors (0.60 to 0.75 KPa), within and around the tumor near the
border between the PZ and the CG (0.41 to 0.87 KPa), in healthy tissue compressed by
the tumor against the prostate external surface (0.50 to 0.92 KPa), and on the contour
of the most constricted segments of the urethra (0.75 to 1.27 KPa). The healthy tissue
enclosed by tumor branches had Von Mises stress values within the intratumoral range.
Massive tumors tended to build up greater values of the Von Mises stress around them.
We observed that the Von Mises stress was slightly higher and the distortion rim was
thicker in the CG.
5.7 BPH hampers PCa growth
After the deformational study of the prostate under the effect of BPH and PCa to calibrate
our model, we analyzed how the patient’s history of BPH affected PCa growth. We
ran two simulations: one without considering BPH and another including it. Fig. 5.6
depicts the growth of the tumor in both scenarios, while Fig. 5.7 and Fig. 5.8 show the
deformational states. The geometry of the patient’s tumor was extracted from the same
MR dataset used to obtain the prostate anatomy. We estimated the stress state of the
prostate caused by years of developing BPH prior to PCa detection at the MR date, σ 0.
This information was introduced as a prestress to compute the baseline hydrostatic and
Von Mises stresses in the mechanotransductive coefficient adjusting tumor dynamics.
Hence, for this purpose, σ = σ 0 +σ 1, where σ 1 are the stresses developed since the
detection of PCa at MR date.
The simulation without BPH rendered similar results to the PZ tumor cases in the previous
section. The patient’s tumor was located in the left basal aspect of the PZ and had a
volume of 0.51 cc. Initially, this tumor grew with massive morphology, early invading the
CG and progressively developing two lobes of preferential growth in the anteriorposterior
direction. This geometry contributed to an early shift in morphology between t = 0.3 and
t = 0.4 years, during which tumor growth was minimally slowed down. Afterwards, the
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Figure 5.6. BPH hampers PCa growth. Growth of the patient’s tumor over 1 year without the influence
of BPH (a1)-(b1) versus considering the patient’s history of benign prostatic enlargement (a2)-(b2). (a1)-(a2)
Tumor growth over the original prostate geometry. (b1)-(b2) Time history of tumor volume (solid line) and
serum PSA (dashed line).
tumor grew faster with fingered morphology, invading all the prostate side where it had
originated from median to basal height in the craniocaudal direction.
The final volume of the tumor was 6.32 cc. The urethra was displaced anteriorly to the
patient’s right and the maximal constriction was 0.30 mm. The distribution and magnitude
of the displacement, hydrostatic stress, and Von Mises stress fields were also analogous
to their counterparts in the simulations for the PZ tumors in the previous section. The
maximum total displacements were in the range 0.85-1.05 mm. The shape instability
reduced displacements by 17.3% and it took until the end of the simulation for them to
recover (t ≈ 0.9).
The inclusion of the patient’s history of BPH produced major changes in tumor growth
and the prostate deformational state. There was no shift in morphology in this simulation.
Instead, the tumor grew as a continuous mass that progressively surrounded the CG
anteriorposteriorly at the basal level of the PZ. The invasion of the CG was minimal and
only involved the border with the PZ. The tumor growth rate was considerably lower than
in the simulation without BPH and the final volume of the cancerous mass was 0.66 cc.
BPH globally dominated the deformation of the prostate by producing a volumetric
expansion. The tumor produced a local swelling deformation that was noticeable on the
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Figure 5.7. Prostate deformation caused by the patient’s tumor with and without considering
BPH. Deformation of the prostate over 1 year produced by the patient’s tumor without the influence of BPH
(a1)-(b1) versus considering the patient’s history of benign prostatic enlargement (a2)-(b2). (a1)-(a2) Length of
the displacement field vector over original anatomy at t = 1 year. The contour of the tumor is depicted with
black curves. (b1)-(b2) Original and deformed geometries of the prostate at t = 1 year.
external surface of the PZ. The urethra was displaced posteriorly to the patient’s right and
its diameter was practically unchanged. The deformation of the prostate caused by this
combination of BPH and PCa produced maximum global displacements between 0.86
and 1.16 mm. These values were attained on the outer region of the tumor within the
PZ. On the opposite side of the cancerous mass, the displacement field created by BPH
within the CG was barely modified by the presence of the growing tumor.
The patient’s history of BPH produced a highly compressive hydrostatic stress field in
the prostate, ranging from -2.90 to -2.20 KPa within the CG and from -0.60 to -0.25 KPa
within the PZ (see Fig. 5.8). The tumor contributed to increase the hydrostatic stress in
the PZ, reaching minima between -0.95 and -0.70 KPa within the tumor and between
-3.70 and -2.90 KPa next to the CG border. BPH led to the accumulation of compressive
stress all around the urethra (-6.20 to -3.00 KPa) and tensile stress at the PZ tissue in the
vicinity of the border between PZ and CG nearby the prostate external boundary (2.00 to
5.90 KPa).
The accumulated deformation by BPH also raised the Von Mises stress in the whole
prostate (see Fig. 5.8). Within the CG, it ranged from 0.10 KPa at inner tissue, far from
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Figure 5.8. Detail of prostate deformation caused by the patient’s tumor with and without
considering BPH. Detail of the deformation of the prostate over 1 year produced by the patient’s tumor
without the influence of BPH (a1)-(d1) versus considering the patient’s history of benign prostatic enlargement
(a2)-(d2). The contour of the tumor is depicted with black curves. (a1)-(a2) Displacement field u1 over
original anatomy at t = 1 year. (b1)-(b2) Displacement field u2 over original anatomy at t = 1 year. (c1)-(c2)
Displacement field u3 over original anatomy at t = 1 year. (d1)-(d2) Von Mises stress (VMS) and hydrostatic
stress (HDR) over original anatomy at t = 1 year. For the simulation including BPH, these values were computed
using σ = σ 0 +σ 1, where σ 0 is a prestress accounting for the history of BPH prior to PCa detection at MR
and σ 1 are the stress fields created by PCa and BPH 1 year afterwards.
both the urethra and the external prostatic boundary, to higher values between 1.30 and
1.80 KPa on the CG border. Within the PZ, the Von Mises stress was maximal on the CG
surface, from 3.50 to 5.00 KPa. The values of the Von Mises stress then decreased toward
the prostate exterior boundary, where they ranged from 1.00 to 2.50 KPa. The tumor
locally increased the Von Mises stress, reaching 1.70 KPa to 2.65 KPa on its outer lateral
convex border within the PZ, within the tumor near its concave border, and surrounding
the tumor tips in craniocaudal direction. The intratumoral values were between 1.50 and
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2.20 KPa. The maximum Von Mises stress was observed along the urethra, especially
along the anterior and posterior walls, ranging from 3.00 to 8.00 KPa.
5.8 Conclusions
In this Chapter, we derive a mechanically-coupled model for PCa growth in order to
explore prostate deformation caused by BPH and the tumor itself as well as the inhibition
of PCa evolution due to mechanical stress. Our model assumes that prostate deformation
is quasistatic and that prostatic tissue behaves as a linear, isotropic, heterogeneous
material. PCa and BPH are introduced as pressure loads in the constitutive equation,
which are restricted to the CG and the tumor volume, respectively. The confinement
of the prostate in the pelvic region is modeled with Winkler boundary conditions on
the external surface of the organ, while free displacement is imposed along the urethra.
Tumor growth inhibition by mechanical stress is represented by a global factor that
decelerates PCa dynamics. The definition of this coefficient relies on a combination of the
hydrostatic stress and the Von Mises stress, and its value range is designed to reproduce
previous experimental and clinical observations on mechanically-restricted tumor growth
[57, 118, 137, 160, 205, 228, 256, 267, 268]..
We studied the deformation of the prostate under the development of BPH, which pro-
duced the volumetric expansion of the prostate [44, 265]. This disease produced slightly
higher displacements craniocaudally and anteriorposteriorly at the basal level. The com-
pression of the PZ dampened the displacement fields elsewhere. Simulation of BPH
during several years would also produce the constriction of the urethra, as cued by the
high Von Mises stress along its trajectory.
Our mechanically-coupled model also captured how PZ tumors deformed the outer poste-
rior surface of the prostate, which would be noticed by a physician during a DRE [265].
The CG tumor produced lower displacements and a uniform and subtle deformation on
the posterior region of the prostate boundary. This is a common difficulty to detect CG
cancers during DRE. The constriction of the urethra along the segments circumvented by
the tumor is likely to produce lower urinary tract symptoms. Even though the displace-
ments decreased after the shape instability, the volumes of the prostate, the CG, and the
PZ were barely modified because the tumor grew faster with the fingered morphology.
Consequently, milder displacement fields expanded over a broader volume of the prostate.
PZ tumors grew slower because they accumulated higher compressive stress and the PZ
was globally more distorted when the tumor grew against the prostate external surface
and the CG border. PZ tumors adapted their shape to overcome those obstacles, favoring
tumoral geometries that also anticipated the shape instability. We also observed that our
model correctly reproduced the mechanical stress fields induced by a growing tumor as
previously described in the literature [57, 109, 118, 137, 205, 228, 256].
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Using computer simulations based on our mechanically-coupled mathematical model of
PCa, we show that a patient’s history of BPH promoted a highly compressive hydrostatic
stress state within the CG and distorted the whole prostate, especially the PZ, hence
increasing the Von Mises stress. The combination of this deformational state with
the mechanical stress fields created by PCa hindered tumor growth, which showed a
favorable pathological evolution characterized by a slow growing rate and the lack of
invasive demeanor. This resulted in a smaller tumor volume, which is more likely
to have lower GS [192, 239] and hence be less aggressive. PCa was unable to grow
beyond a certain thickness that would have motivated a shape instability towards a more
invasive morphology, which would facilitate invasion of seminal vesicles or extracapsular
extension. Instead, the deformational state of the prostate controlled the tumoral volume
and only permitted its development along the less distorted and stressed directions.
Increasing the Von Mises stress caused by both BPH and PCa in the prostatic tissue
between the tumor and the prostate external boundary would also contribute to prevent
the tumor from escaping the prostate.
Linear elasticity is a widely accepted mechanical paradigm in tumor growth models
[56, 61, 125, 160, 163, 267, 268], which provided a simple mechanical framework
for this study. We acknowledge that linear elasticity is an acceptable simplification
for studies featuring small strains and rotations and that the values of strains in the
simulations depicted in Figs. 5.4 - 5.8 are slightly outside the admissible limits for
linear elasticity in a few localized regions along the tumor interface. Additionally, the
prestress σ 0 is just a gross estimate of the stress state in the prostate due to the history
of BPH previous to PCa detection at MR. However, we are only using the stresses as
a means to compute the mechanotransductive factor to adjust tumor dynamics. Our
study also features other major sources of uncertainty beyond linear elasticity, such as
prostate and tumor segmentation, the PCa model itself, or the aforementioned boundary
conditions on the prostate. Nevertheless, our predictive simulations still qualitatively
reproduce the inhibiting effect on tumor growth caused by the tumor mass effect and a
history of BPH prior to PCa detection. Additionally, our simulations reproduce physically
representative deformations caused by tumor and BPH growth phenomena. In the future,
we plan to move beyond the limitations of linear elasticity by constructing a suitable
nonlinear constitutive model to describe the mechanical behavior of prostatic tissue and
by considering geometric nonlinearity.
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CHAPTER 6
Summary, conclusions, and future work
6.1 Summary
In this thesis, we have proposed a computational framework to contribute to the clinical
management of PCa. In this context, we derive a mathematical model for localized
PCa growth, an extension of this model to include the tumor mass effect as well as the
mechanical interaction between PCa and BPH, and a set of isogeometric methods to solve
these models.
Our computational framework for the clinical management of PCa is based on the concept
of mathematical oncology. We devise a clinical management protocol based on current
standards for PCa clinical care that relies on the acquisition of precise imaging data, such
as mpMR images, in order to guide diagnosis and staging. Longitudinal imaging data
for each patient provides the basis to create patient-specific computational tumor growth
models to predict prognosis, design optimal treatments, and monitor the follow-up of the
patient.
Since most cases of PCa are currently diagnosed and treated when the tumor is still local-
ized within the prostate, we devised our mathematical models to describe cancer growth
at this stage of the disease. As localized PCa growth can be seen as an evolving interface
problem, we leverage the phase-field method to account for the coupled dynamics of
healthy and tumoral tissue. The phase-field method enables the implicit definition of the
interface between both types of tissue throughout the level set φ = 0.5, with no need
to explicitly track it. Using reaction-diffusion equations, our model also describes the
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dynamics of a generic nutrient and tissue PSA, i.e., the serum PSA produced per unit
volume of prostatic tissue. Integration of the tissue PSA field over the geometry of the
prostate provides the serum PSA level that would be used by a physician.
We propose the use of IGA to handle the nonlinearity of our model as well as the
complex geometry of the prostate anatomy and the growth morphologies of prostatic
tumors. Isogeometric methods present several interesting advantages over classical FEA
approaches: they are geometrically exact, provide enhanced accuracy per degree of
freedom, and enable higher global continuity (Cp−1 for spline spaces with polynomial
degree p) [1, 66]. We also propose a methodology to obtain patient-specific, three-
dimensional isogeometric prostate meshes from medical images by means of a parametric
mapping method, which deforms a volumetric torus NURBS model to match the surface
of the prostate obtained from the patient’s medical imaging data, such as CT or MR
images.
Our model for localized PCa growth develops steep layers representing the interface
between the tumor and the host tissue. Consequently, we require very fine meshes
to capture the interface accurately. However, a much coarser mesh would suffice to
represent the constant value of the phase field within the healthy tissue or the tumor.
Therefore, we further advocate dynamic mesh adaptivity based on hierarchical refinement
and coarsening to speed up computations, rationalize computational resources, and
facilitate obtaining solutions in a clinical relevant time. We derive a set of efficient
algorithms to accommodate local h-refinement and h-coarsening of hierarchical splines
in IGA. Our methods are based on Bézier projection [234], which we have extended to
hierarchical spline spaces. Since the Bézier extraction operator of hierarchical splines
might not be invertible, we develop a multi-level reconstruction operator that maintains the
locality properties of the projection to overcome this problem. We have also introduced
the function support balance parameter to reduce the overlapping of functions across
hierarchy levels, which results in enhanced numerical conditioning.
In order to investigate the tumor mass effect and the mechanical interaction of BPH
and PCa, we extend our model of localized PCa growth to include the equations of
mechanical equilibrium and define the coupling terms between them and tumor dynamics.
We assume that the deformation induced by BPH and PCa are quasistatic phenomena
and we model prostatic tissue as a linear elastic, heterogeneous, isotropic material. BPH
and PCa are introduced as pressure terms in the constitutive equation acting within
the CG and the tumor, respectively. We imposed Winkler boundary conditions on the
external surface of the prostate to approximate the confinement of the organ within the
pelvic region. The inhibitory effect of the mechanical stress fields is modeled with a
global factor that slows down tumor dynamics and depends on a combination of the Von
Mises stress and the hydrostatic stress. The range of values of this inhibitory factor is
adjusted to match the experimental and clinical observations in previous studies of tumor
growth [57, 118, 137, 160, 205, 228, 256, 267, 268]. Using our mechanically-coupled
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mathematical model of localized PCa growth, we provide a mechanical explanation to
an unresolved clinical debate: why large prostates appear to exert a protective effect
against PCa [36, 55, 92, 126, 145, 184]. We demonstrate that a history of BPH creates
mechanical stress fields in the prostate that hamper PCa growth and limit its invasiveness.
Finally, we calibrated our models and methods using literature data so that we could
reproduce the growth morphologies and developmental features of localized PCa as
observed in experimental results and clinical practice.
6.2 General conclusions
According to the work presented in this thesis, we can draw the following conclusions:
• Predictive medicine and mathematical oncology offer a cutting-edge approach to
medical practice. These new trends may be the key to organize and broaden our
understanding of some critical diseases nowadays, such as PCa, by providing robust,
comprehensive theoretical models integrating all the major known and forthcoming
results from research in biological, biophysical, medical and biomedical sciences
as well as engineering and computational mechanics.
• We believe that the derivation of mathematical models of PCa growth as those
presented in this thesis might be the first step towards devising a complete model
that, within the context of a computational clinical management framework, could
be implemented in medical software to aid physicians in the diagnosis of the disease,
the prediction of prognosis, the design of optimal treatments, and management of
follow-up.
• Our baseline model for localized PCa growth is able to reproduce the two common
morphologies of PCa: spheroidal, or massive, and fingered. This model also
reproduces a known shape instability from the spheroidal pattern to fingered growth.
Results from our computations show that such shift is a tumor response to escape
starvation, hypoxia, and ultimately, necrosis. Hence, branching enables the tumor
to minimize the distance from inner cells to external nutrients, contributing to
cancer survival and further development.
• We have also used this model to perform the first tissue-scale, patient-specific
simulations of PCa patients based on prostatic anatomy extracted from medical
images. The simulated tumor growth morphologies provided similar geometrical
and developmental features to those seen in clinical practice.
• We observed that varying the tumor geometry, the tumor location, or the prostate
anatomy independently determined different patterns of tumor growth. This sug-
gests that the inclusion of the individual’s prostate and tumor geometries is essential
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in order to adequately follow up the progression of the disease in terms of tumor
volume and location as well as PSA production. Introducing the particular anatomy
of a patient in the model is crucial in order to predict the potential risks that PCa
growth may entail, such as prostatic capsule penetration, invasion of nearby tissues
or tumoral expansion to the different parts of the prostate, hence triggering symp-
toms such as impotence or irregularities in urination and ejaculation [259, 265].
• The possibility to predict when these risks or symptoms will appear would be a
major advance in watchful waiting and active surveillance. Hence, the optimization
of these two clinical options to manage the disease, including the modeling and
simulation of PCa, would decrease the overtreatment of patients, in many instances
leaving them relieved or cured after the delivery of the corresponding treatment,
with minimum side effects and a good quality of life.
• Predicting the actual tumor shape and volume within the anatomy of the prostate
of a given patient would also enable optimization of surgery and radiation therapy
planning and delivery, obtaining high precision and efficiency rates.
• According to our tissue-scale, patient-specific simulations of PCa growth, the
biopsy results of a prostate harboring a fingered tumor may provide a lower bound
for the aggressiveness of cancer leading to a dangerous predictive scenario. This
is due to two reasons: first, the biopsy needle may miss the interwoven tumoral
branches and, second, it may target a tumoral branch orthogonally, what would
render an erroneous low tumor percentage in the biopsy sample.
• Ideally, the combination of mpMR imaging and computational modeling and simu-
lation of PCa may eliminate the biopsy of the prostate during PCa diagnosis and
staging, hence dropping an invasive procedure with questionable outcomes and
under continuous debate in the medical community [259, 265]. In fact, the com-
bination of T2-weighted MR imaging, diffusion-weighted MR imaging, dynamic
contrast-enhanced MR imaging and, optionally, MR spectroscopic imaging, has al-
ready been able to detect and stage PCa with high sensitivity and specificity, compa-
rable to those of current standard biopsies [51, 75, 87, 111, 116, 123, 153, 227, 238].
As a result, mpMR imaging is now increasingly regarded as a future option to
biopsy or, at least, a technique to be fused to TRUS-guided biopsy in order to
optimize this procedure [210].
• Tissue PSA allows us to analyze where PSA is being leaked to the bloodstream and
the amount of this PCa biomarker discharged by both healhty and tumoral tissue.
Tissue PSA also links serum PSA to tumor burden in our models. This establishes
a theoretical basis for the link between both dynamics. A corroboration of this
connection arose when we estimated the baseline serum PSA for our simulations.
For a given selection of parameters and the initial tumoral volume, the initial serum
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PSA was intrinsically determined. Therefore, if we began the simulation with a
different serum PSA value, a steep branch would appear until it was readjusted.
• We observe that the predicted evolution of the tumoral volume and that of serum
PSA follow similar dynamics. This behavior is typically seen in low- and
intermediate-risk tumors [229, 253, 254, 259, 265], which are in all cases localized
prostatic tumors.
• The connection between tumor growth and serum PSA dynamics is an ongoing
major debate in the urologic community [259, 265]. Regular screening of PCa
relies on PSA tests but, even though most prostatic adenocarcinomas grow showing
a parallelism between the tumor volume and PSA levels in blood, it is known that
there exists a certain degree of divergence between the dynamics of these two
variables. This may even reach the limit of patients with low PSA and high tumoral
masses in their prostates, or vice versa. Advanced and metastatic PCa may also
exhibit almost no connection between serum PSA and tumor burden. However,
PSA screening has greatly improved the early detection and treatment of PCa,
leading to higher rates of incidence and an improved efficiency in its management
worldwide. Hence, we argue that this biomarker should be implemented in a
mathematical model of PCa, as it permits direct connection with existing clinical
data.
• The simulation of patient-specific, tissue-scale PCa growth is a challenging problem.
It features a moving interface that indicates the boundary between the tumor and
the neighboring healthy tissue. This interface, modeled by means of the phase-field
method, evolves in the complex anatomy of the patient’s prostate driven by nutrients
and hormones. Consequently, this is a problem where an adaptive approach
introduces a key advantage: it provides a mesh with finer elements to support
the interface and coarser elements elsewhere, which leads to dramatic savings of
memory and computational time. Hence, we argue that our adaptive algorithms are
an important enabling technology for the implementation of predictive models of
localized PCa growth in a clinical scenario in an efficient and accurate way.
• We have used our model for localized PCa growth in order to demonstrate the
analysis potential of our adaptive strategies for hierarchical splines. In all the
simulations presented in this thesis we obtained remarkable accuracy with very few
degrees of freedom in comparison to the uniform mesh that the same simulation
would require.
• Our adaptive algorithms enable the resolution of demanding moving interface
problems in science and engineering by means of IGA and leveraging hierarchical
spline spaces within a finite element framework provided by Bézier extraction. Our
technology can also be used to solve problems involving fine-scale features, such
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as internal and boundary layers in advection-dominated flows, stress concentration,
and accurate geometric definitions.
• We calibrated our mechanically-coupled model by performing an analysis of the
prostate deformation by BPH and PCa independently. Overall, our results in terms
of displacements and deformational features for BPH and PCa agree with previous
studies in the medical literature [27, 44, 265]. We also observed that our model
correctly reproduced the mechanical stress fields induced by a growing tumor as
previously described in the literature [57, 109, 118, 137, 205, 228, 256].
• We provide a mechanical explanation to understand why large prostates may
exert a protective effect against PCa. Our simulations show that the development
of BPH over years prior to PCa leads to a deformational state characterized by
high hydrostatic stress within the CG and large Von Mises stress in the PZ. The
combination of these mechanical stress fields with those induced by the growing
tumor hampers the evolution of PCa, which shows favorable pathological features,
such as a slow growth rate and no invasive behavior.
• Our results showing the mechanical inhibition of PCa growth advise performing a
comprehensive examination of the prostate in men without PCa before prescribing
BPH treatments or drugs aimed at reducing the CG volume. Likewise, our results
recommend a close follow-up of those PCa patients receiving these sorts of BPH
drugs. Otherwise, the prostate volumetric decrease could hazardously lower the
mechanical stress fields created by BPH and hence reduce their mechanical restraint
on PCa growth. Indeed, this could partially explain the higher proportion of
more aggressive cancers in the finasteride arm of the Prostate Cancer Prevention
Trial [235], arguably the most controversial result of this milestone study on
chemoprevention of PCa [36, 145, 150, 184].
• Our research on the mechanical interaction between PCa and BPH also calls for
new courses of treatment alleviating BPH symptoms while maintaining a significant
stress level within the prostate for protection against PCa.
• The efforts to shed light on the potential relationships between BPH and PCa have
pointed out promising correlations and mechanisms of interaction [4, 191, 265].
The ensuing research to validate them could greatly benefit from mathematical
modelling in order to organize, comprehend, and provide a solid theory to sustain
these new discoveries and guide future steps [7, 165, 188, 274].
6.3 Future work
The investigations carried out in this thesis opens the door for several research lines to be
addressed in the future. We highlight the following ones:
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• Our description of tumor dynamics can be improved by including several cancerous
species (e.g.: normoxic, hypoxic, and necrotic), which enables a more detailed
simulation of the shape instability; by introducing taxis phenomena to better
describe tumor invasiveness; and by considering other substances that play a major
role in PCa, such as oxygen or testosterone.
• Tissue PSA dynamics can also be enhanced by providing a more precise definition
of tissue PSA production rates, αh and αc, and by refining its equation. This may
require reviewing PSA modeling in the medical literature in order to find further
connections between tumor shape and volume and PSA production. In addition,
we are ignoring prostate growth, which could contribute to PSA increase.
• Since men over 50 have their PSA monitored routinely, we could personalize the
parameters in the tissue PSA equation by leveraging inversion methods, Bayesian
statistics, or machine learning. Longitudinal analysis of PSA dynamics in large
patient cohorts would be required to perform this task.
• Radiation therapy is a viable treatment for a wide variety of PCa patients and
holds the potential to derive personalized plans based on precise imaging data
[259, 265]. Hence, another interesting line of research is exploring the modeling
and simulation of the effects of radiation therapy in PCa with our model, following
previous studies carried out for low grade gliomas [158, 196] and glioblastoma
multiforme [64, 202].
• In parallel with the improvements to the model, we would require to test our isogeo-
metric methods to assess whether they reproduce the new phenomena incorporated
accurately and efficiently, or improve our algorithms otherwise. In particular, we
would like to test our adaptive algorithms with more complex models of PCa
growth involving several tumoral cell species, in which the new interfaces between
them must be accurately represented. We are also interested in leveraging our
adaptive strategies in order to test the accuracy of our models using patient-specific
anatomical and pathological data extracted from medical images, in particular,
from mpMR imaging [51, 75, 87, 111, 116, 123, 153, 227, 238].
• The development of p-, k-, and r-adaptivity of hierarchical spline spaces and
the extension of our adaptive algorithms to the spline forest setting [219, 234]
are challenging and promising lines of research towards the derivation of more
versatile and powerful dynamic adaptive methods in IGA.
• Our mechanically-coupled mathematical model for localized PCa growth could
be improved in numerous directions. First, our anatomic model of the prostate
would benefit from a more precise segmentation of the internal prostatic zones
accompanied by patient-specific mechanical characterization. Second, a spatially
varying definition of Winkler conditions attending to the different tissues and organs
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surrounding the prostate would contribute to render more accurate predictions.
Third, our model would also benefit from a more accurate formulation for BPH
[157, 203, 270] as well as for tumor growth and deformation [56, 125, 160, 163,
205]. Fourth, the mechanotransductive term to adjust tumor dynamics can be
refined, for instance, by testing alternative formulations or differentiating how
mechanical stress affects tumor mobility, proliferation, and apoptosis [57, 118, 160].
Finally, to overcome the limitations of linear elasticity and obtain more accurate
values of displacements and stresses we plan to account for geometric nonlinearity
and investigate alternative constitutive equations for the prostate [110, 134, 173,
256], which typically involve a larger set of elastic parameters that are not easy to
estimate on a patient-specific basis.
• A poroelastic description of PCa growth would help to study the effect of mechani-
cal deformation on nutrient transport [205]. This approach holds the potential to
accurately investigate the heterogeneity of intratumoral metabolism or test patient-
specific drug administration to the tumor in silico.
• We also intend to investigate the impact of BPH drugs causing a prostate vol-
ume decrease on tumor growth by extending our mechanically-coupled model to
incorporate the effect of these drugs, such as dutasteride and finasteride [235, 265].
• We think that our mechanically-coupled model could be exploited to improve
the current technologies for deformable registration of medical images [27] by
providing a theory for the evolution of BPH and PCa. The resulting algorithms
would be of much interest for several applications within the clinical management
of PCa on a tissue-scale, patient-specific basis, such as the accurate follow-up of
tumor growth during active surveillance or the precise planning of surgery and
other treatments [165]. Such technology could also help to detect PCa based
on the deformation of the prostate boundaries and the internal borders between
prostatic regions [208, 263]. Additionally, it could guide biopsies to better stage
and diagnose PCa. Comparing the predictions of the model with new images and
clinical data could also help to discern whether the tumor is progressing towards a
more malignant behavior and to make clinical decisions accordingly [165].
• To gain further knowledge on the mechanisms of PCa growth using our models,
we believe it would be valuable to investigate the mathematical properties of
the equations comprising them, for example, analyzing solvability conditions,
characterizing parameter spaces, and studying the well-posedness of the problem.
• We intend to pursue the validation of our computational framework using longitudi-
nal patient datasets, including high-quality medical images, biochemical data, and
clinical reports. As a previous step, this work will also require the patient-specific








The elaboration of this thesis has resulted in a number of peer-reviewed publications in
international journals as well as contributions in national and international conferences.
In this Appendix, we detail the scientific production associated with this thesis.
A.1 Articles in peer-reviewed international journals
The following articles are directly related with the contents of this thesis:
• G. Lorenzo, M. A. Scott, K. Tew, T. J. R. Hughes, Y. J. Zhang, L. Liu, G. Vilanova,
and H. Gomez. Tissue-scale, personalized modeling and simulation of prostate
cancer growth. Proceedings of the National Academy of Sciences, 113(48):E7663–
E7671, 2016. Associated with Chapter 3.
• G. Lorenzo, M. Scott, K. Tew, T. Hughes, and H. Gomez. Hierarchically refined
and coarsened splines for moving interface problems, with particular application
to phase-field models of prostate tumor growth. Computer Methods in Applied
Mechanics and Engineering, 319:515 – 548, 2017. Associated with Chapter 4.
• G. Lorenzo, P. Dominguez-Frojan, A. Reali, and H. Gomez. Prostate enlargement
due to benign prostatic hyperplasia mechanically hampers prostate cancer growth.
Submitted for publication, 2018. Associated with Chapter 5.
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A.2 Contributions in national and international conferences
The work presented in this thesis is also the object of contributions in the following
national and international conferences:
• G. Lorenzo, P. Dominguez-Frojan, A. Reali, H. Gomez. Prostate enlargement due
to benign prostatic hyperplasia provides mechanical protection against prostate
cancer. 10th European Solid Mechanics Conference (ESMC 2018), Bologna, Italy,
July 2-6, 2018.
• G. Lorenzo, P. Dominguez-Frojan, A. Reali, H. Gomez. Benign enlargement
of the prostate with age mechanically restricts the growth of prostatic tumors.
6th European Conference on Computational Mechanics (ECCM 6) and 7th Euro-
pean Conference on Computational Fluid Dynamics (ECFD 7), Glasgow, United
Kingdom, June 11-15, 2018.
• G. Lorenzo, T.J.R. Hughes, A. Reali, H. Gomez. Un modelo matemático para la
predicción personalizada del crecimiento de cáncer de próstata a escala anatómica
[A mathematical model for the patient-specific prediction of prostate cancer growth
at anatomic scale]. 34 Congreso Nacional de la Sociedad Española de Radiología
Médica (SERAM2018), Pamplona, Spain, May 24-27, 2018.
• G. Lorenzo, M.A. Scott, K. Tew, T.J.R. Hughes, H. Gomez. A computational frame-
work for tissue-scale, patient-specific prediction of prostate cancer growth. 14th
U.S. National Congress on Computational Mechanics (USNCCM14), Montreal,
Canada, July 17-20, 2017.
• G. Lorenzo, M.A. Scott, K. Tew, T.J.R. Hughes, H. Gomez. Tissue-scale, patient-
specific modeling and simulation of prostate cancer. Congress on Numerical
Methods in Engineering (CMN2017), Valencia, Spain, July 3-5, 2017.
• G. Lorenzo, M.A. Scott, K. Tew, T.J.R. Hughes, H. Gomez. Modeling and simu-
lation of prostate cancer: advances in the development of a new patient-specific
tissue-scale diagnostic model. XII World Congress on Computational Mechan-
ics (WCCM XII) and VI Asia-Pacific Congress on Computational Mechanics
(APCOM VI), Seoul, Korea, July 24-29, 2016.
• G. Lorenzo, M.A. Scott, K. Tew, T.J.R. Hughes, H. Gomez. Isogeometric modeling
and analysis of prostate cancer growth: on the development of a new patient-
specific tissue-scale diagnostic model. III International Conference on Isogeometric
Analysis (IGA2015), Trondheim, Norway, June 1-3, 2015.
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Collaboration in other works
B.1 Prostate Meshes for Isogeometric Analysis
One of the central elements of our computational framework for the clinical management
of PCa is the generation of volumetric isogeometric meshes of the patients’ prostates.
There are multiple methodologies to build solid anatomic NURBS models [278, 280].
Because the geometries of the prostate and a solid torus are topologically equivalent,
we leveraged a parametric mapping algorithm [90, 279] to deform a torus solid NURBS
model to match with the prostate surface model obtained from the patient’s T2-weighted
MR images.
In order to create the prostate mesh for our simulations, first we need to construct a
geometric model of the prostate surface. We used 3DSlicer [88] to load the medical
images of our patient and draw the contours of the prostate and the urethra on axial images
using the prostate segmentation as guidance if available. We manually adapt the contours
to best capture the anatomy of the prostate as seen in axial, sagittal, and coronal images.
Using these contours we created a triangular surface model of the prostate. However, this
surface is usually coarse and rough, so we export it to MeshLab [60] to smooth it. The
resulting prostate surface is then checked again over the original medical images to assess
the coherence with observed anatomy.
Then, we build a solid NURBS model of a torus using the classic polar discretization [66].
We also construct its corresponding triangular surface mesh. We define two intersection
curves along the circumferential directions of the prostate and torus surface models in
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order to split each of them into four triangular surface patches, such that the intersection
curves define their boundaries. Then, we build a one-to-one discrete harmonic mapping
f from each surface patch Sitorus and S
i
prostate, i = 1, . . . ,4, to the same planar square
S∗. The splitting curves are mapped onto the boundaries of S∗ by means of a chord
length parameterization. Now, we can deform the torus to match the prostate surface by
combining the parametric maps for both surface models in order to project the external
layer of the torus control mesh onto the prostate surface. Then, we merge the set of
control points calculated using each pair of triangular surface patches Sitorus and S
i
prostate,
i = 1, . . . ,4. We also recalculate the control points to ensure C1 continuity over the
prostate, especially in the region of the splitting curves.
The next step is to compute the remainder of control points to complete the patient-specific
solid NURBS model of the prostate. The outer control points obtained with the previous
procedure can be arranged in 3D ringlike sets along the external perimeter of the prostate
cross section. Following the polar discretization of the original torus, first we determine
the position of the central control points and then we place the inner control points evenly
along each radius. The central control points are placed at the weighted geometric center
of the external control point ring using the squared lengths of the segments joining them
as weights. This ensures that the weighted center is far from the urethra because the
external control points are more distant one another on the outer prostate surface than
along the urethra. This position helps avoiding the generation of concave elements in the
vicinity of the urethra. We may further refine the position of the central control points to
ensure the convexity and overall quality of the elements to perform simulations.
Finally, we globally refine the resulting volumetric mesh of the prostate to meet the
requirements of our computations. We use standard knot insertion, degree elevation, or a
combination of both as defined in [66].
Together with Pablo Dominguez-Frojan, Adrian Lopez-Fouz, Pablo Orosa-Iglesias, and
Guillermo Vilanova, from our group at Universidade da Coruña, we developed a software
that provides a patient-specific volumetric NURBS mesh of a patient’s prostate. This
software is called Prostate Meshes for Isogeometric Analysis or PROMISE and it is
available at
http://caminos.udc.es/gmni/gente/hgomez/pages/software.html
The inputs of the program are a surface model of the prostate including the urethra
or its corresponding volumetric NURBS model, if the user has already computed it
before and only intends to adapt that mesh to new simulation requirements. It is also
necessary to provide a series of properties for its execution, which are intended to control
mesh generation, global mesh refinement, and mesh partition for parallel computations.
PROMISE also features two execution modes that provide the NURBS mesh of the
prostate for a generic IGA code or for compatibility with PetIGA [70], respectively.
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B.2 The equations of cancer
During the research project that has been described in this thesis, we also embraced the
opportunity to present the field of mathematical oncology to the general public. Together
with Guillermo Vilanova (Universidade da Coruña), we wrote a popular science paper
entitled “Las ecuaciones del cáncer [The equations of cancer]” for Investigación y Ciencia
[167], the Spanish edition of Scientific American.
In this work, we describe the scope of mathematical oncology, the difficulties of studying
cancer from a clinical and a computational perspective, the elements in a mathematical
model of cancer growth, the different types of models according to their mathematical
formulation, and the stages of development of tumor growth mathematical models from
initial design to clinical implementation. We also briefly present our baseline model
for localized PCa and isogeometric methods, as well as Guillermo Vilanova’s work on
tumor-induced angiogenesis.
B.3 Ongoing research on computational methods for prostate
cancer
The research presented in Chapter 3, Chapter 4, and Chapter 5 has sparked several open
lines of research that we outlined at the end of each Chapter. During my PhD studies, we
started developing some of them and we plan to continue the investigations in the near
future. We proceed to briefly describe these ongoing contributions:
u A computational framework for PCa growth prediction based on mpMR
imaging
In order to validate our computational methods for the prediction of localized
PCa growth we need to infer the values of the parameters in our model in a
patient-specific manner using the available clinical and imaging data. References
[266–268, 274] provide a methodology to estimate the parameters in a Fisher-
Kolmogorov model of neoadjuvant chemotherapy of breast cancer based on mpMR
imaging. This model only requires two parameters: diffusivity of tumor cells and
net proliferation. A patient-specific heterogeneous map of these parameters can
be estimated from a combination of diffusion weighted MR imaging and dynamic
contrast-enhanced MR imaging. These maps are defined over the anatomy of the
patient’s breast on T1-weighted MR images, which also provides the computational
domain to define the finite element mesh. Using inversion methods it is possible
to estimate the parameter maps from the imaging data at two time points. Then,
imaging data at a third point is used to assess the predictive performance of the
model.
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Our model possesses too many parameters to address patient-specific parameter
estimation by leveraging longitudinal mpMR imaging data from scratch. Hence, we
adapted our theory of prostatic tumor growth to the Fisher-Kolmogorov formulation.
This provided us a similar framework to that presented in [266–268, 274], so that
we can accommodate their methods to PCa cases. In particular, we use T2-weighted
imaging to define the the geometric domain of our problem because it is the standard
imaging technique to contour the prostate and perform radiological studies of the
organ anatomy. Additionally, tissue PSA parameters could be estimated using
regression methods over the history of PSA values of a given patient.
We are currently analyzing inversion methods to estimate the parameters in this
simpler model of PCa in collaboration with Alessandro Reali (Università degli Studi
di Pavia, Italy) and Thomas J.R. Hughes (Institute for Computational Engineering
and Sciences, Austin TX, USA). We also acknowledge the technical assistance
provided by Sandra Fernández-Turnes and Manuel Tasende-Vilariño, from our
group at Universidade da Coruña, in the early stage of this research. In parallel,
we are contacting potential partners in the oncological community to provide us
with longitudinal imaging and clinical datasets. In the future, we plan to extend the
technology emanating from this research to the models presented in this thesis.
u A multispecies model of PCa growth
One of the major results from Chapter 3 is the ability of our baseline model for PCa
to capture the different tumoral morphologies at this stage of the disease, as well as
the shift between them. In Chapter 3 and [165], we explain that this shape instability
is a reaction of the tumor to escape hypoxia and starvation. To better understand
this phenomenon we started to develop a multispecies model of PCa growth on
the basis of our baseline model presented in Chapter 3. Within the tumor, we
consider three tumoral species depending on the oxygen concentration: normoxic,
hypoxic, and necrotic. We require that the sum of the densities of normoxic,
hypoxic and necrotic cells equals the value of the order parameter in our baseline
phase-field formulation, which represents the global tumor cell density. Hence,
we model the dynamics of each cell species with a reaction-diffusion equation but
requiring that each tumoral phase follows the global motion and growth of the
global tumor. The equations modeling the dynamics of normoxic and hypoxic
cell densities include terms describing proliferation in the presence of oxygen and
apoptosis. While normoxic cells are more proliferative and less invasive (i.e., less
diffusive), hypoxic cells are less proliferative and more invasive. Necrotic cells
are modeled with little diffusivity, no proliferation and a certain clearance rate.
We also design a set of three transfer functions that model the transformation of
(1) normoxic cells into hypoxic cells, (2) hypoxic cells into normoxic cells and
(3) hypoxic cells into necrotic cells. These functions rely on two thresholds in
oxygen concentration: one establishing the limit at which normoxic cells undergo
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a transformation into hypoxic cells, or vice versa, and another setting the absolute
minimal oxygen concentration, beyond which hypoxic cells become necrotic. This
formulation is based on previous work on multispecies models of cancer growth
[159, 172, 188, 230, 271].
Our preliminary results in simple 2D scenarios show that once the hypoxic tissue
reaches a certain volume, an initially spheroidal tumor undergoes a morphology
shift towards a fingered pattern. The growing branches eliminate or reduce the
hypoxic fraction because in this geometric configuration the inner tumoral tissue
has better access to nutrients. Whenever a new hypoxic core appears, we observed
that new branching events take place to reduce it. Furthermore, our simulations
reveal almost negligible percentages of necrotic cells within the tumor. Currently,
we are working on the tissue-scale, patient-specific implementation of this model.
We want to thank the assistance provided by Esteban Sañudo-Costoya, from our
group at Universidade da Coruña, in order to improve the equations in the model.
u PSA dynamics after external radiotherapy
External radiotherapy is a common treatment for low and intermediate risk PCa
patients [259, 260, 265]. As we described in Section 2.4.5.4, the patient has its
PSA monitored after completion of the radiation plan because the serum levels
of the biomarker should progressively decrease if cancer has been successfully
treated. The rise of PSA levels, also known as biochemical relapse, is indicative
of PCa recurrence. The surviving tumor should be managed as soon as possible
to maximize the chances of effective cure. An important body of research has
been dedicated to study PSA dynamics after radiotherapy in order to find early
predictors of tumor recurrence [143, 198, 222, 225, 233, 237, 242, 246, 255, 275].
Following the work in [255], we are developing a deterministic mathematical
model to describe PSA dynamics after external radiotherapy in collaboration with
Víctor M. Pérez García (Universidad de Castilla-La Mancha, Spain), Luis Pérez
Romasanta (Hospital General Universitario de Salamanca, Spain), and Alfonso
Mariño (Centro Oncolóxico de Galicia, Spain). Provided that for low and interme-
diate risk patients PSA is likely to be proportional to the number of PCa cells, we
describe serum PSA dynamics after external radiotherapy by means of a decaying
exponential representing the dying cells and a rising exponential related to the
survival fraction.
Our preliminary results show that PSA dynamics after external radiotherapy is
controlled by two key quantities: the relative proportion of dying to survival
cell fractions and the relative time scales of radiation-induced cell death to cell
proliferation in the survival fraction. We also derived an estimate of the biochemical
relapse time based on these values that could help oncologists in the management
of follow-up. Currently we are working on the calibration of our theory using a
patient dataset from the Centro Oncolóxico de Galicia (Spain).
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u Modeling and simulation of external radiotherapy of PCa
This recent line of research also pursues the extension of our computational frame-
work to account for external beam radiation therapy for PCa. We are extending
our baseline and multispecies models with a partial memory model of radiotherapy
[158]. According to this formulation, we assume that radiation instantly kills a
certain percentage of cells with each dose and permanently reduces the prolifer-
ation rate of the tumor from the beginning of the treatment. This formulation of
radiotherapy has been found to better represent tumor dynamics after treatment
than classical tumor surviving fraction approaches [127, 160] and enables the
introduction of the radiation plan schedule, hence opening the door to model hypo-
and hyperfractioning [259, 265]. Additionally, the multispecies model enables the
possibility to introduce the radioresistance of hypoxic cells throughout a higher sur-
viving fraction and a milder reduction of cell proliferation with respect to normoxic
cells.
Our preliminary simulations in simple 2D cases reveal that tumors are effectively
eliminated following similar trends in tumor dynamics as those observed in the
literature. In the future, we plan to extend this model to a tissue-scale, patient-
specific scenario and use longitudinal imaging and clinical datasets to calibrate and
validate the model. We acknowledge the assistance provided by Esteban Sañudo-




Extended summary in Spanish
C.1 Introducción
Según la Organización Mundial de la Salud (WHO), el cáncer de próstata (PCa) es el
segundo cáncer más común y la quinta causa de muerte por cáncer en hombres en todo el
mundo [89]. Los datos son reveladores: en 2012, se estimaron alrededor de 1,095,000
nuevos casos y unas 308,000 muertes en todo el mundo asociadas con este cáncer y
será responsable de unos 161,360 nuevos casos y unas 26,730 defunciones solamente en
EEUU en 2017 [5]. Además, estudios epidemiológicos nacionales en España mostraron
una estimación de 33,370 nuevos casos de PCa en 2015 y de 5,855 muertes por esta
enfermedad en 2014 [96, 224].
En la mayoría de casos, el PCa es un adenocarcinoma, una forma de cáncer que se
origina y desarrolla en tejidos epiteliales con organización glandular, por ejemplo, el
tejido prostático encargado de producir ciertas sustancias del semen [259, 265]. Los
adenocarcinomas surgen como resultado de alteraciones genéticas en los núcleos de
las células, como mutaciones y cambios epigenéticos. Además, la influencia de varios
factores ambientales, como la dieta, pueden promover modificaciones adicionales del
genoma. Las células tumorales exhiben un comportamiento competitivo y aberrante,
caracterizado por una proliferación excesiva y una conducta invasiva. En consecuencia,
pueden poner en peligro la estructura y el normal funcionamiento del tejido al que
pertencen, llegando a amenazar la supervivencia del organismo. Un mismo tumor puede
presentar diferentes grupos de células cancerosas, con diferente metabolismo, entorno
local y agresividad. Las células malignas pueden evolucionar durante su ciclo de vida, y
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entonces pertenecer a un nuevo grupo. La estructura, el comportamiento y la evolución de
un tumor depende de las alteraciones genéticas específicas que lo hayan podido generar y
hayan mantenido su evolución [3].
El desarrollo del adenocarcinoma de próstata requiere de la acumulación gradual de
mutaciones en un conjunto de genes diferentes, que varían de un paciente a otro, pero que
normalmente suman un mínimo de siete [259, 265]. Por tanto, el PCa es más frecuente en
hombres de mayor edad. Como resultado de estas alteraciones del genoma a lo largo de los
años, un inicial desorden moderado del comportamiento celular evoluciona gradualmente
hacia un cáncer avanzado. Según el tumor se va desarrollando, este se vuelve más maligno
y la diferenciación celular disminuye. Este fenómeno evolutivo se denomina progresión
tumoral y, en general, comprende cuatro pasos: (1) proliferación excesiva de células
localizada, (2) proliferación excesiva de células de forma extensiva, (3) invasión de
tejidos cercanos y, finalmente, (4) metástasis, que es el proceso por el cual algunas células
malignas escapan del tumor original, entran en el torrente sanguíneo y migran a otro
tejido, que invaden y colonizan [3, 259, 265].
La práctica médica del PCa se ha desarrollado sobre las bases genéticas y biológicas
anteriormente descritas así como sobre la experiencia acumulada de los doctores que
tratan esta enfermedad [259, 265]. Los protocolos médicos actuales incluyen todas estas
fuentes de conocimiento sobre el PCa en forma de estadísticas para la probabilidad del
estadio del cáncer y el éxito del tratamiento. Brevemente, el PCa es más fácil de curar en
sus fases iniciales, antes de que se vuelva excesivamente agresivo y se extienda fuera de la
próstata pero, desafortunadamente, esta enfermedad casi nunca produce ningún síntoma
hasta que el tumor sea muy grande o haya invadido otros tejidos. Por tanto, la mejor
forma de combatir el PCa es una combinación de prevención y exámenes rutinarios para
una detección precoz. El PCa se suele diagnosticar y tratar cuando todavía está localizado
dentro de la próstata. El PCa localizado se suele tratar con un enfoque curativo, por
ejemplo, con cirugía o radioterapia, mientras que para el PCa avanzado se suelen emplear
estrategias paliativas basadas en terapia hormonal o quimioterapia. Los pacientes de PCa
de bajo riesgo pueden retrasar su tratamiento hasta que el tumor alcanza un estadio óptimo
(vigilancia activa). Los pacientes que no son aptos para un tratamiento curativo local, o
aquellos con una baja esperanza de vida, pueden beneficiarse de un tratamiento paliativo
aplazado, con el objetivo de tratar síntomas específicos de la enfermedad, mientras que
continúan sus exámenes rutinarios (“esperar y ver”).
Además del PCa, en la próstata también se da otra gran patología que afecta a hombres
de edad avanzada: la hiperplasia benigna de próstata (BPH) [259, 265]. Esta enfermedad
consiste en el aumento patológico del volumen de la próstata con la edad, con una
prevalencia creciente desde el 50% en hombres de cincuenta años a alrededor del 70%
en hombres de setenta años [26]. La BPH obstruye el flujo urinario y eyaculatorio,
causando así molestos síntomas del tracto urinario inferior. El PCa y la BPH pueden
coexistir en un mismo paciente y comparten numerosas similitudes [4, 191, 265], que
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han sugerido varias conexiones o interacciones entre ambas patologías. Sin embargo,
carecemos de una evidencia sólida confirmando su existencia. Estudios recientes sobre
extensas series de especímenes quirúrgicos de próstatas han demostrado que los tumores
que se originan en próstatas de mayor tamaño presentan características patológicas
favorables [36, 55, 92, 126, 145, 184]. Estos estudios proporcionan una sólida evidencia
que sugiere que las próstatas grandes pueden ejercer un efecto protector contra el PCa.
Biólogos y médicos se dedican activamente al estudio del PCa intentando arrojar luz sobre
los complejos mecanismos moleculares, biológicos y fisiológicos que explican cómo los
tumores se originan, se desarrollan y se extienden por el cuerpo, analizando también
nuevas opciones para el tratamiento del PCa. A pesar de la cantidad de investigaciones
clínicas y experimentales, carecemos de un modelo teórico completo en el que esta
abundancia de datos se pueda comprender y organizar, guiando también futuros trabajos de
investigación para enriquecer dicho modelo. Tanto el fundamento de estas investigaciones
como la práctica médica común en oncología se basan en patrones estadísticos, que
no son suficientemente precisos para individualizar el diagnóstico, la estimación de la
prognosis, el tratamiento y el seguimiento.
Alternativamente, la medicina predictiva [231, 232] es un enfoque interdisciplinar cuyos
objetivos son la determinación personalizada de la progresión de una enfermedad y del
tratamiento óptimo. Los métodos de la medicina predictiva se basan en la modeliza-
ción matemática y en la simulación por ordenador de la enfermedad y los tratamientos.
Este nuevo enfoque complementa la base estadística y empírica del diagnóstico y la
planificación del tratamiento, que constituye la práctica médica actual. En el caso par-
ticular de la investigación del cáncer, la oncología matemática [7, 53, 97, 188, 274]
es un campo nuevo y prometedor que se dedica al desarrollo de modelos y herramien-
tas computacionales para simular el crecimiento de tumores y el tratamiento del cán-
cer. Aunque ha habido progresos importantes en las décadas recientes, la modeliza-
ción precisa del crecimiento de tumores cancerosos sigue siendo un reto por resolver
[7, 9, 42, 52, 53, 97, 160, 167, 170, 174, 188, 206, 211, 212, 236, 251, 274].
La no-linealidad que suele caracterizar el conjunto de ecuaciones que comprende los
modelos de crecimiento tumoral, la compleja geometría de los modelos anatómicos
personalizados y la intricada morfología que pueden mostrar los tumores en crecimiento
demandan métodos de resolución muy eficientes en términos de memoria y tiempo de
computación. El análisis isogeométrico (IGA) es una tecnología innovadora y de rápido
crecimiento que puede hacer frente a todos estos retos computacionales [66, 130]. El IGA
se puede ver como una generalización del clásico análisis por elementos finitos (FEA)
[132]. En vez de usar los típicos polinomios definidos a trozos, el IGA emplea funciones
más sofisticadas procedentes de los gráficos por ordenador y la geometría computacional,
como las B-splines [66, 84, 130, 195, 204], las Non-Uniform Rational B-splines (NURBS)
[66, 84, 130, 195, 204], y las T-splines [18, 21, 22, 154]. Los métodos isogeométricos
basados en estos espacios funcionales son geométricamente exactos, proporcionan una
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mejor precisión por grado de libertad y permiten una mayor continuidad global (Cp−1
para espacios de splines con grado polinómico p) [1, 66]. Además, el IGA es compatible
con técnicas de adaptatividad dinámica de malla basadas en el concepto de refinamiento
y engrosado jerárquicos [215, 219, 257], que permite la adaptación local de la malla de
forma dinámica a lo largo de la simulación. De este modo, la malla presenta elementos
más finos con funciones de aproximación más sofisticadas cerca del tumor, y elementos
más gruesos en cualquier otro sitio. Esto conduce a un gran ahorro de memoria y tiempo
de computación. Por tanto, las técnicas de adaptatividad dinámica de malla poseen el
potencial para acelerar los cálculos y crear métodos isogeométricos que faciliten la
obtención de soluciones en tiempos clínicamente relevantes.
El PCa ha recibido una atención relativamente pequeña por parte de la comunidad de
oncología matemática [122, 133, 135, 136, 149, 176, 277]. Sin embargo, el PCa puede
ser un candidato ideal para explorar la modelización del crecimiento del cáncer de forma
personalizada y a escala tisular por varias razones:
• El PCa es un gran problema sanitario y un caso paradigmático en el que un modelo
predictivo puede marcar la diferencia en la práctica médica porque actualmente
numerosos pacientes son tratados de forma excesiva o insuficiente [164, 260].
• La imagen médica está emergiendo como herramienta de diagnóstico en PCa.
La imagen médica no se usa de forma generalizada en el diagnóstico del PCa
debido a una falta de confianza en la actuales modalidades de imagen. Sin em-
bargo, la resonancia magnética multiparamétrica (mpMR) se usa normalmente
para monitorizar la evolución de la enfermedad y está emergiendo como una tec-
nología prometedora que se podría utilizar también para el diagnóstico del PCa
[51, 75, 87, 111, 116, 123, 153, 227, 238].
• La próstata es un órgano pequeño, típicamente entre 20 y 80 cc [24, 26, 31, 259,
265, 270], de modo que es factible crear un modelo anatómico personalizado de la
próstata a partir de imágenes médicas para realizar simulaciones predictivas.
• El crecimiento del tumor en un determinado paciente se puede estimar usando
la concentración de un biomarcador del PCa denominado antígeno específico de
próstata (PSA), que se mide con un análisis de sangre y juega un papel crucial
durante el diagnóstico, la selección de tratamiento y el seguimiento de los pacientes
[253, 254, 259, 265].
• Algunos pacientes de PCa no reciben ningún tratamiento pero tienen su PSA
monitorizado y se les toman imágenes médicas periódicamente, por ejemplo,
durante el tiempo que va del diagnóstico al tratamiento o durante los protocolos de
vigilancia aciva y “esperar y ver”. Esto podría abrir la puerta potencialmente a la
validación in vivo de un modelo [261, 274].
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• El IGA proporciona un sofisticado marco computacional que garantiza la precisión
y eficiencia requeridas para realizar simulaciones predictivas del crecimiento de
PCa de forma personalizada y a escala tisular.
• La oncología matemática también es un enfoque prometedor para investigar la
relación entre el PCa y la BPH porque puede proporcionar sólidos mecanismos
de interacción para explicar las evidencias actuales y guiar la futura investigación
clínica.
C.2 Objetivos
El propósito central de esta tesis es proporcionar un marco computacional para la mode-
lización y la simulación del crecimiento de PCa órgano-confinado dentro del contexto
de la oncología matemática. Este objetivo general se puede subdividir en un conjunto de
objetivos de investigación más específicos, los cuales resumimos en los siguientes puntos:
• Definición de un marco computacional para la gestión clínica del PCa. Nues-
tro primer objetivo será diseñar un marco para la gestión clínica del PCa en el que
las tecnologías de la oncología matemática complementen los protocolos médicos
comunes para esta enfermedad. Para este fin, revisamos el conocimiento actual so-
bre las bases biológicas de los tumores prostáticos, los procedimientos estándar en
la gestión clínica del PCa y los desarrollos recientes en la modelización y la simu-
lación matemática de crecimiento de tumores. También revisamos las tecnologías
de imagen médica para PCa actuales y en desarrollo porque proporcionan una gran
cantidad de datos personalizados para importar en una herramienta computacional
de predicción de crecimiento tumoral.
• Diseño de un modelo matemático de crecimiento de PCa personalizado y a
escala tisular. Nuestra intención es definir un modelo matemático personalizado a
escala tisular que describa el crecimiento del PCa localizado, pues este es el estadio
en el que normalmente se diagnostica y trata. La definición del modelo estará basada
en el actual conocimiento biológico y médico de la enfermedad. Identificaremos
y describiremos matemática y físicamente los mecanismos fundamentales que
permiten la construcción de un modelo de crecimiento de tumores protáticos.
Requeriremos que el modelo capture la dinámica acoplada de los tejidos sano y
tumoral y que describa la dinámica de PSA del paciente. Además, estudiaremos
la incorporación de las dinámicas de otras substancias clave en el crecimiento del
PCa al modelo.
• Desarrollo e implementación de algoritmos para resolver las ecuaciones del
modelo y construir mallas personalizadas de la próstata. Para llevar a cabo
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las simulaciones numéricas, desarrollaremos algoritmos basados en el concepto
del IGA. Esta tecnología es ideal para manejar la no-linealidad que caracteriza
los problemas de crecimiento tumoral, la compleja anatomía de la próstata y la
intricada morfología del PCa de forma precisa y eficiente. También exploraremos
las técnicas de adaptatividad dinámica de malla basadas en espacios de splines
jerárquicas para racionalizar los recursos computacionales requeridos, acelerar
los cálculos y desarrollar una tecnología clínicamente relevante. Utilizaremos
nuestras propias librerías o paquetes disponibles (p.e.: Trilinos [120], PETSc [12],
PetIGA [70]) junto con MPI para crear implementaciones de nuestros algoritmos
en paralelo potentes y flexibles. Un enfoque computacional para la predicción del
crecimiento de PCa de forma personalizada y a escala tisular requiere una malla
precisa de la próstata del paciente. Por tanto, también desarrollaremos un algoritmo
para extraer una malla de NURBS a partir de las imágenes médicas del paciente,
como tomografía computerizada (CT) y resonancia magnética (MR). Esta malla se
puede refinar global o localmente a continuación para realizar simulaciones con un
buen nivel de precisión.
• Extensión del modelo para incluir la deformación mecánica de la próstata
causada por el tumor en crecimiento y la BPH. El PCa y la BPH son impor-
tantes enfermedades genitourinarias que pueden coexistir en un mismo paciente
y deformar la próstata a lo largo del tiempo. La idea es acoplar nuestro modelo
matemático para el crecimiento del PCa con las ecuaciones de equilibrio mecánico
para calcular los campos de desplazamiento y tensión mecánica creados por el
tumor en crecimiento y la BPH. También introduciremos un término en la ecuación
que describe la dinámica del tumor para tener en cuenta el efecto inhibidor de los
campos de tensiones mecánicas generadas por el PCa y la BPH. Empleando este
modelo con acoplamiento mecánico, estudiaremos la deformación de la próstata
inducida por el PCa y la BPH tanto de forma independiente como simultánea.
También utilizaremos este modelo para analizar cómo el estado deformacional de
la próstata afecta al crecimiento de tumores e investigar por qué las próstatas de
mayor tamaño son menos propensas a desarrollar tumores con conducta agresiva y
características patológicas adversas. Además, discutiremos diversas aplicaciones
de un modelo con acoplamiento mecánico en el seno de un marco computacional
para la gestión clínica del PCa.
• Calibración de los modelos y de los métodos numéricos para reproducir el
crecimiento de PCa tal y como se observa en la práctica clínica de forma
eficiente y precisa. Analizaremos el rango de valores de los parámetros en las
ecuaciones de nuestros modelos matemáticos y métodos numéricos a fin de re-
producir las morfologías de crecimiento y los detalles clínicos que caracterizan el
crecimiento del PCa en la práctica médica de forma precisa y eficiente.
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C.3 Contribuciones de la tesis
En esta tesis hemos propuesto un marco computacional para contribuir a la gestión clínica
del PCa. En este contexto, hemos derivado un modelo matemático para el crecimiento de
PCa localizado, una extensión de este modelo para incluir la deformación de la próstata
debida al tumor en crecimiento así como la interacción mecánica entre la BPH y el PCa,
y un conjunto de métodos isogeométricos para resolver estos modelos.
Nuestro marco computacional para la gestión clínica del PCa se basa en el concepto
de la oncología matemática. Concebimos un protocolo de gestión clínica inspirado en
la asistencia clínica estándar que se basa en la obtención de datos precisos de imagen
médica, como imágenes de mpMR, a fin de guiar el diagnóstico y la estadificación.
Datos longitudinales de imagen médica para cada paciente proporcionan la base para
crear modelos computacionales personalizados de crecimiento tumoral para predecir el
prognóstico, diseñar tratamientos óptimos, y monitorizar el seguimiento del paciente.
Dado que la mayoría de casos de PCa se diagnostican y tratan cuando el tumor está todavía
localizado dentro de la próstata, hemos desarrollado nuestros modelos matemáticos para
describir el crecimiento del cáncer en este estadio de la enfermedad. Como el crecimiento
de PCa localizado se puede ver como un problema de interfaz móvil, empleamos el método
de campo de fase para reproducir la dinámica acoplada de los tejidos sano y tumoral. El
método de campo de fase permite definir implícitamente la interfaz entre ambos tipos de
tejido mediante un conjunto de nivel, sin necesidad de hacer un seguimiento explícito.
Usando ecuaciones de reacción-difusión, nuestro modelo también describe las dinámicas
de un nutriente genérico y del PSA tisular, es decir, el PSA en sangre producido por
unidad de volumen de tejido prostático. La integración del campo de PSA tisular sobre
la geometría de la próstata proporciona el PSA en sangre que puede ser usado por un
médico.
Nuestras simulaciones emplean el IGA para calcular el crecimiento de PCa de forma
precisa y eficiente. Proponemos una metodología para obtener mallas de la próstata
isogeométricas tridimensionales personalizadas a partir de imágenes médicas por medio
de un método de mapeo paramétrico, que deforma un modelo NURBS volumétrico de
un toro hasta hacerlo coincidir con la superficie de la próstata extraída de los datos de
imagen médica del paciente, como imágenes de CT o MR.
Nuestro modelo de crecimiento de PCa localizado desarrolla capas abruptas que represen-
tan la interfaz entre el tumor y el tejido que lo contiene. Consecuentemente, se requieren
mallas muy finas para capturar la interfaz con precisión. Sin embargo, una malla mucho
más gruesa bastaría para representar el valor constante del campo de fase dentro del
tejido sano o del tumor. Por tanto, proponemos adicionalmente el uso de técnicas de
adaptatividad dinámica de malla basadas en el concepto de refinamiento y engrosado
jerárquicos. Estas técnicas pueden contribuir a acelerar los cálculos, a reducir los recursos
computacionales necesarios y a realizar simulaciones predictivas en tiempos clínicamente
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relevantes. Presentamos un conjunto de algoritmos para la adaptatividad local tipo h de
splines jerárquicas para su uso en IGA. Nuestros métodos se basan en la proyección de
Bézier [234], una eficiente técnica de proyección local sin cuadratura, que extendemos
a la configuración jerárquica. En este caso, los operadores de extracción pueden no ser
invertibles. Para afrontar este problema desarrollamos un operador de reconstrucción
multinivel que mantiene las propiedades locales de la proyección. También introducimos
un parámetro de balance para controlar la superposición de funciones jerárquicas, lo que
supone un mejor condicionamiento numérico.
Para explorar la deformación de la próstata inducida por el tumor en crecimiento y la
interacción entre PCa y BPH, extendemos nuestro modelo de crecimiento de PCa para
incluir las ecuaciones de equilibrio mecánico y definir los términos de acoplamiento entre
estas y la dinámica tumoral. Siguiendo estrategias previas de acoplamiento mecánico,
suponemos que la deformación de la próstata es un proceso cuasiestático y modelamos
el tejido prostático como un material elástico lineal, heterogéneo e isotrópico. El con-
finamiento de la próstata en la región pélvica se modela por medio de condiciones de
contorno tipo Winkler sobre la superficie exterior del órgano, mientras que a lo largo de
la uretra se impone desplazamiento libre. La BPH y el PCa se modelan como términos
de presión en la ecuación constitutiva del tejido prostático actuando sobre las correspon-
dientes regiones protáticas afectadas. Por último, el efecto inhibidor de los campos de
tensión mecánica es estimado con un factor global que ralentiza la dinámica del tumor.
Este coeficiente depende de una medida de las condiciones de carga y la energía elástica
almacenada, de modo que elegimos una combinación de la tensión de Von Mises y la
tensión hidrostática para este fin. El rango de valores de este factor inhibidor se ajusta para
reproducir las observaciones experimentales y clínicas en estudios previos de crecimiento
tumoral [57, 118, 137, 160, 205, 228, 256, 267, 268]. Empleando nuestro modelo de cre-
cimiento de PCa localizado con acoplamiento mecánico, proporcionamos una explicación
mecánica para un debate clínico sin resolver: por qué las próstatas de mayor tamaño
parecen ejercer un efecto protector frente al PCa [36, 55, 92, 126, 145, 184]. Nuestras
simulaciones demuestran que un historial de BPH crea campos de tensión mecánica en la
próstata que dificultan el crecimiento del PCa y limitan su invasividad.
Finalmente, calibramos nuestros modelos y métodos empleando datos obtenidos de la
literatura de modo que pudiésemos reproducir las morfologías de crecimiento y las
características de desarrollo del PCa localizado tal y como se observan en resultados
experimentales y la práctica clínica.
C.4 Conclusiones




• La medicina predictiva y la oncología matemática ofrecen un enfoque innovador
en la práctica médica. Estas nuevas tendencias podrían ser la clave para organizar y
ampliar nuestro conocimiento sobre ciertas enfermedades críticas en la actualidad,
como el PCa, proporcionando modelos teóricos completos y robustos que integren
todos los principales resultados existentes y venideros procedentes de la investi-
gación en ciencias biológicas, biofísicas, médicas y biomédicas, así como de la
ingeniería y la mecánica computacional.
• Creemos que la construcción de modelos matemáticos de PCa como los presentados
en esta tesis podría ser el primer paso hacia la obtención de un modelo completo
que, dentro del contexto de un marco de gestión clínica computacional, podría ser
implementado en software clínico para ayudar a los médicos en el diagnóstico de
la enfermedad, la predicción de prognosis, el diseño de tratamientos óptimos y la
realización del seguimiento.
• Nuestro modelo base de crecimiento de PCa localizado es capaz de reproducir
las dos morfologías comunes del PCa: esferoidal, o masiva, y ramificada. Este
modelo también reproduce una conocida inestabilidad de forma que da paso de la
morfología esferoidal a la ramificada. Los resultados de nuestros cálculos muestran
que este cambio morfológico es una respuesta tumoral para evitar la inanición, la
hipoxia y, finalmente, la necrosis. De este modo, la ramificación permite al tumor
minimizar la distancia desde la células más interiores a los nutrientes exteriores,
contribuyendo a la supervivencia del tumor y su ulterior desarrollo.
• También hemos usado nuestro modelo para realizar las primeras simulaciones
de crecimiento de PCa de forma personalizada y a escala tisular basadas en la
anatomía prostática de pacientes que extrajimos de imágenes de CT o MR. Estas
simulaciones muestran progresiones tumorales similares a aquellas observadas en
la práctica clínica en términos de geometría y evolución.
• Observamos que al variar la geometría tumoral, la posición del tumor o la anatomía
de la próstata independientemente se obtuvieron diferentes patrones de crecimiento
tumoral. Esto sugiere que la inclusión de la próstata y el tumor de cada individuo es
esencial para realizar un seguimiento adecuado de la progresión de la enfermedad
en términos de posición y volumen del tumor así como de producción de PSA.
Introducir en el modelo la anatomía prostática específica del paciente es crucial
para poder predecir los potenciales riesgos que el PCa puede suponer, como la
penetración de la cápsula prostática, la invasión de tejidos cercanos o la expansión
tumoral a las diferentes partes de la próstata, provocando así síntomas como
impotencia o irregularidades en la micción o la eyaculación [259, 265].
• La posibilidad de predecir cuándo aparecerán estos riesgos o síntomas sería un
gran avance en los protocolos de “esperar y ver” y vigilancia activa. De este modo,
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la optimización de estas dos opciones clínicas para hacer frente a la enfermedad,
incluyendo la modelización y simulación del PCa, podría reducir el exceso de
tratamiento de los pacientes, dejándolos en muchos casos aliviados o curados tras
la administración del correspondiente tratamiento, con mínimos efectos secundarios
y una buena calidad de vida.
• La predicción de la forma y volumen reales del tumor dentro de la anatomía de la
próstata de un determinado paciente también permitiría optimizar la cirugía y la
planificación y la administración de radioterapia, obteniendo altas precisiones y
tasas de eficiencia.
• De acuerdo con nuestras simulaciones de crecimiento de PCa personalizadas y a
escala tisular, los resultados de la biopsia de una próstata con tumor ramificado
podrían proporcionar una cota inferior de la agresividad del cáncer conduciendo a
un peligroso escenario predictivo. Esto se debe a dos razones: primero, la aguja
de la biopsia podría sortear las ramas entretejidas del tumor y, segundo, también
podría alcanzar una rama tumoral ortogonalmente, lo que podría dar lugar a un
bajo porcentaje erróneo de tejido tumoral en la muestra de la biopsia.
• Idealmente, la combinación de la imagen por mpMR y la modelización y la simu-
lación computacional del PCa podría eliminar la biopsia de la próstata durante el
diagnóstico y el estadiaje de la enfermedad, abandonando así un procedimiento
invasivo con resultados cuestionables y en continuo debate en la comunidad médi-
ca [259, 265]. De hecho, la combinación de imágenes de MR potenciada en T2,
MR potenciada en difusión, estudio dinámico de MR potenciada con contraste y,
opcionalmente, espectroscopía por MR ha permitido ya la detección y estadiaje
del PCa con sensibilidad y especificidad elevadas, comparabales con las asociadas
a las biopsias comunes actuales [51, 75, 87, 111, 116, 123, 153, 227, 238]. Como
resultado, la imagen por mpMR se está considerando cada vez más como una futura
opción en lugar de la biopsia o, al menos, como una técnica que se puede fusionar
con la biopsia por TRUS para optimizar este procedimiento [210].
• El PSA tisular nos permite analizar dónde el PSA se filtra al torrente sanguíneo y
la cantidad de este biomarcador del PCa vertido por tanto el tejido sano como el
tumoral. El PSA tisular también relaciona el PSA en sangre con la carga tumoral
en nuestros modelos. Esto establece una base teórica para la relación entre ambas
dinámicas. Una confirmación de esta conexión surgió cuando estimamos el PSA
en sangre inicial para nuestras simulaciones. Para una selección de parámetros y
un volumen tumoral inicial dados, el PSA en sangre inicial estaba intrínsecamente
determinado. Por tanto, si empezábamos la simulación con un valor de PSA en
sangre distinto, una rama abrupta aparecía hasta que este se reajustaba.
• Observamos que la predicción de la evolución del volumen del tumor y la del
PSA en sangre siguen una dinámica semejante. Este comportamiento se observa
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típicamente en tumores de riesgo bajo o intermedio [229, 253, 254, 259, 265], que
en todos los casos son tumores prostáticos localizados.
• La conexión entre el crecimiento tumoral y la dinámica del PSA en sangre es un
continuo debate en la comunidad urológica [259, 265]. Los exámenes rutinarios
de PCa están basados en la medición del PSA pero, aún cuando la mayoría de
adenocarcinomas prostáticos crecen mostrando un paralelismo entre el volumen
de tumor y los niveles de PSA en sangre, se sabe que existe un cierto grado de
divergencia entre las dinámicas de estas dos variables. Esto puede llegar al límite
de pacientes con bajo PSA y grandes masas tumorales en sus próstatas, o viceversa.
El PCa avanzado y metastático puede también exhibir casi ninguna conexión entre
el PSA en sangre y la carga tumoral. Sin embargo, los exámenes rutinarios de
PSA han mejorado la detección y el tratamiento precoz del PCa, llevando a altas
tasas de incidencia y a una eficiencia mejorada en su gestión en todo el mundo.
Por tanto, nosotros defendemos que este biomarcador debe ser implementado en
un modelo matemático de PCa, pues permite una conexión directa con los datos
clínicos existentes.
• La simulación personalizada del crecimiento del PCa a escala tisular es un problema
exigente. Presenta una interfaz móvil que indica el contorno que separa el tumor
del tejido sano circundante. Esta interfaz, modelada por medio del método de
campo de fase, evoluciona dentro de la compleja anatomía de la próstata del
paciente condicionada por nutrientes y hormonas. Consecuentemente, este es un
problema donde un enfoque adaptativo introduce una ventaja clave: proporciona
una malla con elementos más finos para representar la interfaz y elementos más
gruesos en el resto del dominio computacional, lo cual conduce a un gran ahorro
de memoria y tiempo de computación. Por tanto, nosotros creemos que nuestros
algoritmos adaptativos son una importante tecnología para poder implementar
modelos predictivos de PCa localizado en un escenario clínico de forma precisa y
eficiente.
• Hemos empleado nuestro modelo de crecimiento de PCa para demostrar el potencial
para el análisis de nuestras estrategias adaptativas para splines jerárquicas. En todas
las simulaciones presentadas en esta tesis obtuvimos una notable precisión con muy
pocos grados de libertad en comparación con la malla uniforme que se requeriría
para realizar la misma simulación.
• Nuestros algoritmos adaptativos permiten la resolución de problemas exigentes de
interfaz móvil en ciencia e ingeniería mediante IGA y empleando espacios de spli-
nes jerárquicas en un marco de elementos finitos proporcionado por la extracción
de Bézier. Nuestra tecnología también se puede usar para resolver problemas que
cuentan con aspectos de escalas finas, como capas internas y de contorno en flujos
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dominados por convección, concentración de tensiones y definiciones geométricas
precisas.
• Calibramos nuestro modelo con acoplamiento mecánico realizando un análisis de la
deformación de la próstata causada por el tumor y la BPH de forma independiente.
En general, nuestros resultados en términos de desplazamientos y aspectos defor-
macionales para la BPH y el PCa concuerdan con estudios previos en la literatura
médica [27, 44, 265]. También observamos que nuestro modelo reprodujo correcta-
mente los campos de tensión mecánica inducidos por un tumor en crecimiento tal y
como se ha descrito previamente en la literatura [57, 109, 118, 137, 205, 228, 256].
• Proponemos una explicación mecánica para comprender por qué las próstatas
grandes pueden ejercer un efecto protector contra el PCa. Nuestras simulaciones
muestran que el desarrollo de BPH durante años antes del PCa conduce a un
estado deformacional caracterizado por una elevada tensión hidrostática dentro de
la glándula central (CG) y una gran tensión de Von Mises en la zona periférica
(PZ) de la próstata. La combinación de estos campos de tensión mecánica con
aquellos inducidos por el tumor en crecimiento dificulta la evolución del PCa, que
presenta características patológicas favorables, como una lenta tasa de crecimiento
y ausencia de comportamiento invasivo.
• Nuestros resultados sobre la inhibición mecánica del crecimiento de PCa reco-
miendan realizar un examen exhaustivo de la próstata en hombres sin PCa antes
de prescribir tratamientos o medicamentos para la BPH orientados a reducir el
volumen de la CG. Análogamente, nuestros resultados también recomiendan un
seguimiento intenso de pacientes de PCa que reciban este tipo de medicamentos
para la BPH. En caso contrario, la disminución de volumen prostático podría
rebajar peligrosamente los campos de tensión mecánica creados por la BPH y
reducir así la restricción mecánica sobre el crecimiento del PCa. De hecho, esto
podría explicar parcialmente la mayor proporción de cánceres más agresivos en
el grupo de finasterida del Prostate Cancer Prevention Trial [235], lo cual podría
decirse que es el resultado más controvertido de este estudio fundamental sobre la
quimioprevención del PCa [36, 145, 150, 184].
• Nuestra investigación sobre la interacción mecánica entre PCa y BPH también
sugiere el desarrollo de nuevas formas de tratamiento aliviando los síntomas de
BPH mientras se mantiene un nivel tensión significante en la próstata como medida
de protección frente al PCa.
• Los esfuerzos para arrojar luz sobre las potenciales relaciones entre el PCa y
la BPH han señalado correlaciones prometedoras y mecanismos de interacción
[4, 191, 265]. La consiguiente investigación para validarlos podría beneficiarse
en gran medida de la modelización matemática a fin de organizar, comprender y
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proporcionar una sólida teoría que apoye estos nuevos descubrimientos y guíe los
pasos a dar en el futuro [7, 165, 188, 274].
C.5 Futuras líneas de trabajo
El trabajo desarrollado en esta tesis abre la puerta a diversas líneas de investigación que
serán abordadas en el futuro. Resaltamos las siguientes:
• Nuestra descripción de la dinámica tumoral se puede mejorar incluyendo varias
especies cancerosas (p.e.: normóxicas, hipóxicas y necróticas), lo cual permite
una simulación más detallada de la inestabilidad morfológica; introduciendo fe-
nómenos de taxis para describir mejor la invasividad del tumor; y considerando
otras sustancias que juegan un papel importante en PCa, como el oxígeno o la
testosterona.
• La dinámica del PSA tisular se puede mejorar proporcionando una definición más
precisa de las tasas de producción de PSA tisular y refinando su ecuación. Esto
puede requerir una revisión de la modelización del PSA en la literatura médica
para encontrar conexiones adicionales entre la forma y el volumen del tumor y la
producción de PSA. Además, estamos ignorando el crecimiento prostático, que
podría contribuir al incremento del PSA.
• Dado que los hombres de más de 50 años tienen su PSA monitorizado de forma
rutinaria, podríamos personalizar los parámetros en la ecuación del PSA tisular
empleando métodos de inversión, estadística Bayesiana, o técnicas de machine
learning. Se requerirían análisis longitudinales de dinámica de PSA para realizar
este trabajo.
• La radioterapia es un tratamiento viable para una gran variedad de pacientes
de PCa y posee el potencial para desarrollar planes personalizados basados en
datos precisos de imagen médica [259, 265]. Por tanto, otra interesante línea
de investigación es explorar la modelización y simulación de los efectos de la
radioterapia del PCa en nuestro modelo, siguiendo la estela de estudios previos
realizados en glioma de bajo grado [158, 196] y glioblastoma multiforme [64, 202].
• En paralelo con las mejoras del modelo, también necesitaríamos comprobar nues-
tros métodos isogeométricos para evaluar si reproducen los nuevos fenómenos
incorporados de forma precisa y eficiente, o mejorar nuestros algoritmos en caso
contrario. En particular, nos gustaría examinar nuestros algoritmos adaptativos en
modelos más complejos de crecimiento de PCa incluyendo varias especies celulares
tumorales, en los que las nuevas interfaces entre ellas deben ser representadas de
forma precisa. También estamos interesados en usar nuestras estrategias adaptativas
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para evaluar la precisión de nuestros modelos usando datos anatómicos y patológi-
cos personalizados extraídos de imágenes médicas, en particular, de imágenes de
mpMR [51, 75, 87, 111, 116, 123, 153, 227, 238].
• El desarrollo de la adaptatividad tipo p, k y r de espacios de splines jerárquicas y
la extensión de nuestros algoritmos adaptativos a la configuración de los bosques
de splines [219, 234] son líneas de investigación exigentes y prometedoras hacia la
derivación de métodos dinámicos adaptativos más versátiles y potentes en IGA.
• Nuestro modelo con acoplamiento mecánico para el crecimiento de PCa locali-
zado se puede mejorar en varios aspectos. Primero, nuestro modelo anatómico
de la próstata se podría beneficiar de una segmentación más precisa de las zonas
prostáticas internas acompañada de una caracterización mecánica personalizada.
Segundo, una definición de las condiciones tipo Winkler que varíe en el espacio
según los diferentes tejidos y órganos que rodean la próstata contribuiría a obtener
predicciones más precisas. Tercero, nuestro modelo también se podría beneficiar
de una formulación más precisa para la BPH [157, 203, 270] así como para el
crecimiento y deformación tumorales [56, 125, 160, 163, 205]. Cuarto, el término
de mecanotransducción para ajustar la dinámica del tumor se puede refinar, por
ejemplo, probando formulaciones alternativas o diferenciando cómo las tensio-
nes mecánicas afectan a la mobilidad, la proliferación y la apoptosis en el tumor
[57, 118, 160]. Por último, para superar las limitaciones de la elasticidad lineal y
obtener valores más precisos de desplazamientos y tensiones planeamos tener en
cuenta la no-linealidad geométrica e investigar ecuaciones constitutivas alternativas
para la próstata [110, 134, 173, 256], que típicamente incluyen un mayor conjunto
de parámetros elásticos que no son fáciles de estimar de forma personalizada.
• Una descripción poroelástica del crecimiento de PCa ayudaría a estudiar el efecto
de la deformación mecánica en el transporte de nutrientes [205]. Este enfoque
tiene el potencial para investigar con precisión la heterogeneidad del metabolismo
intratumoral o ensayar de forma personalizada la administración de medicamentos
al tumor in silico.
• También pretendemos investigar el efecto de medicamentos para la BPH que causan
una disminución del volumen de la próstata en el crecimiento tumoral extendiendo
nuestro modelo con acoplamiento mecánico para incorporar el efecto de estos
medicamentos, como la dutasterida y la finasterida [235, 265].
• Pensamos que nuestro modelo con acoplamiento mecánico podría ser explotado
para mejorar las actuales tecnologías de registro deformable de imágenes médicas
[27] proporcionando una teoría para la evolución de la BPH y el PCa. Los algorit-
mos resultantes podrían ser de gran interés para varias aplicaciones en la gestión
clínica del PCa de forma personalizada y a escala tisular, como un seguimiento
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detallado del crecimiento del tumor durante vigilancia activa o la planificación
precisa de la cirugía u otros tratamientos [165]. Dicha tecnología también podría
ayudar a detectar el PCa a partir de la deformación de los contornos de la próstata
y de los bordes internos entre las regiones prostáticas [208, 263]. Además, también
podría guiar biopsias para mejorar la estadificación y el diagnóstico del PCa. Com-
parando las predicciones del modelo con nuevas imágenes y datos clínicos también
podría ayudar a discernir si el tumor está progresando hacia un comportamiento
más maligno y a tomar las correspondientes decisiones clínicas [165].
• Para profundizar nuestro conocimiento en los mecanismos de crecimiento de PCa
usando nuestros modelos creemos que sería interesante investigar las propiedades
matemáticas de las ecuaciones que los constituyen, por ejemplo, analizar las
condiciones de existencia de soluciones, caracterizar los espacios paramétricos y
estudiar las condiciones bajo las que el problema está bien planteado.
• Nuestra intención es perseguir la validación de nuestro marco computacional
usando bases de datos longitudinales de pacientes, incluyendo imágenes médicas
de alta calidad, datos bioquímicos e informes clínicos. Como paso previo, este
trabajo también requerirá la calibración personalizada de los parámetros con los
datos disponibles en las imágenes del paciente y su historial clínico.
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APPENDIX D
Extended summary in Galician
D.1 Introdución
Segundo a Organización Mundial da Saúde (WHO), o cancro de próstata (PCa) é o
segundo cancro máis común e a quinta causa de morte por cancro en homes en todo
o mundo [89]. Os datos son reveladores: en 2012, estimáronse ao redor de 1,095,000
novos casos e unhas 308,000 mortes en todo o mundo asociadas con este cancro e será
responsable duns 161,360 novos casos e unhas 26,730 defuncións soamente en EEUU
en 2017 [5]. Ademais, estudos epidemiolóxicos nacionais en España amosaron unha
estimación de 33,370 novos casos de PCa en 2015 e de 5,855 mortes por esta enfermidade
en 2014 [96, 224].
Na maioría de casos, o PCa é un adenocarcinoma, unha forma de cancro que se orixina
e desenvolve en tecidos epiteliais con organización glandular, por exemplo, o tecido
prostático encargado de producir certas substancias do seme [259, 265]. Os adenocarci-
nomas xorden como resultado de alteracións xenéticas nos núcleos das células, como
mutacións e cambios epixenéticos. Ademais, a influencia de varios factores ambientais,
como a dieta, poden promover modificacións adicionais do xenoma. As células tumorais
exhiben un comportamento competitivo e aberrante, caracterizado por unha proliferación
excesiva e unha conduta invasiva. En consecuencia, poden poñer en perigo a estrutura e o
normal funcionamento do tecido ao que pertencen, chegando a ameazar a supervivencia
do organismo. Un mesmo tumor pode presentar diferentes grupos de células cancerosas,
con diferente metabolismo, entorno local e agresividade. As células malignas poden
evolucionar durante o seu ciclo de vida, e entón pertencer a un novo grupo. A estrutura, o
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comportamento e a evolución dun tumor dependen das alteracións xenéticas específicas
que o poidan xerar e manteñan a súa evolución [3].
O desenvolvemento do adenocarcinoma de próstata require da acumulación gradual de
mutacións nun conxunto de xenes diferentes, que varían dun paciente a outro, pero que
normalmente suman un mínimo de sete [259, 265]. Polo tanto, o PCa é máis frecuente en
homes de maior idade. Como resultado destas alteracións do xenoma ao longo dos anos,
unha inicial desorde moderada do comportamento celular evoluciona gradualmente cara a
un cancro avanzado. Segundo o tumor vaise desenvolvendo, este vólvese máis maligno e a
diferenciación celular disminúe. Este fenómeno evolutivo denomínase progresión tumoral
e, en xeral, comprende catro pasos: (1) proliferación excesiva de células localizada, (2)
proliferación excesiva de células de forma extensiva, (3) invasión de tecidos próximos e,
finalmente, (4) metástase, que é o proceso polo cal algunhas células malignas escapan
do tumor orixinal, entran no torrente sanguíneo e migran a outro tecido, que invaden e
colonizan [3, 259, 265].
A práctica médica do PCa desenvólvese sobre as bases xenéticas e biolóxicas anterior-
mente descritas así como sobre a experiencia acumulada dos doutores que tratan esta
enfermidade [259, 265]. Os protocolos médicos actuais inclúen todas estas fontes de
coñecemento sobre o PCa en forma de estatísticas para a probabilidade do estadio do
cancro e o éxito do tratamento. Brevemente, o PCa é máis fácil de curar nas súas fases
iniciais, antes de que se volva excesivamente agresivo e se estenda fóra da próstata pero,
desafortunadamente, esta enfermidade case nunca produce ningún síntoma ata que o
tumor sexa moi grande ou invada outros tecidos. Polo tanto, a mellor forma de combater
o PCa é unha combinación de prevención e exames rutinarios para unha detección precoz.
O PCa é normalmente diagnosticado e tratado cando aínda está localizado dentro da
próstata. O PCa localizado é comunmente tratado cun enfoque curativo, por exemplo,
con cirurxía ou radioterapia, mentres que para o PCa avanzado é máis usual empregar
estratexias paliativas baseadas en terapia hormonal ou quimioterapia. Os pacientes de
PCa de baixo risco poden retrasar o seu tratamento ata que o tumor acada un estadio
óptimo (vixilancia activa). Os pacientes que non son aptos para un tratamento curativo
local, ou aqueles cunha baixa esperanza de vida, poden beneficiarse dun tratamento
paliativo aprazado, co obxectivo de tratar síntomas específicos da enfermidade, mentres
que continúan os seus exames rutinarios (“esperar e ver”).
Ademais do PCa, na próstata tamén se dá outra gran patoloxía que afecta a homes de
idade avanzada: a hiperplasia benigna de próstata (BPH) [259, 265]. Esta enfermidade
consiste no aumento patolóxico do volume da próstata coa idade, cunha prevalencia
crecente dende o 50% en homes de cincuenta anos ata ao redor do 70% en homes de
setenta anos [26]. A BPH obstrúe o fluxo urinario e exaculatorio, causando así molestos
síntomas do tracto urinario inferior. O PCa e a BPH poden coexistir nun mesmo paciente
e comparten numerosas similitudes [4, 191, 265], que suxiren varias conexións ou inter-
accións entre ambas patoloxías. Porén, carecemos dunha evidencia sólida confirmando
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a súa existencia. Estudos recentes sobre extensas series de especímenes quirúrxicos de
próstatas demostraron que os tumores que se orixinan en próstatas de maior tamaño
presentan características patolóxicas favorables [36, 55, 92, 126, 145, 184]. Estes estudos
proporcionan unha sólida evidencia que suxire que as próstatas grandes poden exercer un
efecto protector contra o PCa.
Biólogos e médicos dedícanse activamente ao estudo do PCa intentando botar luz sobre
os complexos mecanismos moleculares, biolóxicos e fisiolóxicos que explican como
os tumores se orixinan, se desenvolven e se estenden polo corpo, analizando tamén
novas opcións para o tratamento do PCa. Malia a cantidade de investigacións clínicas e
experimentais, carecemos dun modelo teórico completo no que esta abundancia de datos
se poida comprender e organizar, guiando tamén futuros traballos de investigación para
enriquecer devandito modelo. Tanto o fundamento destas investigacións como a práctica
médica común en oncoloxía baséanse en patróns estatísticos, que non son suficientemente
precisos para individualizar a diagnose, a estimación da prognose, o tratamento e o
seguimento.
Alternativamente, a medicina preditiva [231, 232] é un enfoque interdisciplinario cuxos
obxectivos son a determinación personalizada da progresión dunha enfermidade e do
tratamento óptimo. Os métodos da medicina preditiva baséanse na modelización matemá-
tica e na simulación por ordenador da enfermidade e os tratamentos. Este novo enfoque
complementa a base estatística e empírica da diagnose e a planificación do tratamento,
que constitúe a práctica médica actual. No caso particular da investigación do cancro, a on-
coloxía matemática [7, 53, 97, 188, 274] é un campo novo e prometedor que se dedica ao
desenvolvemento de modelos e ferramentas computacionais para simular o crecemento de
tumores e o tratamento do cancro. Aínda que houbo progresos importantes nas décadas re-
centes, a modelización precisa do crecemento de tumores cancerosos segue sendo un reto
por resolver [7, 9, 42, 52, 53, 97, 160, 167, 170, 174, 188, 206, 211, 212, 236, 251, 274].
A non-linealidade que acostuma caracterizar o conxunto de ecuacións que comprende
os modelos de crecemento tumoral, a complexa xeometría dos modelos anatómicos
personalizados e a intricada morfoloxía que poden amosar os tumores en crecemento
demandan métodos de resolución moi eficientes en termos de memoria e tempo de
computación. A análise isoxeométrica (IGA) é unha tecnoloxía innovadora e de rápido
crecemento que pode facer fronte a todos estes retos computacionais [66, 130]. A IGA
pódese ver como unha xeneralización da clásica análise por elementos finitos (FEA)
[132]. En vez de usar os típicos polinomios definidos a trozos, a IGA emprega funcións
máis sofisticadas procedentes dos gráficos por ordenador e a xeometría computacional,
como as B-splines [66, 84, 130, 195, 204], as Non-Uniform Rational B-splines (NURBS)
[66, 84, 130, 195, 204], e as T-splines [18, 21, 22, 154]. Os métodos isoxeométricos
baseados nestes espazos funcionais son xeometricamente exactos, proporcionan unha
mellor precisión por grado de liberdade e permiten unha maior continuidade global (Cp−1
para espazos de splines con grado polinómico p) [1, 66]. Ademais, a IGA é compatible
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con técnicas de adaptatividade dinámica de malla baseadas no concepto de refinamento e
engrosado xerárquicos [215, 219, 257], que permite a adaptación local da malla de forma
dinámica ao longo da simulación. Deste xeito, a malla presenta elementos máis finos con
funcións de aproximación máis sofisticadas preto do tumor, e elementos máis grosos en
calquera outro sitio. Isto conduce a un gran aforro de memoria e tempo de computación.
Polo tanto, as técnicas de adaptatividade dinámica de malla posúen o potencial para
acelerar os cálculos e crear métodos isoxeométricos que faciliten a obtención de solucións
en tempos clinicamente relevantes.
O PCa está recibindo unha atención relativamente pequena por parte da comunidade
de oncoloxía matemática [122, 133, 135, 136, 149, 176, 277]. Porén, o PCa pode ser
un candidato ideal para explorar a modelización do crecemento do cancro de forma
personalizada e a escala tisular por varias razóns:
• O PCa é un gran problema sanitario e un caso paradigmático no que un modelo pre-
ditivo pode marcar a diferenza na práctica médica porque actualmente numerosos
pacientes son tratados de forma excesiva ou insuficiente [164, 260].
• A imaxe médica está emerxendo como ferramenta de diagnose en PCa. A imaxe
médica non se usa de forma xeneralizada na diagnose do PCa debido a unha falta
de confianza nas actuais modalidades de imaxe. Porén, a resonancia magnética
multiparamétrica (mpMR) úsase normalmente para monitorizar a evolución da
enfermidade e está emerxendo como una tecnoloxía prometedora que se podería
utilizar tamén para a diagnose do PCa [51, 75, 87, 111, 116, 123, 153, 227, 238].
• A próstata é un órgano pequeno, tipicamente entre 20 e 80 cc [24, 26, 31, 259, 265,
270], de modo que é factible crear un modelo anatómico personalizado da próstata
a partir de imaxes médicas para realizar simulacións preditivas.
• O crecemento do tumor nun determinado paciente pódese estimar usando a concen-
tración dun biomarcador do PCa denominado antíxeno específico de próstata (PSA),
que se mide cunha análise de sangue e xoga un papel crucial durante a diagnose, a
selección de tratamento e o seguimento dos pacientes [253, 254, 259, 265].
• Algúns pacientes de PCa non reciben ningún tratamento pero teñen o seu PSA
monitorizado e tómanselles imaxes médicas periodicamente, por exemplo, durante
o tempo que vai da diagnose ao tratamento ou durante os protocolos de vixilancia
aciva e “esperar e ver”. Isto podería abrir a porta potencialmente á validación in
vivo dun modelo [261, 274].
• A IGA proporciona un sofisticado marco computacional que garante a precisión e
eficiencia requeridas para realizar simulacións preditivas do crecemento de PCa de
forma personalizada e a escala tisular.
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• A oncoloxía matemática tamén é un enfoque prometedor para investigar a relación
entre o PCa e a BPH porque pode proporcionar sólidos mecanismos de interacción
para explicar as evidencias actuais e guiar a futura investigación clínica.
D.2 Obxectivos
O propósito central desta tese é proporcionar un marco computacional para a modelización
e a simulación do crecemento de PCa órgano-confinado dentro do contexto da oncoloxía
matemática. Este obxectivo xeral pódese subdividir nun conxunto de obxectivos de
investigación máis específicos , os cales resumimos nos seguintes puntos:
• Definición dun marco computacional para a xestión clínica do PCa. O noso
primeiro obxectivo será deseñar un marco para a xestión clínica do PCa no que
as tecnoloxías da oncoloxía matemática complementen os protocolos médicos
comúns para esta enfermidade. Para esta fin, revisamos o coñecemento actual sobre
as bases biolóxicas dos tumores prostáticos, os procedementos estándar na xestión
clínica do PCa e os desenvolvementos recentes na modelización e a simulación
matemática do crecemento de tumores. Tamén revisamos as tecnoloxías de imaxe
médica para PCa actuais e en desenvolvemento porque proporcionan unha gran
cantidade de datos personalizados para importar nunha ferramenta computacional
de predición do crecemento tumoral.
• Deseño dun modelo matemático de crecemento de PCa personalizado e a es-
cala tisular. A nosa intención é definir un modelo matemático personalizado a
escala tisular que describa o crecemento do PCa localizado, pois este é o estadio
no que normalmente se diagnostica e trata. A definición do modelo estará baseada
no actual coñecemento biolóxico e médico da enfermidade. Identificaremos e des-
cribiremos matemática e fisicamente os mecanismos fundamentais que permiten a
construción dun modelo de crecemento de tumores protáticos. Requiriremos que o
modelo capture a dinámica acoplada dos tecidos san e tumoral e que describa a di-
námica de PSA do paciente. Ademais, estudaremos a incorporación das dinámicas
doutras substancias clave no crecemento do PCa ao modelo.
• Desenvolvemento e implementación de algoritmos para resolver as ecuacións
do modelo e construír mallas personalizadas da próstata. Para levar a cabo as
simulacións numéricas, desenvolveremos algoritmos baseados no concepto da IGA.
Esta tecnoloxía é ideal para manexar a non-linealidade que caracteriza os problemas
de crecemento tumoral, a complexa anatomía da próstata e a intricada morfoloxía do
PCa de forma precisa e eficiente. Tamén exploraremos as técnicas de adaptatividade
dinámica da malla baseadas en espazos de splines xerárquicas para racionalizar
os recursos computacionais requeridos, acelerar os cálculos e desenvolver unha
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tecnoloxía clinicamente relevante. Empregaremos as nosas propias librarías ou
paquetes dispoñibles (p.e.: Trilinos [120], PETSc [12], PetIGA [70]) xunto con
MPI para crear implementacións dos nosos algoritmos en paralelo potentes e
flexibles. Un enfoque computacional para a predición do crecemento de PCa
de forma personalizada e a escala tisular require unha malla precisa da próstata
do paciente. Polo tanto, tamén desenvolveremos un algoritmo para extraer unha
malla de NURBS a partir das imaxes médicas do paciente, como tomografía
computerizada (CT) e resonancia magnética (MR). Esta malla pódese refinar global
ou localmente a continuación para realizar simulacións cun bo nivel de precisión.
• Extensión do modelo para incluír a deformación mecánica da próstata cau-
sada polo tumor en crecemento e a BPH. O PCa e a BPH son importantes
enfermidades xenitourinarias que poden coexistir nun mesmo paciente e deformar
a próstata ao longo do tempo. A idea é acoplar o noso modelo matemático para o
crecemento do PCa coas ecuacións de equilibrio mecánico para calcular os campos
de desprazamento e tensión mecánica creados polo tumor en crecemento e a BPH.
Tamén introduciremos un termo na ecuación que decribe a dinámica do tumor para
ter en conta o efecto inhibidor dos campos de tensións mecánicas xeradas polo
PCa e a BPH. Empregando este modelo con acoplamento mecánico, estudaremos a
deformación da próstata inducida polo PCa e a BPH tanto de forma independente
como simultánea. Tamén utilizaremos este modelo para analizar como o estado
deformacional da próstata afecta ao crecemento de tumores e investigar por que
as próstatas de maior tamaño son menos propensas a desenvolver tumores con
conduta agresiva e características patolóxicas adversas. Ademais, discutiremos
diversas aplicacións dun modelo con acoplamento mecánico no contexto dun marco
computacional para a xestión clínica do PCa.
• Calibración dos modelos e dos métodos numéricos para reproducir o crece-
mento do PCa tal e como se observa na práctica clínica de forma eficiente e
precisa. Analizaremos o rango de valores dos parámetros nas ecuacións dos nosos
modelos matemáticos e métodos numéricos a fin de reproducir as morfoloxías de
crecemento e os detalles clínicos que caracterizan o crecemento do PCa na práctica
médica de forma precisa e eficiente.
D.3 Contribucións da tese
Nesta tese propuxemos un marco computacional para contribuír á xestión clínica do PCa.
Neste contexto, derivamos un modelo matemático para o crecemento de PCa localizado,
unha extensión deste modelo para incluír a deformación da próstata debida ao tumor en
crecemento así como a interacción mecánica entre a BPH e o PCa, e un conxunto de
métodos isoxeométricos para resolver estes modelos.
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O noso marco computacional para a xestión clínica do PCa baséase no concepto da
oncoloxía matemática. Concibimos un protocolo de xestión clínica baseado na asistencia
clínica estándar que se basea na obtención de datos precisos de imaxe médica, como
imaxes de mpMR, a fin de guiar a diagnose e a estadificación. Datos lonxitudinais de
imaxe médica para cada paciente proporcionan a base para crear modelos computacionais
personalizados de crecemento tumoral para predicir a prognose, deseñar tratamentos
óptimos e monitorizar o seguimento do paciente.
Xa que a maioría de casos de PCa se diagnostican e tratan cando o tumor está aínda
localizado dentro da próstata, desenvolvimos os nosos modelos matemáticos para describir
o crecemento do cancro neste estadio da enfermidade. Como o crecemento do PCa
localizado se pode ver como un problema de interface móbil, empregamos o método de
campo de fase para reproducir a dinámica acoplada dos tecidos san e tumoral. O método
de campo de fase permite definir implicitamente a interface entre ambos tipos de tecido
mediante un conxunto de nivel, sen necesidade de facer un seguimento explícito. Usando
ecuacións de reacción-difusión, o noso modelo tamén describe as dinámicas dun nutriente
xenérico e do PSA tisular, é dicir, do PSA en sangue producido por unidade de volume de
tecido prostático. A integración do campo de PSA tisular sobre a xeometría da próstata
proporciona o PSA en sangue que pode ser usado por un médico.
As nosas simulacións empregan a IGA para calcular o crecemento de PCa de forma precisa
e eficiente. Propoñemos unha metodoloxía para obter mallas da próstata isoxeométricas
tridimensionais personalizadas a partir de imaxes médicas por medio dun método de
mapeo paramétrico, que deforma un modelo NURBS volumétrico dun toro ata facelo
coincidir coa superficie da próstata extraída dos datos de imaxe médica do paciente, como
imaxes de CT ou MR.
O noso modelo de crecemento de PCa localizado desenvolve capas abruptas que repre-
sentan a interface entre o tumor e o tecido que o contén. Consecuentemente, requírense
mallas moi finas para capturar a interface con precisión. Porén, unha malla moito máis
grosa bastaría para representar o valor constante do campo de fase dentro do tecido san
ou do tumor. Polo tanto, propoñemos adicionalmente o uso de técnicas de adaptatividade
dinámica de malla baseadas no concepto de refinamento e engrosado xerárquicos. Estas
técnicas poden contribuír a acelerar os cálculos, a reducir os recursos computacionais
necesarios e a realizar simulacións preditivas en tempos clinicamente relevantes. Presen-
tamos un conxunto de algoritmos para a adaptatividade local tipo h de splines xerárquicas
para o seu uso en IGA. Os nosos métodos baséanse na proxección de Bézier [234], unha
eficiente técnica de proxección local sen cuadratura, que estendemos á configuración xe-
rárquica. Neste caso, os operadores de extracción poden non ser invertibles. Para afrontar
este problema desenvolvemos un operador de reconstrución multinivel que mantén as
propiedades locais da proxección. Tamén introducimos un parámetro de balance para con-
trolar a superposición de funcións xerárquicas, o que supón un mellor condicionamento
numérico.
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Para explorar a deformación da próstata inducida polo tumor en crecemento e a interacción
entre PCa e BPH, estendemos o noso modelo de crecemento de PCa para incluír as
ecuacións de equilibrio mecánico e definir os termos de acoplamento entre estas e a
dinámica tumoral. Seguindo estratexias previas de acoplamento mecánico, supoñemos
que a deformación da próstata é un proceso cuasiestático e modelamos o tecido prostático
como un material elástico lineal, heteroxéneo e isotrópico. O confinamento da próstata
na rexión pélvica modélase por medio de condicións de contorno tipo Winkler sobre a
superficie exterior do órgano, mentres que ao longo da uretra se impón desprazamento
libre. A BPH e o PCa modélanse como termos de presión na ecuación constitutiva do
tecido prostático actuando sobre as correspondentes rexións prostáticas afectadas. Por
último, o efecto inhibidor dos campos de tensión mecánica é estimado cun factor global
que ralentiza a dinámica do tumor. Este coeficiente depende dunha medida das condicións
de carga e a enerxía elástica almacenada, de modo que eliximos unha combinación da
tensión de Von Mises e a tensión hidrostática para este fin. O rango de valores deste
factor inhibidor axústase para reproducir as observacións experimentais e clínicas en
estudos previos de crecemento tumoral [57, 118, 137, 160, 205, 228, 256, 267, 268].
Empregando o noso modelo de crecemento de PCa localizado con acoplamento mecánico,
proporcionamos unha explicación mecánica para un debate clínico sen resolver: por
que as próstatas de maior tamaño parecen exercer un efecto protector fronte ao PCa
[36, 55, 92, 126, 145, 184]. As nosas simulacións demostran que un historial de BPH crea
campos de tensión mecánica na próstata que dificultan o crecemento do PCa e limitan a
súa invasividade.
Finalmente, calibramos os nosos modelos e métodos empregando datos obtidos da literatu-
ra de modo que puidésemos reproducir as morfoloxías de crecemento e as características
de desenvolvemento do PCa localizado tal e como se observan en resultados experimentais
e a práctica clínica.
D.4 Conclusións
De acordo co traballo presentado nesta tese, podemos extraer as seguintes conclusións:
• A medicina preditiva e a oncoloxía matemática ofrecen un enfoque innovador na
práctica médica. Estas novas tendencias poderían ser a chave para organizar e
ampliar o noso coñecemento sobre certas enfermidades críticas na actualidade,
como o PCa, proporcionando modelos teóricos completos e robustos que integren
tódolos principais resultados existentes e vindeiros procedentes da investigación en
ciencias biolóxicas, biofísicas, médicas e biomédicas, así como da enxeñaría e a
mecánica computacional.
• Cremos que a construción de modelos matemáticos de PCa como os presentados
nesta tese podería ser o primeiro paso cara á obtención dun modelo completo
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que, dentro do contexto dun marco de xestión clínica computacional, podería
ser implementado en software clínico para axudar aos médicos na diagnose da
enfermidade, na predición de prognose, no deseño de tratamentos óptimos e na
realización do seguimento.
• O noso modelo base de crecemento de PCa localizado é capaz de reproducir as
dúas morfoloxías comúns do PCa: esferoidal, ou masiva, e ramificada. Este modelo
tamén reproduce unha coñecida inestabilidade de forma que dá paso da morfoloxía
esferoidal á ramificada. Os resultados dos nosos cálculos amosan que este cambio
morfolóxico é unha resposta tumoral para evitar a inanición, a hipoxia e, finalmente,
a necrose. Deste xeito, a ramificación permite ao tumor minimizar a distancia dende
as células máis interiores aos nutrientes exteriores, contribuíndo á supervivencia
do tumor e ao seu ulterior desenvolvemento.
• Tamén empregamos o noso modelo para realizar as primeiras simulacións de
crecemento de PCa de forma personalizada e a escala tisular baseadas na anatomía
prostática de pacientes que extraemos de imaxes de CT ou MR. Estas simulacións
amosan progresións tumorais similares a aquelas observadas na práctica clínica en
termos de xeometría e evolución.
• Observamos que ao variar a xeometría tumoral, a posición do tumor ou a anatomía
da próstata independientemente se obtiveron diferentes patróns de crecemento
tumoral. Isto suxire que a inclusión da próstata e do tumor de cada individuo é
esencial para realizar un seguimento adecuado da progresión da enfermidade en
termos de posición e volume do tumor así como de produción de PSA. Introducir no
modelo a anatomía prostática específica do paciente é crucial para poder predicir
os potenciais riscos que o PCa pode supoñer, como a penetración da cápsula
prostática, a invasión de tecidos próximos ou a expansión tumoral ás diferentes
partes da próstata, provocando así síntomas como impotencia ou irregularidades na
micción ou na exaculación [259, 265].
• A posibilidade de predicir cando aparecerán estes riscos ou síntomas sería un
gran avance nos protocolos de “esperar e ver” e vixilancia activa. Deste xeito, a
optimización destas dúas opcións clínicas para facer fronte á enfermidade, incluíndo
a modelización e simulación do PCa, podería reducir o exceso de tratamento dos
pacientes, deixándoos en moitos casos aliviados ou curados trala administración do
correspondente tratamento, con mínimos efectos secundarios e unha boa calidade
de vida.
• A predición da forma e do volume reais do tumor dentro da anatomía da próstata
dun determinado paciente tamén permitiría optimizar a cirurxía e a planificación e
a administración de radioterapia, obtendo altas precisións e taxas de eficiencia.
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• De acordo coas nosas simulacións de crecemento de PCa personalizadas e a escala
tisular, os resultados da biopsia dunha próstata con tumor ramificado poderían
proporcionar unha cota inferior da agresividade do cancro conducindo a un perigoso
escenario preditivo. Isto se debe a dúas razóns: primeiro, a agulla da biopsia podería
sortear as ramas entretecidas do tumor e, segundo, tamén podería alcanzar unha
rama tumoral ortogonalmente, o que podería dar lugar a unha baixa porcentaxe
errónea de tecido tumoral na mostra da biopsia.
• Idealmente, a combinación da imaxe por mpMR e a modelización e a simulación
computacional do PCa podería eliminar a biopsia da próstata durante a diagnose
e a estadiaxe da enfermidade, abandonando así un procedemento invasivo con
resultados cuestionables e en continuo debate na comunidade médica [259, 265].
De feito, a combinación de imaxes de MR potenciada en T2, MR potenciada
en difusión, estudo dinámico de MR potenciada con contraste e, opcionalmente,
espectroscopía por MR xa permitiu a detección e estadiaxe do PCa con sensibilidade
e especificidade elevadas, comparabales coas asociadas ás biopsias comúns actuais
[51, 75, 87, 111, 116, 123, 153, 227, 238]. Como resultado, a imaxe por mpMR
estase a considerar cada vez máis como unha futura opción en lugar da biopsia ou,
cando menos, como unha técnica que se pode fusionar coa biopsia por TRUS para
optimizar este procedemento [210].
• O PSA tisular permítenos analizar onde o PSA se filtra ao torrente sanguíneo e
a cantidade deste biomarcador do PCa vertido tanto polo tecido san como polo
tumoral. O PSA tisular tamén relaciona o PSA en sangue coa carga tumoral
nos nosos modelos. Isto establece unha base teórica para a relación entre ambas
dinámicas. Unha confirmación desta conexión xurdiu cando estimamos o PSA
en sangue inicial para as nosas simulacións. Para unha selección de parámetros e
un volume tumoral inicial dados, o PSA en sangue inicial estaba intrinsecamente
determinado. Polo tanto, se empezabamos a simulación cun valor de PSA en sangue
distinto, unha rama abrupta aparecía ata que este se reaxustaba.
• Observamos que a predición da evolución do volume do tumor e a do PSA en sangue
seguen unha dinámica semellante. Este comportamento obsérvase tipicamente en
tumores de risco baixo ou intermedio [229, 253, 254, 259, 265], que en tódolos
casos son tumores prostáticos localizados.
• A conexión entre o crecemento tumoral e a dinámica do PSA en sangue é un
continuo debate na comunidade urolóxica [259, 265]. Os exames rutinarios de PCa
están baseados na medición do PSA pero, aínda cando a maioría de adenocarci-
nomas prostáticos crecen amosando un paralelismo entre o volume de tumor e os
niveis de PSA en sangue, sábese que existe un certo grado de diverxencia entre as
dinámicas destas dúas variables. Isto pode chegar ao límite de pacientes con baixo
PSA e grandes masas tumorais nas súas próstatas, ou viceversa. O PCa avanzado e
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metastático pode tamén exhibir case ningunha conexión entre o PSA en sangue e
a carga tumoral. Porén, os exames rutinarios de PSA melloraron a detección e o
tratamento precoz do PCa, levando a altas taxas de incidencia e a unha eficiencia
mellorada na súa xestión en todo o mundo. Polo tanto, nós defendemos que este
biomarcador debe ser implementado nun modelo matemático de PCa, pois permite
unha conexión directa cos datos clínicos existentes.
• A simulación personalizada do crecemento do PCa a escala tisular é un problema
esixente. Presenta unha interface móbil que indica o contorno que separa o tumor
do tecido san circundante. Esta interface, modelada por medio do método de
campo de fase, evoluciona dentro da complexa anatomía da próstata do paciente
condicionada por nutrientes e hormonas. Consecuentemente, este é un problema
onde un enfoque adaptativo introduce unha vantaxe chave: proporciona unha malla
con elementos máis finos para representar a interface e elementos máis grosos no
resto do dominio computacional, o cal conduce a un drástico aforro de memoria e
tempo de computación. Polo tanto, nós cremos que os nosos algoritmos adaptativos
son unha importante tecnoloxía para poder implementar modelos preditivos de PCa
localizado nun escenario clínico de forma precisa e eficiente.
• Empregamos o noso modelo de crecemento de PCa para amosar o potencial para
a análise das nosas estratexias adaptativas para splines xerárquicas. En tódalas
simulacións presentadas nesta tese obtivemos unha notable precisión con moi
poucos grados de liberdade en comparación coa malla uniforme que se requiriría
para realizar a mesma simulación.
• Os nosos algoritmos adaptativos permiten a resolución de problemas esixentes de
interface móbil en ciencia e enxeñaría mediante IGA e empregando espazos de
splines xerárquicas nun marco de elementos finitos proporcionado pola extracción
de Bézier. A nosa tecnoloxía tamén se pode usar para resolver problemas que
contan con aspectos de escalas finas, como capas internas e de contorno en fluxos
dominados por convección, concentración de tensións e definicións xeométricas
precisas.
• Calibramos o noso modelo con acoplamento mecánico realizando unha análise da
deformación da próstata causada polo tumor e a BPH de forma independente. En
xeral, os nosos resultados en termos de desprazamentos e aspectos deformacionais
para a BPH e o PCa concordan con estudos previos na literatura médica [27, 44,
265]. Tamén observamos que o noso modelo reproduciu correctamente os campos
de tensión mecánica inducidos por un tumor en crecemento tal e como se describiu
previamente na literatura [57, 109, 118, 137, 205, 228, 256].
• Propoñemos unha explicación mecánica para comprender por que as próstatas
grandes poden exercer un efecto protector contra o PCa. As nosas simulacións
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amosan que o desenvolvemento da BPH durante anos antes do PCa conduce a un
estado deformacional caracterizado por unha elevada tensión hidrostática dentro da
glándula central (CG) e unha gran tensión de Von Mises na zona periférica (PZ) da
próstata. A combinación destes campos de tensión mecánica con aqueles inducidos
polo tumor en crecemento dificulta a evolución do PCa, que presenta caracterís-
ticas patolóxicas favorables, como unha lenta taxa de crecemento e ausencia de
comportamiento invasivo.
• Os nosos resultados sobre a inhibición mecánica do crecemento de PCa recomendan
realizar un exame exhaustivo da próstata en homes sen PCa antes de prescribir
tratamentos ou medicamentos para a BPH orientados a reducir o volume da CG.
Analogamente, os nosos resultados tamén recomendan un seguimento intenso de
pacientes de PCa que reciban este tipo de medicamentos para a BPH. En caso
contrario, a disminución de volume prostático podería rebaixar peligrosamente os
campos de tensión mecánica creados pola BPH e reducir así a restrición mecánica
sobre o crecemento do PCa. De feito, isto podería explicar parcialmente a maior
proporción de cancros máis agresivos no grupo de finasterida do Prostate Cancer
Prevention Trial [235], o cal podería decirse que é o resultado máis controvertido
deste estudio fundamental sobre a quimioprevención do PCa [36, 145, 150, 184].
• A nosa investigación sobre a interacción mecánica entre PCa e BPH tamén suxire
o desenvolvemento de novas formas de tratamento aliviando os síntomas de BPH
mentres se mantén un nivel de tensión significante na próstata como medida de
protección fronte ao PCa.
• Os esforzos para botar luz sobre as potenciais relacións entre o PCa e a BPH
sinalaron correlacións prometedoras e mecanismos de interacción [4, 191, 265].
A conseguinte investigación para validalos poderíase beneficiar en gran medida
da modelización matemática a fin de organizar, comprender e proporcionar unha
sólida teoría que apoie estes novos descubrimentos e guíe os pasos a dar no futuro
[7, 165, 188, 274].
D.5 Futuras liñas de traballo
O traballo desenvolvido nesta tese abre a porta a diversas liñas de investigación que serán
abordadas no futuro. Resaltamos as seguintes:
• A nosa descrición da dinámica tumoral pódese mellorar incluíndo varias especies
cancerosas (p.e.: normóxicas, hipóxicas e necróticas), o cal permite unha simulación
máis detallada da inestabilidade morfolóxica; introducindo fenómenos de taxe para
describir mellor a invasividade do tumor; e considerando outras substancias que
xogan un papel importante en PCa, como o osíxeno ou a testosterona.
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• A dinámica do PSA tisular pódese mellorar proporcionando unha definición máis
precisa das taxas de produción de PSA tisular e refinando a súa ecuación. Isto pode
requirir unha revisión da modelización do PSA na literatura médica para encontrar
conexións adicionais entre a forma e o volume do tumor e a produción de PSA.
Ademais, estamos ignorando o crecemento prostático, que podería contribuír ao
incremento do PSA.
• Dado que os homes de máis de 50 anos teñen o seu PSA monitorizado de for-
ma rutinaria, poderiamos personalizar os parámetros na ecuación do PSA tisular
empregando métodos de inversión, estatística Bayesiana ou técnicas de machine
learning. Requiriríanse análises lonxitudinais de dinámica de PSA para realizar
este traballo.
• A radioterapia é un tratamento viable para unha gran variedade de pacientes
de PCa e posúe o potencial para desenvolver plans personalizados baseados en
datos precisos de imaxe médica [259, 265]. Polo tanto, outra interesante liña de
investigación é explorar a modelización e a simulación dos efectos da radioterapia
do PCa no noso modelo, seguindo o camiño de estudos previos realizados en
glioma de baixo grado [158, 196] e glioblastoma multiforme [64, 202].
• En paralelo coas melloras do modelo, tamén necesitariamos comprobar os nosos
métodos isoxeométricos para avaliar se reproducen os novos fenómenos incor-
porados de forma precisa e eficiente, ou mellorar os nosos algoritmos en caso
contrario. En particular, gustaríanos examinar os nosos algoritmos adaptativos en
modelos máis complexos de crecemento de PCa incluíndo varias especies celulares
tumorais, nos que as novas interfaces entre elas deben ser representadas de forma
precisa. Tamén estamos interesados en usar as nosas estratexias adaptativas para
avaliar a precisión dos nosos modelos usando datos anatómicos e patolóxicos
personalizados extraídos de imaxes médicas, en particular, de imaxes de mpMR
[51, 75, 87, 111, 116, 123, 153, 227, 238]. .
• O desenvolvemento da adaptatividade tipo p, k e r de espazos de splines xerárquicas
e a extensión dos nosos algoritmos adaptativos á configuración dos bosques de
splines [219, 234] son líneas de investigación esixentes e prometedoras cara á
derivación de métodos dinámicos adaptativos máis versátiles e potentes en IGA.
• O noso modelo con acoplamento mecánico para o crecemento de PCa localizado
pódese mellorar en varios aspectos. Primeiro, o noso modelo anatómico da próstata
poderíase beneficiar dunha segmentación máis precisa das zonas prostáticas inter-
nas acompañada dunha caracterización mecánica personalizada. Segundo, unha
definición das condicións tipo Winkler que varíe no espazo segundo os diferentes
tecidos e órganos que rodean a próstata contribuiría a obter predicións máis preci-
sas. Terceiro, o noso modelo tamén se podería beneficiar dunha formulación máis
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precisa para a BPH [157, 203, 270] así como para o crecemento e a deformación
tumorais [56, 125, 160, 163, 205]. Cuarto, o termo de mecanotransdución para
axustar a dinámica do tumor pódese refinar, por exemplo, probando formulacións
alternativas ou diferenciando como as tensións mecánicas afectan á mobilidade,
á proliferación e á apoptose no tumor [57, 118, 160]. Por último, para superar as
limitacións da elasticidade lineal e obter valores máis precisos de desprazamentos e
tensións planeamos ter en conta a non-linealidade xeométrica e investigar ecuacións
constitutivas alternativas para a próstata [110, 134, 173, 256], que tipicamente in-
clúen un maior conxunto de parámetros elásticos que non son fáciles de estimar de
forma personalizada.
• Unha descrición poroelástica do crecemento de PCa axudaría a estudar o efecto da
deformación mecánica no transporte de nutrientes [205]. Este enfoque ten o poten-
cial para investigar con precisión a heteroxeneidade do metabolismo intratumoral
ou ensaiar de forma personalizada a administración de medicamentos ao tumor in
silico.
• Tamén pretendemos investigar o efecto de medicamentos para a BPH que causan
unha disminución do volume da próstata no crecemento tumoral estendendo o noso
modelo con acoplamento mecánico para incorporar o efecto destes medicamentos,
como a dutasterida e a finasterida [235, 265].
• Pensamos que o noso modelo con acoplamento mecánico podería ser explotado
para mellorar as actuais tecnoloxías de rexistro deformable de imaxes médicas
[27] proporcionando unha teoría para a evolución da BPH e o PCa. Os algoritmos
resultantes poderían ser de gran interese para varias aplicacións na xestión clínica
do PCa de forma personalizada e a escala tisular, como un seguimento detallado do
crecemento do tumor durante vixilancia activa ou a planificación precisa da cirurxía
ou outros tratamentos [165]. Devandita tecnoloxía tamén podería axudar a detectar
o PCa a partir da deformación dos contornos da próstata e dos bordes internos
entre as rexións prostáticas [208, 263]. Ademais, tamén podería guiar biopsias
para mellorar a estadificación e a diagnose do PCa. Comparando as predicións
do modelo con novas imaxes e datos clínicos tamén podería axudar a discernir
se o tumor está progresando cara a un comportamento máis maligno e a tomar as
correspondentes decisións clínicas [165].
• Para afondar o noso coñecemento nos mecanismos de crecemento de PCa usando os
nosos modelos cremos que sería interesante investigar as propiedades matemáticas
das ecuacións que os constitúen, por exemplo, analizar as condicións de existencia
de solucións, caracterizar os espazos paramétricos e estudar as condicións baixo as
que o problema está ben plantexado.
• A nosa intención é perseguir a validación do noso marco computacional usando
bases de datos lonxitudinais de pacientes, incluíndo imaxes médicas de alta calidade,
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datos bioquímicos e informes clínicos. Como paso previo, este traballo tamén
requirirá a calibración personalizada dos parámetros cos datos dispoñibles nas
imaxes do paciente e o seu historial clínico.
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